66th ASH Annual Meeting: Author Index L

La Barba, G.

2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

La Fauci, M.

3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

La Ferlita, A.

1611 - Transcriptome Analysis at Locus-Specific Resolution Identified Alteration in Human Endogenous Retroviruses, a Class of Transposable Elements in Mantle Cell Lymphoma
4350 - Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
4371 - Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling

La, J.

161 - Optimized Multi-Class VTE-BERT Large Language Model for Prediction of Cancer Associated Thrombosis Phenotype
812 - External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations
3641 - Implementation of Automated Thrombosis and Bleeding Risk Assessment in Cancer Patients Undergoing Systemic Therapy
3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
3962 - Dietary Tryptophan Contributes to Indoleamine 2,3-Dioxygenase 1(IDO-1)-Mediated Cancer-Associated Venous Thrombogenicity in Mice
4013 - Circulating Tumor DNA Predicts Venous Thromboembolism in Minority Patients with Cancers

La Nasa, G.

2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

La Starza, R.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
147 - Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Laadem, A.

2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Laajala, E.

329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity

Laan, S. N.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Labarre, A.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Labaudiniere, R.

3372 - Small Molecule Kinetic Stabilizers Reduce Amyloidogenicity of Free Light Chain Proteins of Diverse Sequences in λ Light Chain Amyloidosis

Labedz, A.

4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

LaBelle, J.

4953 - Cerebral Hemodynamics Improve in Adults with Sickle Cell Disease after Gene Therapy

Labere, B.

2540 - Circulating T Follicular Helper Cells in Pediatric Immune Cytopenias

Labi, V.

2746 - Roles of TET2 Loss in B Cell Transformation

Labianca, R.

4023 - Fibrinogen and D-Dimer Predict Venous Thromboembolism (VTE) in a Prospective Observational Cohort of Metastatic Breast Cancer Patients

Labopin, M.

508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Laborde, J.

3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis

Labouré, G.

1986 - Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple Myeloma

Labrador, J.

320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Labrador, J.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Labrano Elias, M.

3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study

Labropoulou, V.

3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Labropoulou, V.

3257 - Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma

Labrouche-Colomer, S.

3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Labussiere-vallet, H.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Labussière-Wallet, H.

505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

LaCasce, A. S.

400 - Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Lacayo, N. J.

4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Lacaze, P.

303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Lacerda, M. P.

772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
1524 - Safety and Efficacy of Venetoclax, Cytarabine and Metformin for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Lachaine, J.

5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Lachance, S.

1502 - UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia
4916 - Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Lachmann, H. J.

890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Lachot, S.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Lachowiez, C. A.

62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Lachowiez, C. A.

2855 - Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Lack, J.

2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease

Lacombe, V.

2674 - Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

Lacy, M.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Lad, D. P.

2919 - Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy

Lade, S.

1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Ladel, L.

4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
4582 - ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures

Ladetto, M.

237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
2269 - A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III

Ladevèze, R. D.

2018 - Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes

Ladha, A.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Ladhani, N. N.

793 - Ferric Derisomaltose Versus Iron Sucrose in Pregnancy (FLIP): A Retrospective Observational Study on Outpatient Intravenous Iron Infusion Capacity

Ladisa, F.

3268 - A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma

Ladon, D.

3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms

Lae, S. J.

2556 - Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Laenen, A.

3664 - Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Laetsch, T. W.

2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
3429 - The Role of Gut Microbiota in Modulating Efficacy and Adverse Effects of CAR T-Cell Therapy in the Pediatric Population

Lafage-Pochitaloff, M.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Lafaurie, M.

549 - Risk of Acute Myeloid Leukemia in Adults with Primary Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonists: A French Nationwide Population-Based Study

Lafave, L.

326 - KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Lafeuille, M. H.

3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study

Lafeuille, P.

2077 - Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Lafont, E.

1915 - Latent Nuclear Antigen Flow-FISH Improves the Detection of Circulating Viroblasts during KSHV/HHV-8-Associated Multicentric Castleman Disease Flares

Laframboise, T.

2756 - PTPN12 Is Targetable and Context-Specific TSG in -7/del7q Myeloid Neoplasia
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4303 - Identification of Tumor Suppressors and Synthetic Lethal Targets in -7/del7q Myeloid Neoplasms By Iterative Computational Analysis Coupled with Experimental Validation

LaFrance, N.

1599 - CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma
4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Lafuente, M.

4351 - Genetic Characterization of Marginal Zone Lymphomas in Tissue and cfDNA
4566 - Diagnostic Challenges in Patients with Clinical Suspicion of Myeloproliferative Neoplasms and JAK2V617F≤1%

Lagana, A.

357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
589 - BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Lagani, V.

1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Laganson, A.

2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Lage, L. A. D.

4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
4458 - Outcomes and Toxicity Profile in Elderly and Very-Elderly Diffuse Large B-Cell Lymphoma Patients: A Real-World and Comparative Study Involving Three Different Dose-Modulated Anthracycline-Based Immunochemotherapy Regimens in LATAM

Lagerlöf, I.

235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Lagkouvardos, I.

780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Lagneaux, L.

3229 - Extracellular Vesicles from Chronic Lymphocytic Leukemia Cells Promote Leukemia Aggressiveness By Inducing the Differentiation of Monocytes into Nurse-like Cells Via an RNA-Dependent Mechanism

Lagresle-Peyrou, C.

2201 - Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Laharwal, M. M.

2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Lähdesmäki, H.

1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes

Lahman, M.

3438 - NK-like Skewing As the Key Driver of T Cell Dysfunction in AML: Implications for Enhancing TCR-T Cell Therapy Efficacy

Lahoud, O. B.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
5155 - Characterization and Comparative Outcomes of Younger Multiple Myeloma Patients

Lahrmann, C.

206 - Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutatedand KMT2A-rearranged Leukemia

Lähteenmäki, H.

329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Lahuerta Palacios, J. J.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Lai, A.

1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia

Lai, A.

5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts

Lai, B.

4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Lai, C. E.

736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
1525 - Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm
2911 - Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Lai, C. H.

3310 - Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1

Lai, H. Y.

3134 - Uncovering Non-Canonical Signalling Mediated By JAK2V617F in Myeloproliferative Neoplasms

Lai, J. S.

3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Lai, M.

2794 - Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients

Lai, M.

4457 - Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Lai, P.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Lai, S.

4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Lai, S. W.

3966 - Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Lai, S.

1028 - A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease

Lai, S.

2256 - Relationship between Frequency of Treatment Administration, Adherence to Treatment, and Quality of Life in Patients with Hemophilia a or Hemophilia B, with or without Inhibitors: A Real-World Survey
2314 - Unmet Needs in People with Hemophilia Receiving Prophylaxis Treatment: A Real-World Survey
5078 - Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients

Lai, T. H.

3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Lai, W.

1605 - Single-Cell Analysis Reveals an Exhaustion of TEM and CTL CD8⁺ T Cells in Hemophagocytic Lymphohistiocytosis with EBV Infection

Lai, W. H.

1569 - Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia
3603 - In Vitro Drug Profiling to Guide Treatment for Relapse/Refractory AML

Lai, X.

97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Lai, X.

420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE

Lai, Y.

4500 - Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring

Lai, Y. T.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lai, Y. T.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lai, Y.

711 - Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)
3937 - Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Lai, Y.

350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial

Lai, Y.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram

Lai, Y.

2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia
4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)

Lai, Z.

2790 - EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases

Laine, D.

479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Lainey, E.

1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Laister, R. C.

1411 - Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL
4179 - Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma

Laitinen, H.

4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Lake, A.

3574 - Gene Therapy for Sickle Cell Disease Is Associated with a Decreased Transplant Length of Stay and Similar Rates of Short-Term Complications Compared to Allogeneic Matched Sibling Stem Cell Transplant: A Single Center Experience

Lake, L. L.

3633 - Patient-Centered Management of Heavy Menstrual Bleeding on Anticoagulants: An International Survey

Lake, N. J.

4054 - Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

Lakhani, K.

1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Lakhmapurkar, U.

3686 - Efficacy and Safety of Zoledronic Acid in Sickle Cell Disease Associated Bone Disorders :Single Centre Experience

Lakhotia, R.

750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Lakhotiya, K.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4573 - Elucidating the Somatic Genetic Rescue Underlying Del(20q) Myeloid Neoplasms

Lakhwani, S.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain
3159 - Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML
3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

Lakkaraja, M.

1179 - Fetal and Neonatal Alloimmune Thrombocytopenia: Risk of ICH in Second Pregnancy and Treatments to Maintain an Adequate Platelet Count

Lakkimsetti, M.

1428 - Epidemiological Trends of Acute Lymphoid Leukemia in Individuals Younger Than 20 Years across 204 Countries and Territories from 1990-2021: A Benchmarking Global Analysis
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021

Lakos, G.

1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

Laks, D.

3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification

Lakshmi, K. M.

1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
4879 - EASIX_d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Lakshmi Narasimhan, M.

2110 - Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Lakshmikanthan, S.

2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Lal, A.

2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Lalayanni, C.

1323 - Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group

Lalefar, N.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Laliberté, F.

697 - Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Lally, C.

1098 - Estimated Prevalence of β-Thalassemia in the United States in 2023

Lalonde, L.

167 - The Inflammatory Cytokine IL17 Tunes and Amplifies the Erythropoietic Response to Erythropoietin In Vivo

Lalwani, K.

3851 - Mouse Models of Hereditary Xerocytosis-Associated PIEZO1 Mutations Reveal Genotype-Phenotype Differences in Hematological Defects and Iron Loading

Lam, B. D.

161 - Optimized Multi-Class VTE-BERT Large Language Model for Prediction of Cancer Associated Thrombosis Phenotype
3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule

Lam, B.

1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Lam, C.

1417 - The Polymeric Drug Pamd-Ch17 Induces Mitochondrial Dysfunction and Has Anti-Leukemic Effects

Lam, E.

1193.1 - Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)

Lam, E.

3327 - Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Lam, J.

537 - LDB1 Establishes Multi-Enhancer Networks to Regulate Erythroid Gene Expression

Lam, J. C.

4192 - Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Lam, K.

2767 - The Proteostasis Network Is a Therapeutic Target in Acute Myeloid Leukemia

Lam, L. T.

4966 - Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Lam, M. Q.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Lam, N.

4789 - Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor

Lam, S.

4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Lam, S.

1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
1569 - Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia
2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML
2763 - HPK1 Inhibition and Venetoclax Combination Suppressed AML By Enhancing Cytotoxic T-Cell Response to Leukaemia
3603 - In Vitro Drug Profiling to Guide Treatment for Relapse/Refractory AML

Lam, W.

1226 - “Endothelialized” Hemostasis-on-a-Chip Reveals Rapid Platelet Recruitment By Locally Concentrated Ultra-Large Von Willebrand Factor (VWF) Release from Endothelial Cells Surpasses Plasma and Platelet VWF in Initiating Hemostasis
2248 - Noninvasive, Accessible, Smartphone App for at-Home Hemoglobin Monitoring in Sickle Cell Disease

Lam, W.

687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease

Lam, W.

1399 - Inhibition of Threonine Tyrosine Kinase Suppressed TP53-mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway
1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML
3603 - In Vitro Drug Profiling to Guide Treatment for Relapse/Refractory AML

Lama, C.

1281 - Hallmarks of Transcriptional Heterogeneity in Human Hematopoietic Stem Cells across 382 Donors

Lamanna, F.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Lamanna, N.

1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Lamanna, N.

4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Lamao, Q.

3405 - Changes in Glycosylation on the Cell Surface Result in Highly Potent and Long-Lasting Allogeneic CAR-T Therapy in Patients

Lamarca Eraso, L.

320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Lamarca Eraso, L.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lamarca, L.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Lamarre, A.

2623 - Clinical Significance of Incidental Central Venous Catheter-Related Thrombosis in Children Previously Treated for Cancer

Lamartina, L.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Lamas Rodriguez, B.

2111 - Current Challenges in the Assessment of Related Donors for Hematopoietic Stem Cell Transplantation

Lamb, J.

1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Lamb, L. S.

4823 - Inb-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma Delta T Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide

Lamba, J. K.

103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
1394 - Immunotherapeutic Potential and In Vivo Targeting of CD33 Splice Variant Isoform
1543 - Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients
2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4327 - Genome-Wide Association Study of Metabolites in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia Identified Novel Metabolite Quantitative Trait Loci

Lambert, C.

1205 - Impact of Emicizumab on Mental Liberation in Adult Patients with Severe and Moderate Factor VIII Deficiency
2636 - Levels, Determinants and Predictive Value of D-Dimer in Patients on Long-Term Direct Oral Anticoagulant for Venous Thrombo-Embolic Disease

Lambert, J. F.

2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria

Lambert, J.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)

Lambert, J.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Lambert, J.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Lambert, J.

659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Lambert, J.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

Lambert, L.

1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma

Lambert, M. P.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis
1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)
1268 - Standardized Prophylactic Platelet Transfusion Dose for Infants Decreases Platelet Exposure without Increasing Bleeding or Transfusion Frequency
2317 - Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry
- On the Horizon: Upcoming New Agents for the Management of ITP

Lamble, A.

462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1555 - Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML – Only KRAS Mutations Are Associated with Adverse Outcome
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Lambo, S.

953 - Targeted Protein Degradation Reveals a Repressive Role of Mecom at the CEBPA Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia

Lambris, J.

2608 - Red Blood Cell-Derived Particles Induce Endothelial Damage Via the Alternative Complement Pathway

Lammens, T.

4994 - Ultra-Deep Sequencing and Single Cell Multi-Omics Characterize Measurable Residual Disease and Identify Therapy-Survived Clone in Pediatric Acute Myeloid Leukemia

Lamo-Espinosa, J. M.

879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Lamonica, M. S.

3900 - Low Bone Density Associates with Severe Outcomes in Young Adults with Sickle Cell Disease

LaMotte, J. E.

394 - Neurocognitive Screening and Neighborhood Impact for Children and Adolescents with Sickle Cell Disease

Lampertico, P.

1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Lampron, S.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Lampson, B.

107 - Analysis of Avapritinib Clinical Trial Data Generates a Highly Accurate Predictive Model for Advanced Systemic Mastocytosis Versus Indolent Systemic Mastocytosis Based on Peripheral Blood Testing
3164 - Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Lamure, S.

846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Lamure, S.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Lamy, T.

979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry
- Large Granular Lymphocyte Leukemia: A Clonal Disorder with Autoimmune Manifestations

Lan, J.

2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Lan, K.

4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)

Lan, L.

2570.1 - Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Lan, M.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Lan, Q.

4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma

Lan, Y.

1162 - Ras-Associated Autoimmune Lymphoproliferative Disorder: Retrospective Case Series

Lan, Z.

5189 - Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

Lanaro, C.

1109 - Cereblon-Based Compounds for Induction of HbF
3868 - Novel Selective HDAC1/2 Inhibitor 2-Aminobenzamide Derivative Potently Induces Fetal Hemoglobin

Lance, E. I.

3882 - Feasibility of Validating a Screening Tool for Neurocognitive Function in Adults with SCD

Lancellotti, C.

105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Lancelot, M. M.

1079 - BMI-1 Transduced Human Erythroid Cells: A Representative System for Modeling Transcriptional Programs during Terminal Erythroid Differentiation

Lancet, J. E.

60 - AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
354 - High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Lancho Lavilla, P.

5050 - Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

Lanciotti, M.

1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders

Lancman, G.

1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Landau, D. A.

1604 - Transcriptomic and Epigenomic Landscape of Hairy Cell Leukemia at Single-Cell Resolution
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Landau, H. J.

81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
3665 - A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Lander, C.

3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused

Lander, E.

4039 - Transcription Factor Networks Disproportionately Enrich for Heritability of Blood Cell Phenotypes

Landever, O.

3247 - Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®

Landgren, O.

Landier, W.

Landman-Parker, J.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Landoni, A. I.

2093 - Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay

Landrieu, V.

3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Landrin, V.

1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma

Landry, F.

169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Landry, J. J.

1282 - A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy

Lands, L.

2261 - Routine Screening of African American Males in Hematology Oncology Clinic for G6PD Deficiency: A Prospective Comparative Study of a Pharmacogenomic Panel Versus Standard Enzyme Assay

Lands, R. H.

1910 - Preliminary Observations Using 99m-Tc-Peptide p5+14 for the Detection of AL Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
4641 - Characterization of AT02 Bioactivity and an Assessment of Its Potential Use As an Amyloid-Clearing Therapeutic for AL Amyloidosis

Landsburg, D. J.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
1699 - Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
1750 - Clinical Activity of Tisagenlecleucel in Large B Cell Lymphomas According to the 5^th Edition of the Who Classification
2275 - Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone
3083 - Title: Development of a Pathologic Prognostic Index (PPI) for Newly Diagnosed Large B Cell Lymphoma Patients Treated with R-CHOP
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2^nd Line CAR T Therapy

Landwehr, M.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
4012 - Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis
4186 - Clinical Outcomes of Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Autologous Chimeric Antigen Receptor T-Cell Therapy: A Meta-Analysis of 1,154 Patients Included in Clinical Trials

Landy, E.

1159 - Elucidation of Human Invariant NKT Cell Immunophenotypes to Provide Insights for Future Universal Donor Derived Cellular Therapeutics

Lane, A. C.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial
544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial

Lane, A. A.

321 - Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
4265.1 - Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Lane, H.

805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Lane, J.

1886 - CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4^CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Lane, M.

737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Lane, P. A.

5006 - Lapses in Appointment Attendance Among Children with Sickle Cell Disease in the First Five Years of Life

Lane, S. W.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia
476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
1006 - Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
1346 - Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments
1347 - Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1^c-Flt3^ITD Acute Myeloid Leukemia
1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3222 - A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Lane, W. J.

102 - Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes

Lanfranchi, A.

2142 - Improvement of Survival By Use of New Tecniques of Manipulation after Haploidentical Hematopoietic Stem Cell Transplantation: Report of 230 Transplants in Paediatric Patients with Primary Immunodeficiencies and Oncological Diseases

Lanfranchi, A.

2526 - Investigating Neutropenia in FNIP1 Deficiency: A CRISPR/Cas9 Model in HL-60 Cells

Lanfranco, J.

3961 - Proteolysis of Annexin A2 Leads to Inflammasome-Mediated Proinflammatory Response in Human Sepsis

Lang, A.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Lang, D.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

Lang, F.

1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Lang, F.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation

Lang, F.

1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Lang, I.

3397 - TNFR2, GITR and DR3 Agonists Exert Distinct Response Durations in Treg-Mediated Acute Graft-Versus-Host Disease Protection

Lang, K. S.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Lang, M.

1792 - High Resolution Chest Computed Tomography Responses for a Cohort of Erdheim–Chester Disease Patients with Pulmonary Involvement
3166 - Long Term Follow-up of Methotrexate and Cytarabine in Adult Patients with Langerhans Cell Histiocytosis

Lang, N.

4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Lang, P.

512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Lang, P.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Lang, S. M.

799 - Longitudinal Assessment of Myocardial Fibrosis in Sickle Cell Disease

Lang, S.

4036 - Transplant Dose As a Determinant of Proliferative Response and Long-Term Reconstitution of the Hematopoietic Stem Cell Pool

Lang, T.

1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Lang, V.

5202 - "It Was Bootstrap All the Way": Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States

Lang, W.

4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment

Lang, W.

4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes

Lang, X.

1786 - Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Lang, X.

958 - KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Langberg, K.

7 - Erythroid Ferritin Chains In Vivo Are Dispensable for Hemoglobinization but Play a Critical Non-Canonical Role in Erythropoietin Signaling

Langenau, D. M.

202 - In Vivo Genetic Screen Identifies Chromatin Remodeling Gene SET As a Collaborating Oncogenic Driver in Initiation and Maintenance of Acute Lymphoblastic Leukemia

Langenhorst, J.

4876 - Standard Fludarabine Dosing Results in Overexposure in Young Children Undergoing Hematopoietic Cell Transplantation

Langer, I.

3427 - In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA^®) Anti-CD20 CAR

Langer, J.

2098 - The Impact of Stem Cell Mobilization Regimen on Outcomes after Autologous Transplant for Multiple Myeloma

Langerak, A.

3906 - Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Langerbeins, P.

1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Langfitt, D. M.

2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Langie, J.

317 - Genome-Wide Association Study of Acute Lymphoblastic Leukemia in Hispanic/Latino Children Identifies a Putatively Novel Risk Locus at Chromosome 5q31.1

Langlais, B.

243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
2299 - Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial

Langlois, M. A.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Langmuir, P.

4985 - Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization

Langmuir, T.

3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease

Langner, A.

914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Langouët, M.

3471 - Development of a UM171-Supported, CD33 Epitope-Engineered Blood Stem Cell Graft for Advanced AML Therapies

Langowski, J. L.

3481 - KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-Cell Malignancies

Langstein, H.

4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Langstein, J.

1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Langston, A.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
3521 - Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Lanham, S.

1847 - Single-Cell Transcriptional Characteristics of the Unresponsive Cluster Surviving Anergy in IGHV1-69 CLL

Lanham, T. M.

1203 - Small Molecule Compounds for Heparin Reversal and Their Use in Heparin Quantitation

Lanic, M. D.

4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Lanino, L.

104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1^del5q): Outcomes and Response to Treatment
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Lankester, A. C.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Lankford, A.

3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia

Lannert, K. W.

3955 - Warfarin Exposure Leads to Loss of Binding of Emicizumab to Factor IX

Lannon, M.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Lansigan, F.

1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Lantz, Jr., J.

791 - Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

Lantz, O.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Lanza, F.

733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Lanzarone, G.

3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Lanzkron, S.

2244 - Self-Described Identity, Pain, and Self Efficacy: A Mixed Methods Study in Adults with Sickle Cell Disease (SCD)
2301 - Intersection of Pain-Related Healthcare Utilization with Neighborhood Factorsin Adults Living with Sickle Cell Disease
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2481 - In Vivo Sickle Cell Blood Rheology in Humans with Ventral Tongue Microscopy
3622 - Establishing a Definition of Transition of Care in Sickle Cell Disease: National Alliance of Sickle Cell Disease Centers Consensus
3623 - Paths Grant: Using the Hub and Spoke Model to Improve Access to Care for Adults Living with Sickle Cell Diseases
3882 - Feasibility of Validating a Screening Tool for Neurocognitive Function in Adults with SCD
5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises
- Challenges in Data Quality: Where EHR Data Acquisition Approaches and Highly-Curated Datasets Intersect (1)

Lao, S.

484 - Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

Lao-Sirieix, P.

963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Laoharawee, K.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Lapalombella, R.

2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
4134 - The Hyperbolic NAMPT Inhibitor RPT1G Synergizes with BCL-2 Family Inhibitors and Helps Overcome Venetoclax Resistance in Acute Myeloid Leukemia Cells

Lapen, K.

3040 - Very Low Dose Radiotherapy (VLDRT) with 4 Gy for Potentially-Curable Indolent Non-Hodgkin Lymphomas

Laperche, J. C.

5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Lapeyre-Mestre, M.

549 - Risk of Acute Myeloid Leukemia in Adults with Primary Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonists: A French Nationwide Population-Based Study

Lapietra, G.

2844 - Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Lapillonne, H.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Lapite, A.

5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

LaPlant, B. R.

580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
3045 - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results

Lapointe, A.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study

Laporte, J.

2363 - Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Lappin, K. M.

4110 - Investigating the Potential of Spliceosome Mutations to be Used As Biomarkers for Directing Immune Checkpoint Blockade Therapies in Myeloid Malignancies

Lapping-Carr, G.

2502 - Triaging Acute Chest Syndrome Clinical Decision-Making Using Bedside SaO₂/FiO₂ Ratio

Laprie-Santenac, M.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Laqua, A.

636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Lara, A.

959 - Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Lara Chica, M.

3395 - Role of Antiapoptotic Protein Mcl1 in Graft-Versus-Host Disease

Lara, D.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Lara-Astiaso, D.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Lara-Chica, M.

2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation

Laranjeira, A.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

Larcher, L.

1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)

Lardizabal, A.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Lareau, C.

926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Larfors, G.

2255 - Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study

Larghero, J.

596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Laribi, K.

349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms
584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Lariviere, B.

3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Lariviere, M.

4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2^nd Line CAR T Therapy

Larizza, I. S.

2163 - Medication Adherence in Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation

Lark, P.

2330 - Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation

Larkin, D. F.

1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Larkin, K. T.

1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Larkin, N.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Larocca, A.

2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Larocca, A.

898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Larocca, L. M.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Laroche, M.

2550 - A Freeze-Dried Platelet-Derived Hemostat Decreases Bleeding in a Novel Murine Model of Type 1 Hermansky-Pudlak Syndrome

Larochelle, A.

1273 - CD38 Inhibition Enhances Human Hematopoietic Stem Cell Maintenance in Ex Vivo Cultures

Larochelle, M. R.

5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Larouche, A.

3697 - Impact of Obesity on Anticoagulation Dosing and Clinical Outcomes in Pediatric Patients with Venous Thrombo-Embolism

Larran, A. A.

4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Larrayoz, M.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
1409 - Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma
1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Larsen, A.

3826 - Integrative Hematology Oncology Fellowship: A Descriptive Analysis of the First Accredited Program in the United States

Larsen, B.

1088 - Young Women with Iron Deficiency Anemia Demonstrate Cerebral Metabolic Stress to Maintain Cerebral Oxygen Metabolism

Larsen, E. C.

2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group

Larsen, J. S.

495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Larsen, M. K.

1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial

Larsen, S. R.

1445 - Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 "Sublime” Study
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4952 - Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

Larsen, T. S.

650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies
1638 - Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy
2991 - Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings
3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022

Larson, D. P.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Larson, L.

4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Larson, M.

3490 - TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Larson, M. C.

1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Larson, M. L.

3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Larson, R.

475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Larson, R. A.

218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1432 - Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Larson, R. P.

148 - A Synthetic Receptor Enables Breakthrough Scale Manufacturing of iPSC-Derived CD19-CAR Cell Therapies for Hematologic and Autoimmune Diseases
502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates
2046 - Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Larson, S. M.

675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
4824 - First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Larson, S.

2300 - Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System

Larsson, J.

4036 - Transplant Dose As a Determinant of Proliferative Response and Long-Term Reconstitution of the Hematopoietic Stem Cell Pool

Lasa Eguialde, M.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Lasa, M.

889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Lasarte, J. J.

4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Lasater, E. A.

1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo

Laschen, M.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Lash, B. W.

5016 - Revisiting the Use of Unfractionated Heparin As VTE Prophylaxis: A Single Institution, Retrospective Review

Lashansky, A.

1181 - Pediatric Extreme Thrombocytosis, Etiology, Management and Outcome

Lashbrook, K.

4131 - Crispri Essentiality Screen Reveals the Essential Enhancers and Oncogenes Comprising the “Regulome” of the Notch-Collaborating Transcription Factor ETS1 in Human T-ALL

Lasho, T. L.

440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1326 - Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41^MT Germline Predisposition Syndrome
3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
- Spectrum of Bone Disease in Adult Patients with Telomere Biology Disorders

Lasia, A.

4218 - A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Lasica, M.

860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Lasn, A.

2353 - Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Lasocki, A.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Lassel, L.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Lassila, R.

2640 - Low-Molecular-Weight Heparin Benefited Outpatients with High Risk of Venous Thromboembolism Early in COVID-19 Pandemics

Last, A.

3381 - The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma

Last-Koopmans, S.

3330 - Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Lastorino, D.

532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Laszlo, G. S.

2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Latacz, M.

42 - Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Latagliata, R.

242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study

Latal, V.

2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group

Latchford, T.

386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Latger-Cannard, V.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Latham, T. S.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial
289 - Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia
542 - Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts
544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial
2242 - Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH)
2312 - Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data Hub
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial

Latif, A. L.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Latif, A.

4004 - Caplacizumab Resistance in Immune Thrombotic Thrombocytopenic Purpura (TTP) Mediated By VWF A1 Domain Missense Mutation

Latif Sami, H.

1119 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States: National Inpatient Data Base Study from 2012-2020
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States

Latif, T.

4824 - First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Latif, T.

3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Latiri, M.

2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

Latoch, E.

1587 - Rare Candidate Variants for Germline Predisposition to Childhood Lymphomas: Go Beyond Aberrations in DNA Repair Genes

Latorre, A.

4055 - Fetal-Derived B-1 Cells Can Reduce Atherosclerotic Progression in the Clonal Hematopoiesis Condition

Latour, E.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Latour, S.

1915 - Latent Nuclear Antigen Flow-FISH Improves the Detection of Circulating Viroblasts during KSHV/HHV-8-Associated Multicentric Castleman Disease Flares

Latournerie, V.

2511 - Evaluation of Sleep Apnea in Adult Sickle Cell Disease; About 107 SS and Sβ°Thal Patients

Latremouille-Viau, D.

3812 - Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States

Latry Kuhn, C.

4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Lattanze, M.

3624 - One ST3P Further: Optimizing Transition Care for Pediatric Sickle Cell Patients at Atrium Health

Lattimore, S.

3698 - Patient Satisfaction at United States Hemophilia Treatment Centers in 2023

Lau, A.

2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes

Lau, B. W.

3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Lau, C.

3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Lau, C.

4470 - Prior History of Severe Infection in Children, Adolescents and Young Adults with Lymphoma As Proxy for Inborn Errors of Immunity: Prevalence and Impact on Post-Lymphoma Outcomes

Lau, L. S.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Lau, S. C. D.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Laubach, J.

590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4747 - Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Laubach, J. P.

492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
3304 - Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Laudati, C.

1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Lauer, E. M.

856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Lauer, M.

2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Launay, P.

1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Laurance, S.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies
2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia
3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Laureana, R.

75 - High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Laurent, C.

1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Laurenti, E.

2659 - Multimodal Single Cell Analysis Reveals Hematopoietic Changes across the Human Lifespan
2673 - Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation
- Hematopoietic Stem Cell Commitment to the Myeloid Lineage

Laurenti, L.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
1873 - Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax–Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
3237 - CRISTALLO: Results from a Phase III Trial of Venetoclax–Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine–Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
5111 - Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study

Lauria, A.

3991 - Role of Factor VIII in Angiogenesis, Vessel Stability and the Regulation of Extracellular Matrix Proteins

Lauridsen, R. K.

4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Lauriello, A.

3623 - Paths Grant: Using the Hub and Spoke Model to Improve Access to Care for Adults Living with Sickle Cell Diseases
5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Laurino, M.

33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Lauritsen, T. B.

115 - Incidence and Risk of Therapy-Related Myeloid Neoplasms in Solid Cancer: A Danish National Population-Based Matched Cohort Study
5179 - Incidence and Risk of Therapy-Related Myeloid Neoplasms in Non-Myeloid Hematological Malignancies: A National Population-Based Matched Cohort Study

Lausen, B.

2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1

Lausman, A.

3701 - "There Is so Much Power in Just Believing Someone": Understanding the Lived Experiences of Women with Heavy Vaginal Blood Loss

Lauvau, G.

1591 - North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist
1720 - Safety and Efficacy of AZT-Interferon-α with Belinostat (AI-BEL) for HTLV-1 Related Adult T-Cell Leukemia-Lymphoma
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Lauw, M. N.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
701 - Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy

Lauziere, K.

4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Lavelle, D. E.

1115 - A Novel Oral Prodrug AN233 Induces Fetal Hemoglobin Expression in Sickle Cell Disease Mice and Baboons

Lavelle, W.

2965 - Multi-Modal Analysis Reveals the Differences between Double Expressor and Non-Double Expressor Primary Central Nervous System Lymphomas

Lavender, B.

2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Lavergne, J.

2644 - Transcriptomic Analysis Shows a Common Multi-Organ Inflammatory/Complement Signature in Hemolysis-Induced Damage

Laverick, P.

5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Laverty, M. S.

2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

Lavery, C. L.

1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease
3924 - Trafficking, Not Lymphoproliferation, Promotes Lymphadenopathy in Idiopathic Multicentric Castleman Disease

Lavi, N.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Lavie, A.

2777 - Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Lavie, D.

578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
1734 - Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
1875.2 - Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Lavilla, E.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Lavilla-Rubira, E.

320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Lavin, M.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Law, A.

3953.1 - A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Law, A.

687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease

Law, A. D.

2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

Law, J.

3618 - Lower Emergency Severity Index Assignment Results in Faster Time to First Analgesia in Patients with Sickle Cell Disease

Lawal, R. A.

798 - Minority Patients in the NIH RUNX1-FPDMM Natural History Study Present Mostly with Large Deletions Affecting RUNX1

Lawendowski, C.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Lawler, M. E.

1343 - Distinct Cell-Intrinsic and Extrinsic Consequences of TLR2 Activation Drive Pleiotropic Effects in AML Affecting Overall Survival

Lawless, S.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Lawo, J. P.

3346 - Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis

Lawrence, R.

959 - Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Lawrence, R.

5005 - Assessing Social Media Preferences and Developing Digital Health Care Transition Education Materials for Emerging Adults with Sickle Cell Disease: A Mixed Method Pilot Study

Lawryk, B.

2598 - Impact of Tranexamic Acid Administration on Postpartum Hemorrhage in Women with Von Willebrand Disease Receiving Recombinant VWF at Delivery: The VWD Woman Trial

Lawson, A.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Lawson, M.

928 - Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling

Lawson, S.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Lawson-Michod, K.

1098 - Estimated Prevalence of β-Thalassemia in the United States in 2023

Lawton, S.

3778 - Daratumumab, Bortezomib and Dexamethasone for Previously Treated Myeloma – Comparing Real-World Outcomes in England to the Castor Phase III Clinical Trial

Laxe, S.

787 - Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project
3510 - Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Layman, H.

4854 - Multiplexed Cytokine Assessment of T- and NK-Cell Responses to Tumor Cells: Parallel Assessment of Biomarkers Associated with Efficacy, Safety, and Persistence

Layshe, N.

3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Layton, D. M.

2497 - Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease

Layton Lesmana, H.

1082 - A Novel GATA1 (E200K) Germline Mutation Causing Hydrops Fetalis with Spontaneous Resolution of Erythropoiesis

Lazana, I.

2155 - Low Dose Post-Transplant Cyclophosphamide in Combination with Alemtuzumab As Gvhd-Prophylaxis Is Associated with Improved Outcomes and Safe Side Effect Profile in HLA-Mismatched Unrelated Transplantation

Lazar, A. J.

1059 - Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Lazar, H.

553 - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)

Lazar, S.

2609 - Inflammasome Cytokine Secretion in Heparin-Induced Thrombocytopenia Is Supported By Platelet-Derived Mediators and Complement

Lazareth, A.

4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Lazarevic, V.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Lazarian, G.

758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Lazaro, E.

979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)

Lazaro, H.

182 - An Important Role for P-Selectin in Thrombotic Microangiopathy
184 - HDL and HDL-Mimetic Nanoparticles Prevent Induced TTP and Interrupt the Course of Ongoing Episodes of the Disease
3864 - Erythrocytes from Sickle Cell Mice Activate the Endothelium and Blood Cells and Induce Vaso-Occlusion When Transfused into ADAMTS13-Deficient Mice: Role of Lipid Degradation

Lazarro, E.

4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Lazarus, H. M.

779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Lazaryan, A.

2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Lazo-Langner, A.

4007 - Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

Lazorchak, A. S.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Lazowski, A.

3962 - Dietary Tryptophan Contributes to Indoleamine 2,3-Dioxygenase 1(IDO-1)-Mediated Cancer-Associated Venous Thrombogenicity in Mice

Lazrak, A.

501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity

Lazris, D.

2596 - Glycoprotein 1bM Assay and Von Willebrand Disease: A Change in Diagnosis

Lazzari, L.

2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Lazzaro, A.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
5169 - Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Lazzaro, A.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Lazzaroni, F.

2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

Lazzarotto, D.

274 - Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Le, A. K.

3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Le, A.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Le, B.

2323 - Co-Morbidities Associated with Depression and Anxiety in Older Patients with Hemophilia

Le Bourgeois, A.

1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy
2137 - Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin
3506 - Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor
4882 - Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Le Bousse-Kerdilès, M. C.

4516 - Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Le Bras, E.

1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Le Bras, F.

3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry

Le Bris, Y.

4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Le, B.

1173.1 - Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients

Le Calloch, R.

745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Le Camus, C.

719 - Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial

Le, C. C.

3428 - Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Le Clech, L.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Le Corvoiser, P.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients

le Coutre, P.

475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Le, D. T.

4345 - Impact of a Functional NKG2D Genetic Variant on Lymphoma Susceptibility and NK Cell Immune Response to Epstein Barr Virus

Le Du, K.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Le Du, K.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Le, D.

4045 - Dnmt3a and Tet2-Driven Clonal Hematopoiesis Have Opposing Effects on the Pathogenesis of Alzheimer’s Disease

Le Gac, F.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Le Gal, G.

815 - Long-Term Outcomes of Patients with Isolated Sub-Segmental Pulmonary Embolism Managed without Anticoagulant Therapy
1249 - Characterizing Diagnostic Investigations for Suspected Pulmonary Embolism in Postpartum Individuals
4007 - Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

Le Gall, J. B.

3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Le Garff-Tavernier, M.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Le Gouill, S.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Le, H.

4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy

Le, H. H.

2392 - Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
5170b - Real-World Step-up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database

Le, H.

2234 - Self-Supervised Learning Based Characterization of Bone Marrow Biopsies for Enhanced Diagnosis of Hematologic Disorders
3916 - Self-Supervised Learning Model Accurately Diagnoses Hemophagocytic Lymphohistiocytosis from Histology Images

Le, J.

3998 - Streptococcus Gordonii Binds VWF Via Its Sialoglycan-Binding Adhesins Under Shear to Initiate Infective Endocarditis

Le, K.

2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Le, K.

4755 - Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) – the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Le, L. H.

4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Le Maitre, A.

4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Le Marchand, L.

4703 - The Impact of Lifestyle Factors and Occupational Exposure on Multiple Myeloma Risk in the Multiethnic Cohort Study

Le, M. S.

2556 - Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Le, M. K.

Le Nguyen, H. T.

4905 - Abatacept and Post Transplant Cyclophosphamide Based Regimen for Graft Versus Host Disease Prevention in High-Risk Stem Cell Transplantation from Unrelated Donor Is Safe and Feasible, with Low Non- Relapse Mortality

Le Noir, S.

2964 - Aberrant Isotype Class Switch Recombination Reactivation Leads to a Genome Wide Genomic Instability in Follicular Lymphoma

Le, P. Q.

293 - Biomarkers of Hemolysis, Hemostasis, and Endothelial Activation Are Associated with Clinical Outcomes in Children with Sickle Cell Disease: An 8-Year Prospective Study

Le Pogam, A.

4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Le, R.

2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome

Le, S.

3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Le, T.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Le Toumelin-Braizat, G.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Le Van Kim, C.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies

Le van kim, C.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

le-Gall, M.

2455 - Comprehensive Analysis of Changes in the Proteome during Maturation of Nascent Human Bone Marrow Reticulocytes into Red Cells

Leach, C.

1380 - Ex-Vivo Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Acute Myeloid Leukemia
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

Leach, S.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Leadbetter, J.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Leader, A.

15 - Non-Driver Genomic Alterations and Venous Thromboembolism in Myeloproliferative Neoplasms
1261 - Venous Thromboembolism Incidence in Patients with Cancer and Factor XI Deficiency
1762 - Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner
2263 - Retrieval Augmented Generation for the Detection of Major Bleeding Events in the Electronic Health Record
2625 - Peri-Procedural Anticoagulation Interruption in Acute Cancer Associated Thrombosis
2632 - Bleeding in Lung Cancer Patients Receiving Therapeutic Anticoagulation While Being Treated with VEGF and EGFR Inhibitors
- Management of Anticoagulation in Patients With Brain Metastasis

Leader, A.

816 - Comparison of Anticoagulants in the Prevention of Arterial Thromboembolism in Patients with Cancer and Venous Thromboembolism: A Population-Based Cohort Study
1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Leaf, R. K.

- Porphyria Cutanea Tarda: A Unique Iron-Related Disorder

Leahy, J.

2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
4191.1 - Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia

Leahy, L.

467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, in Patients with Non-Hodgkin’s Lymphoma
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Leahy, T. P.

1525 - Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Leaker, M.

3824 - Communication Training in Pediatric Hematology/Oncology: A Canadian National Needs Assessment

Leal, A. D.

2802 - Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings

Leal, A.

3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Lean, Y.

2399 - Assessing the Relationship between Self-Efficacy and Mental Health Amongst Patients Undergoing Hematopoietic Stem Cell Transplant

Leardini, D.

3499 - Antibiotic Resistance Genes Peak before Hematopoietic Stem Cell Transplant in Pediatric Blood Cancer Patients
- Biallelic Germline Variants in SH2B3 Cause a Multisystem Developmental Disorder Characterized By a Transient Neonatal Myeloproliferative Disorder, Subsequent Thrombocytosis, and Autoimmune Manifestations in Childhood

Learn, C.

610 - Temporal Association and Risk Window for Secondary Malignancies Post CAR-T
2361 - Venous Thromboembolism Following CAR-T Therapy in Lymphoma Patients - Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS) Database
5102 - Comparative Analysis of Mortality from Serious Adverse Events Associated with CAR-T Therapies

Leather, A.

3496 - Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Leautez, S.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Leavitt, A. D.

1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Lebbe, C.

1915 - Latent Nuclear Antigen Flow-FISH Improves the Detection of Circulating Viroblasts during KSHV/HHV-8-Associated Multicentric Castleman Disease Flares
4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Lebeau, P.

5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis

Lebel, E.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Lebel, E.

1016 - Plasma Cell Specific cfDNA Methylation Patterns Differentiate MGUS, SMM and MM and Predict Biochemical and Clinical Progression to MM

Lebensburger, H.

395 - Identifying Access to Mental Healthcare Services for Pediatric Patients Living with Sickle Cell Disease

Lebensburger, J. D.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
803 - Sickle Cell Genotype and Biomarkers of Endothelial Dysfunction Predict Early Kidney Disease in Patients with APOL1 High Risk Variants
3886 - The Natural History of Glomerular Hyperfiltration in Sickle Cell Disease
- Your Next Job - How to Identify Academic Opportunities with the Best Payback

Leber, B.

2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Leberre, M.

2403 - Key Drivers for Treatment Choice in Lenalidomide-Exposed and Refractory Multiple Myeloma Patients in the Real World. Analysis Conducted in the EU5 Countries and the US

Lebid, A.

3437 - Natural Killer and Gamma Delta T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases
4821 - Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism

LeBlanc, D.

3581 - In Vitro and In Vivo Potency Differences between AAVRh74var and AAV5 Vectors Encoding the Same High-Activity Human Factor IX Variant, FIX-R338L, Expression Cassette: Implications for Hemophilia B Gene Therapy

Leblanc, M.

5069 - How Does Cognition Impact Healthcare Transition Skills, Engagement and Utilization in Young Adults Living with Sickle Cell Disease?

Leblanc, M.

3123.2 - S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Leblanc, R.

1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Leblanc, T.

548 - Adolescents and Young Adults with Secondary Chronic Immune Thrombocytopenia: A Switzerland/France Collaboration Project
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

LeBlanc, T. W.

117 - Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
2330 - Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant
2401 - An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
2422 - Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study
2437 - Perceptions of Treatment Tolerability and Its Relationship to Income in Patients with Hematologic Malignancy: Findings from the Cancer Experience Registry
2855 - Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
3367 - Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
3716 - Barriers to Care Identified and Interventions Provided By Cancer Support Community’s Proactive CAR T Navigation Program: Bridging the Gap in Patient & Caregiver Needs
3762 - The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe
3815 - Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
- Breakout 4: Developing a Palliative Care/Difficult Discussion Curriculum

LeBlanc, Z.

5088 - Role of Social Determinants of Health on Infection-Related Hospitalizations in Pediatric Hematopoietic Stem Cell Transplant Patients within the First 100 Days Post-Transplant in an Underserved State

Leblay, N.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Leblebisatan, G.

1191 - Analysis of Durability of Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients with Immune Thrombocytopenia

LeBlond, V.

4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Leboeuf, N. R.

321 - Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Lebon, D.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Lebon, D.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Lebras, L.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Lebrecht, D.

1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?

Lebreton, P.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Lecapitaine, A. L.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Lech-Maranda, E.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
3242 - MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Lechman, E. R.

946 - Modeling Clonal Hematopoiesis Due to Chromosome 13q Deletion in Human Hematopoietic Stem Cells

Lechner, A.

2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Lechner, K.

644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Lechowicz, M. J.

1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Leclaire, C.

2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment

Leclerc, M.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Lecornec, N.

1329 - Hematological Landscape of Adult Patients with Diamond-Blackfan Anaemia Syndrome (DBAS): Results from the French DBA Cohort
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Lecumberri Villamediana, R.

889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Lederer, C.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Ledesma, C.

2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Ledesma-Carbayo, M. J.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Leduc, M.

2455 - Comprehensive Analysis of Changes in the Proteome during Maturation of Nascent Human Bone Marrow Reticulocytes into Red Cells

Ledwith, B.

1396 - A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)

Lee, A.

5185 - Living with CML: A Qualitative Analysis

Lee, A. I.

18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
2319 - Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
- Adult Classical Hematology
- Wellness

Lee, A.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Lee, B. H.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Lee, B. J.

1517 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia
4908 - Final Results of a Prospective Observational Study Using Budesonide, Added to Ptcy-Based Gvhd Prophylaxis, for Prevention of Acute GI Gvhd after Allogeneic Transplantation

Lee, B. H.

126 - NT-I7, a Long-Acting Interleukin-7 Molecule, Promotes T Cell Reconstitution Following Radiation Injury through Thymic-Dependent and Independent Pathways

Lee, C.

4059 - Transcriptomic Analysis of Clonal Hematopoiesis in Non-Small Cell Lung Carcinoma Unveils a Tumorigenic and Dysregulated Immune Profile

Lee, C.

469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Lee, C.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Lee, C. J.

470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4900 - Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4780.1 - Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Lee, C.

855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

Lee, C.

4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Lee, C. Y.

87 - Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity

Lee, C. Y.

4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Lee, C. H.

3553 - Impact of Early Antibiotic De-Escalation on Mortality in Febrile Neutropenia in Patients with Hematologic Malignancy Receiving Treatment: A Meta-Analysis

Lee, C. R.

3921 - Navigating Lineage Options: A Data-Driven Quest to Uncover T Cell Fate Decision Trajectories

Lee, C. Y.

831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma
1431 - Premature Immune Aging in Survivors of Childhood Hematologic Malignancies
4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Lee, C.

4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Lee, D.

2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Lee, D.

96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Lee, D. J.

1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Lee, D. A.

329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity

Lee, D.

2267 - Toxicity Outcomes in Phase 1 Lymphoma Trials: Variable Reporting with High Use of Minimising Language in Published Abstracts at International Conferences
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1^st FLOR Study
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
5139 - Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language

Lee, D.

5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Lee, D. Y.

4468 - A Comparative Study of [¹⁸f]FDG PET and MRI for Evaluating Treatment Response in Primary CNS Lymphoma Patients Undergoing High-Dose Methotrexate Therapy

Lee, D.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Lee, E. C. Y.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lee, E.

77 - Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

Lee, G.

1448 - Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience
3460 - Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy

Lee, G. M.

2605 - Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)

Lee, G. W.

1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Lee, G. W.

3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07

Lee, H.

775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients

Lee, H.

3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Lee, H.

2104 - Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide

Lee, H. J.

1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Lee, H. C.

767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Lee, H. J.

4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, H. H.

1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Lee, H. J.

2617 - Can Machine Learning Supplant the Plasmic Score in Improving the Early Diagnosis of Thrombotic Thrombocytopenic Purpura?

Lee, H. S.

2678 - Chemotherapy-Induced Bone Defects Stem from Skeletal Progenitor Dysfunction

Lee, H. S.

4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, H.

591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Lee, H.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Lee, H. G.

4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Lee, H.

2209 - Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer

Lee, H.

668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma

Lee, H. Y.

150 - Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery System

Lee, H. P.

1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Lee, H. J.

458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
611 - Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3045 - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Lee, H.

4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Lee, H. J.

3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07

Lee, I. Y.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Lee, J. H.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, J.

1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Lee, J.

632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
4125 - Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Lee, J.

2654 - Murine Model of Bloom Syndrome Demonstrates Radiation Survivability Altered By Gut Microbiota

Lee, J. J.

2782 - ATR Inhibition and Replication Stress Converge on a BCL6-Mediated Reversal of the Dark Zone Signature in DLBCL

Lee, J. S.

279 - Health Equity Impacts of Funding Emicizumab in People with Severe Hemophilia a in the US: An Aggregate Distributional Cost-Effectiveness Analysis
3699 - Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database
5078 - Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Lee, J. B.

4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Lee, J.

4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Lee, J. H.

1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Lee, J. H.

2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Lee, J.

3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Lee, J. S.

668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma

Lee, J. H.

3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Lee, J. O.

1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Lee, J.

4229 - Comprehensive Genomic Profiling (CGP) of Acute Lymphoblastic Leukemias with Foundation One Heme Identifies Actionable Genomic Alterations and Biomarkers

Lee, J. H.

21 - “Platelet Fatigue” during Cold Storage
1269 - Reduction of Lactate Production By Phospholipase C Inhibition in Cold Stored Platelets

Lee, J. H.

1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
2057 - Tumor-Primed CD3⁺CD56⁺natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, J. Y.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Lee, J. W.

1354 - AML Stem Cell Clearance By Inhibiting Selenoprotein Biosynthesis That Causes Cgas-Sting Activation and Ferroptosis

Lee, J.

4768 - Human Lung Organoid Model of Bronchiolitis Obliterans Syndrome Following Hematopoietic Cell Transplantation

Lee, J. Y.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lee, J.

3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Lee, J. S.

388 - Evaluating the Comprehensive Geriatric Assessment Model As an Assessment Tool to Predict Chemotoxicity in Elderly Patients with Lymphoma
3004 - Spatial-Resolved Transcriptomics Reveals Immune Landscape Variations in Primary Central Nervous System Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)
3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies
3660 - Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity

Lee, J.

772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Lee, J.

4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Lee, J. H.

3604 - Development of a Personalized Microfluidic Platform for Improving Treatment Efficiency in Multiple Myeloma

Lee, J. W.

1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Lee, J. M.

1468 - Measurable Residual Disease in Adult B Lymphoblastic Leukemia: A Study of Concordance between Multiparametric Flow Cytometry, Next-Generation Sequencing of Immunoglobulin Gene Rearrangements, and Quantitative PCR

Lee, J.

2723 - AML Cells Have Increased Mitochondrial RNA Degradation and Inhibiting This Degradation Promotes Cell Differentiation, Decreases Viability, and Increases Sensitivity to Immune-Mediated Killing

Lee, J.

4976 - Blood Preservation Workflows for Single Cell Technologies Using Off-the-Shelf Reagents

Lee, J.

2057 - Tumor-Primed CD3⁺CD56⁺natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Lee, J. L.

1375 - ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53-Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Lee, J. Y.

4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)

Lee, J. H.

2616 - Leveraging Generative Artificial Intelligence in Diagnosis of Thrombotic Microangiopathies: Focus on Thrombotic Thrombocytopenic Purpura

Lee, J.

4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, K.

1941 - The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Lee, K. P.

3350 - Role of Tryptophan Metabolizing Enzymes in Multiple Myeloma Survival
3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)
4666 - Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Lee, K.

3265 - Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma

Lee, K.

563 - Compartmentalized Niche and Spatially Heterogenous Inflammatory Landscape Regulate Tet2^+/-- Mediated Clonal Hematopoiesis

Lee, K. J.

1418 - TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL
2761 - M2-like Macrophages Transfer Mitochondria to Acute Myeloid Leukaemia Cells Via Tunnelling Nanotubes Promoting Therapy Resistance

Lee, K. S.

3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study

Lee, K. H.

4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Lee, L. H.

2612 - Dilute Russel Viper Venom Time (DRVVT) Ratio Predicts the Identification of Triple Positive Antiphospholipid Antibody Profile

Lee, L. W.

2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Lee, L.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Lee, L.

10 - In a Mouse Model of β-Thalassemia Intermedia Pregnancy, Maternal Iron Overload and Anemia Adversely Impact Fetal Development Regardless of Fetal Genotype

Lee, L.

5078 - Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Lee, L.

3699 - Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database

Lee, L. S.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Lee, M.

2482 - Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Lee, M. H.

246 - Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression
3188 - Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
4560 - Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms

Lee, M. J.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Lee, M. G.

668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma

Lee, M. Y.

2315 - Risk of Hematologic Malignancies in Patients with Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study

Lee, M. W.

3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07
3557 - The Expression of TIM3 on Marrow-Infiltrating T Cells Is Increased in Patients with Blood Cancers Who Relapse Early after Hematopoietic Stem Cell Transplantation
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, N.

2315 - Risk of Hematologic Malignancies in Patients with Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study

Lee, Jr., N.

3190 - DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha
4558 - Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera
4568 - Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Lee, N. C.

439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study

Lee, N.

501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity

Lee, N.

3962 - Dietary Tryptophan Contributes to Indoleamine 2,3-Dioxygenase 1(IDO-1)-Mediated Cancer-Associated Venous Thrombogenicity in Mice

Lee, P.

1796 - Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Lee, R.

4719 - Genome-Wide Association Study Identifies Novel Loci Associated with Survival in Multiple Myeloma

Lee, R. X.

1416 - A Combinatorial Functional Precision Medicine Platform to Evaluate Immunotherapy-Based Combinations in Non-Hodkin Lymphoma

Lee, S.

3432 - Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes

Lee, S. M.

4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, S. W.

3557 - The Expression of TIM3 on Marrow-Infiltrating T Cells Is Increased in Patients with Blood Cancers Who Relapse Early after Hematopoietic Stem Cell Transplantation

Lee, S. W.

1659 - Prognostic Analysis of Colorectal Extranodal Marginal Zone Lymphoma of MALT Type: Clinical Outcomes and Implications
4468 - A Comparative Study of [¹⁸f]FDG PET and MRI for Evaluating Treatment Response in Primary CNS Lymphoma Patients Undergoing High-Dose Methotrexate Therapy

Lee, S.

726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Lee, S.

828 - CCRL2 As a Novel Target in Acute Erythroid Leukemia

Lee, S.

4039 - Transcription Factor Networks Disproportionately Enrich for Heritability of Blood Cell Phenotypes

Lee, S.

2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Lee, S.

1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Lee, S. H.

64 - Deciphering the AML Niche: RNA Sequencing and Spatial Transcriptomics Reveal Diverse Transcriptomic Landscapes in Responders Vs. Non-Responders
754 - Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Lee, S.

1468 - Measurable Residual Disease in Adult B Lymphoblastic Leukemia: A Study of Concordance between Multiparametric Flow Cytometry, Next-Generation Sequencing of Immunoglobulin Gene Rearrangements, and Quantitative PCR
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

Lee, S. B.

3604 - Development of a Personalized Microfluidic Platform for Improving Treatment Efficiency in Multiple Myeloma

Lee, S. T.

1738 - Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
3025 - Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Lee, S. Y.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Lee, S.

1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Lee, S.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Lee, S. H.

4192 - Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Lee, S.

3089 - Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older

Lee, S.

2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Lee, S. H.

4755 - Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) – the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Lee, S.

2327 - Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden

Lee, S. C.

344 - MDS-Associated SF3B1 Mutations Promote Aberrant Hematopoietic Cell Fate Choice By Disrupting Mediator Kinase Module Component CDK8
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Lee, S.

692 - Immunopeptidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
2149 - Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease: First Pre-Planned Interim Analysis of a Randomized Trial
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Lee, S.

659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Lee, S. J.

98 - Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study
688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study
2330 - Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Lee, S. J.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Lee, S. E.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
1799 - Ropeginterferon in Low-Risk Patients with Polycythemia Vera
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3170 - Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

Lee, S. T.

4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1^st FLOR Study
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Lee, T.

2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse

Lee, T.

503 - Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Lee, W.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma

Lee, W. S.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Lee, Y.

3652 - Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Lee, Y. J.

1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)

Lee, Y.

2218 - SCA-AD, a Novel Method to Uniformly Identify Cells across Single-Cell RNA Sequencing Datasets, Applied to Adult and Pediatric Self-Renewing AML Cells

Lee, Y.

1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Lee, Y. C.

701 - Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis

Lee, Y. Y.

1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Lee, Y.

2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease

Lee, Y.

4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lee, Y.

4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Lee, Y.

2209 - Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer

Lee, Z.

2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lee-Miller, C. A.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Lee-Six, H.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Lee-Sundlov, M. M.

2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Lee-Sundlov, M. M.

3952 - Serum O-Glycan Antigenicity in Pediatric Immune Thrombocytopenia Predicts Disease Persistence

Leebeek, F. W.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd
3578 - Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B
- The Promise of Gene Therapy for Severe Hemophilia A

Leedom, T.

916 - W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Lees, H.

637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment

Leesang, T.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Lefebure, M.

1873 - Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax–Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
3237 - CRISTALLO: Results from a Phase III Trial of Venetoclax–Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine–Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Lefebvre, T.

1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Lefèvre, N.

293 - Biomarkers of Hemolysis, Hemostasis, and Endothelial Activation Are Associated with Clinical Outcomes in Children with Sickle Cell Disease: An 8-Year Prospective Study

Legarff, M.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Legendre, C.

3274 - Comprehensive Assessment of Immunoglobulin Translocation Detection in Multiple Myeloma By Whole Genome Sequencing

Legendre, H.

3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Legenne, P.

2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Leger, K.

116 - Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Leger, R. R.

1242 - Ticagrelor Interference in the Serotonin-Release Assay

Legg, A.

55 - A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Legg, S. R.

905 - Donor XCR1⁺ and CD11b⁺ Dendritic Cells Determine the Severity of Th1 and Th17-Dependent Acute Gvhd within the Gastrointestinal Tract

Legge, S. E.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Legiec, W. M.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Leglise, C.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Legrand, F.

4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Legrand, O.

478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Legros, L.

478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
4516 - Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms

Legscha, K. J. J.

2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8⁺ T Cells: Implication for Cancer Cellular Therapy
3444 - Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex

Leguay, F.

827 - Targeting Mitochondrial Metabolism to Promote Viral Mimicry and Type I Interferon Response in Acute Myeloid Leukemia

Leguay, T.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Lehander, M.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis

Lehigh, P.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease

Lehman, S.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Lehmann, L. E.

3574 - Gene Therapy for Sickle Cell Disease Is Associated with a Decreased Transplant Length of Stay and Similar Rates of Short-Term Complications Compared to Allogeneic Matched Sibling Stem Cell Transplant: A Single Center Experience

Lehmann, S.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Lehmann, T.

1764 - Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms
2413 - Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax + HMA – Insights from a Prospective Real-World Study in Switzerland and Austria

Lehners, M.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia

Lehnertz, B.

3471 - Development of a UM171-Supported, CD33 Epitope-Engineered Blood Stem Cell Graft for Advanced AML Therapies

Lehotzky, D.

61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Lehtiö, J.

1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Lei, B.

4972 - Analytical Validation of a Next-Generation Sequencing Assay for Detecting Minimal Residual Disease in Lymphoid Malignancies

Lei, B.

2038 - Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 Eradicate Antigen-Heterogeneous Multiple Myeloma, Address Antigen Escape and Enhance Expansion

Lei, H.

1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study

Lei, K.

915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Lei, L.

3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Lei, M.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Lei, N.

2037 - Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia

Lei, T.

2996 - Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lei, W.

2087 - Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Lei, X.

2899 - A Multicenter Clinical Study of Cccg - APL-2017 in the Treatment of Children with Acute Promyelocytic Leukemia

Lei, X.

786 - Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Lei, Y.

3927 - Identification of Megakaryocytes As a Functional Component of Circulation Blood

Lei, Y.

1119 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States: National Inpatient Data Base Study from 2012-2020
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States

Leib, G.

76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Leiba, M.

3288 - Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

Leiba, R.

4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Leick, M. B.

2025 - Novel CD2-Targeting Trispecific Immune Effector Cell Engager (TRIEC) Coupled with CD19 CAR-T Overcomes Resistant B-Cell Lymphoma

Leiding, J. W.

3489 - Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study
3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis

Leidy, S.

2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Leifer, E.

695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Leighton, J. S.

61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Leighton, J. C.

2386 - Impact of Protein Energy Malnutrition on Hospitalized Patients with Multiple Myeloma: A United States Population-Based Cohort Study

Leiken, M. D.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Leilich, M.

1392 - Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Leip, E.

4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Leiro, M.

3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect

Leis, J. F.

1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
3252 - Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors

Leisch, M.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Leisenring, W. M.

2146 - CMV Specific T Cell Polyfunctionality after HCT: A Detailed Analysis of the Impact of Steroid Exposure, Immunosuppressive Regimens and Viral Reactivation

Leiser, R.

2590 - Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B

Leister, J.

795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate

Leitch, C.

2062 - Vididencel, a Leukemia-Derived Dendritic Cell Vaccine, Acts Synergistically with Azacitidine/Venetoclax Treatment in a Preclinical AML Model

Leitch, H. A.

4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Leitch, S.

1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
4752 - Carfilzomib-Based Induction in Untreated Myeloma with Carfilzomib Post-Transplant Consolidation (KIWI): An Investigator-Initiated Phase II Trial

Leite, T.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
2114 - Assessing Risk of Infectious Episodes in Patients Post Hematopoietic Stem Cell Transplantation Using Pre-Transplant Baseline Colonization Screening

Leitinger, N.

- Heme and Macrophage Metabolism.

Leiva, O.

246 - Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression
3188 - Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms

Leivas, A.

3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
3442 - CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Lejeune, C.

1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Lejman, M.

1462 - Chromothripsis Is Enriched at Relapse of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia and Cooccurs with Loss of Function of TP53 and RB1 Genes

Lek, M.

4054 - Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

Lekah, E.

4887 - Hemorrhagic Cystitis after Allogeneic or Autologous Hematopoietic Cell Transplantation in Pediatric Patients: Continuous Versus Intermittent Mesna

Lekakis, L. J.

337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma

Lekakis, M.

829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Lelas, A.

2337 - Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

Leleu, X.

770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
4721 - Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis

Leleu, X.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Lely, T. A.

129 - Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)

Lemaire, P.

4316 - Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Lemarie, K.

351 - Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Lemarquis, A. L. L.

637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment

Lemarquis, A. L. L.

501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation

Lemasle, E.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Lembo, P.

5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Lemech, C.

1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Lemecha Shukare, M.

3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Lemgart, V.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Lemieux, B.

3620 - Feasibility, Safety and Effectiveness of Intranasal Fentanyl in the Treatment of Acute Pain Episodes Among Adults with Sickle Cell Disease: A Retrospective Single Center Study

Lemieux, C.

778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Lemieux, M.

43 - The Follicular Lymphoma and Chronic Lymphocytic Leukemia Proliferative Microenvironment at Single-Cell Resolution

Lemmens, K.

2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Lemmon, V. P.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Lemoal, G.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Lemoine, J.

504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Lemoli, R. M.

245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
1471 - Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2893 - Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
4239 - Excellent Outcome in NPM1-mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Lemonnier, F.

1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Lenard, A.

725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia

Lenart, A. W.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
2992 - Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics
4453 - Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Lendvai, N.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Leng, F.

3252 - Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors

Leng, J.

4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Leng, Q.

1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Leng, S.

3016 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study
3722 - Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
1875.2 - Nemtabrutinib Versus Ibrutinib or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The Phase 3, Open-Label, Randomized Bellwave-011 Study

Leng, S.

1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
3738 - Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events

Lengerke, C.

49 - MRC2+ AML Stem Cells Reveal the Role of Proline Metabolism in Venetoclax Resistance
417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia
419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia
1353 - Characterization of a Human Bone Marrow-Derived CRISPR/Cas9 Cell Model for Chronic Myeloid Leukemia
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4464 - Primary Vitreoretinal Lymphoma: A Comprehensive Retrospective Analysis of 65 Cases at Two European Centers
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Lengil, T.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Lengline, E.

2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission

Lenhart, D.

623 - Targeted Induction of Hepatocyte Nuclear Factor 4α Protects Acute Kidney Injury By Upregulating Hemopexin Biosynthesis during Acute Hemolytic Events in Sickle Mice

Lenhart, S. C.

623 - Targeted Induction of Hepatocyte Nuclear Factor 4α Protects Acute Kidney Injury By Upregulating Hemopexin Biosynthesis during Acute Hemolytic Events in Sickle Mice
624 - Heme-Mediated Tau Phosphorylation Is Critical for Neuroaxonal Damage and Cognitive Impairment in Sickle Cell Disease

Lenk, L.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Lennox, A.

4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Lenoir, W. F.

4970 - Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein Interaction Methodology

Lentz, R. A.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Lentz, S. R.

551 - Impaired Platelet Function in Ehlers–Danlos Syndrome: Insights from Human Subjects and a Murine Model

Lentzsch, S.

256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
360 - Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis
1914 - Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial
1929 - Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study
1936 - Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Lenz, G.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
2177 - Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) – Treatment Options and Outcomes at a Large AML Referral Center
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Lenz, G.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Leon, A.

2255 - Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study

Leon, C.

2140 - Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease

Leon, S.

1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma

Leon Triana, O.

3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Leonard, A. K.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease
5067 - Kidney Outcomes after Hematopoietic Cell Transplantation in Children and Young Adults with Sickle Cell Disease
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Leonard, D.

5058 - Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia

Leonard, J. T.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Leonard, J. P.

110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma
1693 - Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Leonard, R.

4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Leonardi, G.

2610 - Exploration of Purinergic Signaling Pathways As a Mechanism of Platelet Activation in Antiphospholipid Syndrome

Leonardo, F. C.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies

Leoncin, M.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
274 - Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Leone, G.

4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Leone, G.

1763 - Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

Leone, S.

1809 - A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

Leonetti Crescenzi, S.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Leong, D. P.

703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Leong, R.

4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Leong, T.

1072 - Mechanics of Spectrin As a Stiff Polymer

Leong, W. Z.

1354 - AML Stem Cell Clearance By Inhibiting Selenoprotein Biosynthesis That Causes Cgas-Sting Activation and Ferroptosis

Leongamornlert, D.

1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT

Leoni, A.

4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Leoni, C.

2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level

Leoni, M.

214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias

Leoni, S.

1069 - Evaluating the Clinical Impact of Hemoglobinopathy and Hereditary Red Blood Cell Disorder Co-Inheritance in a Cohort of 315 Patients
3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Leonowens, C.

980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Leotta, M.

3975 - Management and Outcomes of Pregnancy and Childbirth in Known and Unknown Hemophilia Carriers: 10 Years Retrospective Evaluation from Southern Italy

Leow, C. C.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

LePage, N.

4689 - The Disproportional Burden of Multiple Myeloma

Lepic, K.

3822 - Development of an Electronic Learning Module for CAR-T Education in Canadian Hematology Residents

Lepic, K. L.

2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Leporace, A. P.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study

Leporace, A.

4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Leppä, A. M.

1292 - Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A^R882- Mutant Hematopoietic Stem Cells

Leppä, S.

237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Leppä, S.

342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Lepretre, S.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Leprevost, F.

203 - ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell MYB Enhancer in the T-Cell Leukemia Context

LeQuellec, S.

3578 - Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Lerch, K.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Lerner, D.

2698 - Higher Graft Failure after Haploidentical in Comparison to Matched Related and Unrelated Stem Cell Transplantation for Severe Aplastic Anemia: A Single-Center Retrospective Study

Lerner, I.

3904 - Circulating Erythroblasts Are Associated with Specific Characteristics in Adult Patients with Sickle Cell Disease: The Drepablast Study

Lerner, J.

3084 - The Role of Intensive Chemotherapy and Radiotherapy in Plasmablastic Lymphoma: Optimizing Survival Outcomes

Leroy-Carita, F.

4757.2 - Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Lerro, C.

2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity

Lerro, C. C.

3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome

Lesan, V.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Leshchenko, V. V.

1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance

Leshchiner, I.

926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Lesley, R.

341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
2794 - Exposure-Response Analysis and Quantitative Systems Pharmacology Modeling for Optimal RP2D Selection of AZD0486 in Follicular Lymphoma Patients

Leslie, C.

234 - A Single-Cell Atlas of Classical Mantle Cell Lymphoma Reveals Paired Tumor-Immune Malignant States Correlating with Prognosis

Leslie, L. A.

340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
4367 - Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Leslie, L. A.

864 - 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Lesniewski, L.

- Age-Related Endothelial Function

Lesokhin, A. M.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4732 - Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Lesperance, J.

4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Lesprit, E.

1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Lessen, D. S.

337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study

Lessi, F.

1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Lestang, E.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Lester, S. C.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Lester, W.

4005 - The Quest for Effective and Well-Tolerated Treatment for Congenital TTP: Half a Century of Experience in the United Kingdom

Letai, A. G.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Letailleur, V.

3506 - Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Letestu, R.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Letestu, R.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Lethagen, S.

714 - Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study

Lethebe, B. C.

554 - Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Letouzé, E.

4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Letovsky, S.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Letson, C.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1

Leuenberger, G.

2203 - High-Throughput Drug Repurposing Identifies SN-38 As a Potent Inhibitor of AML with Synergistic Effects in Combination with PARP and BCL-2 Inhibitors for Treating KMT2A-Rearranged Leukemias

Leukam, M.

4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Leung, A. Y.

1399 - Inhibition of Threonine Tyrosine Kinase Suppressed TP53-mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway
1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
1569 - Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia
2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML
2763 - HPK1 Inhibition and Venetoclax Combination Suppressed AML By Enhancing Cytotoxic T-Cell Response to Leukaemia
3603 - In Vitro Drug Profiling to Guide Treatment for Relapse/Refractory AML

Leung, E. W.

4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Leung, E.

4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Leung, E. H.

2 - Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging

Leung, G. M.

3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Leung, K. T.

1545 - Single-Cell Transcriptomic Analyses Reveal Distinctive Immune Features between Childhood and Adult Acute Myeloid Leukemia

Leung, K.

4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)

Leung, K.

3192 - TET1 Drives Myelodysplastic Syndromes and Represents a Promising Therapeutic Target

Leung, M. K. G.

1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
1796 - Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Leung, N.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Leung, R. Y.

2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1

Leung, S. Y.

1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML
2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML

Leung, W.

577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Leung, W.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies
4941 - Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR_αβ-Depleted Haplo-HSCT

Leutner, M.

2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Leval, A.

2255 - Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study

Levato, L.

3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Levavi, H.

1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia
4230 - Predictors of Survival in Core Binding Factor Acute Myeloid Leukemia: An Analysis of the National Cancer Database
5182 - Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis

Leveille, E.

632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
976 - Metabolic Determinants of Ferroptosis in B-Cell Lymphoma
1412 - Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma

Levenga, H.

1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Levent, A.

3709 - Inhibitors Significantly Impair Quality of Life for Hemophilia a Patients
5107 - Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US

Leventaki, V.

2999 - NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK+ Anaplastic Large Cell Lymphoma

Leveque, E.

4353 - Clonal Dominance in Follicular Lymphoma: A Predictor of Poor Prognosis and Histological Transformation
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Leverger, G.

548 - Adolescents and Young Adults with Secondary Chronic Immune Thrombocytopenia: A Switzerland/France Collaboration Project
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Levesque, J. P.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia
1286 - Endothelial Protein C Receptor CD201 Enables Identification of Transplantable Mouse Hematopoietic Stem Cells in Inflammatory Conditions Unlike SCA1

Levi, T.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Levin, M. D.

586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3330 - Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma
3371 - Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)
4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
4739 - Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma – Long-Term Follow-up of the HOVON 143 Trial

Levin-Furtney, S.

826 - REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML

Levine, A. M.

2976 - HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors

Levine, A.

4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Levine, B.

588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
2051 - Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy
3473 - In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing
- Consequences of Engineered Eﬀector Cell Therapies

Levine, C.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

Levine, J.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Levine, K.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Levine, N.

1231 - Platelet Factor 4 Enhances Endothelial Cell Antimicrobial Activity in Vitro and Promotes Bacterial Clearance In Vivo, Improving Sepsis Outcomes

Levine, R. M.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease

Levine, R. L.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
823 - Crebbp Inhibition Potentiates JAK2 Inhibition in Post-MPN Acute Myeloid Leukemia
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse
2712 - TET2 and TP53 Mutations Cooperate in Leukemia Development and Modulate the Response to Inflammation
2713 - Codon-Specific Differences in RAS Mutations in AML and Differential Response to Therapeutic Agents
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Levings, M.

- Heterogeneity of Cells in Transplantation

Levinson, A. L.

1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo

Levinte, D.

3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Levis, M. J.

213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
2436 - The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
4278 - Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Levitan, B. S.

1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Levitsky, H.

3437 - Natural Killer and Gamma Delta T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases
4820 - Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy

Levitz, D.

3152 - Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Levrat, E.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Levy, C.

1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria

Levy, J. H.

4026.1 - Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Cardiac Surgery Patients: Protocol Update for an Ongoing Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study

Levy, J.

3642 - Impact of Rapid Latex Immunoassay (LIA) Implementation on Management of Heparin Induced Thrombocytopenia (HIT): A Retrospective Single Institution Study

Levy, M.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
2470 - Osteoblast-Derived Erythroferrone Regulates Stress Erythropoiesis

Levy, M.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Levy, M. Y.

479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)
3700 - Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results
4632 - Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Levy, M. Y.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)

Levy, P. S.

3637 - Standardized Approach to Peri-Operative and Peri-Procedural Chemical Venous-Thromboembolism Prophylaxis

Levy, R.

4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Levy, R. J.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Levy, V.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Levy-Mendelovich, S.

430 - A Novel Murine Model Rebalancing Coagulation Enables Gene Therapy Studies for Severe Protein C Deficiency, a Lethal Pro-Thrombotic Disorder

Lewalle, Sr., P.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Lewalle, P.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
4929 - Return to Work after Allogeneic HSCT: Further Insights in the Patients-Related Predictive Factors (The SOPRALLO Project)

Lewandowski, K.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Lewis, A. R.

784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Lewis, A. M.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
4772 - Mitochondrial Augmentation of Hematopoietic Stem and Progenitor Cells As a New Therapeutic Approach for Myelodysplasia

Lewis, A. M.

2247 - Sleep Health in Children and Adolescent with Sickle Cell Disease
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy

Lewis, C.

3915 - HLH: Time to Transplant; A 10-Year UK Retrospective Cohort Study

Lewis, C. A.

1878 - Ktx-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4;14) Multiple Myeloma Preclinical Models
2205 - Characterization of the Biochemical Activity of Ktx-1001, a Selective Small Molecule NSD2 Inhibitor, in Surface Plasmon Resonance (SPR)
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

Lewis, D. J.

235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Lewis, J.

3788 - Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma

Lewis, J.

301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial

Lewis, J.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms

Lewis, J.

371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
950 - Systematic Evaluation of GAPs and Gefs Identifies ARHGAP45 As a Targetable Leukemia-Specific Dependency

Lewis, J.

3406 - Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia

Lewis, J.

1088 - Young Women with Iron Deficiency Anemia Demonstrate Cerebral Metabolic Stress to Maintain Cerebral Oxygen Metabolism
2220 - Sickle Cell Anemia Impacts Brain Age in Children

Lewis, K. L.

1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Lewis, L. S.

1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Lewis, L. D.

3830 - The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune-Antibody-Mediated Hemolytic Anemia

Lewis, M.

1430 - Increased Environmental Temperature Damages DNA and Is an Emerging Health Risk That Correlates with Rates of Acute Lymphoblastic Leukemia (ALL) in Europe

Lewis, S.

1331 - Outcomes of Germline Genetic Testing in Children with Hematologic Malignancies Undergoing Allogeneic Transplantation
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia

Lewis, V. A.

3464 - Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Lewis, W.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease

Lewis-Gonzalez, J.

2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis

Lewkowitz, A. K.

3707 - Iron Deficiency in Pregnancy Is Ubiquitous

Ley, T. J.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
1333 - Recurrent Amplification of Chromosome 7 in Murine AML with Dnmt3a^R878H and Npm1^cA Mutations Identifies Gab2 As a Possible Therapeutic Target in AML
4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations
4107 - Reduced CBFB Expression Causes Compensatory Upregulation of RUNX1 Expression, Defining a Feedback Loop That May be Relevant for AML Pathogenesis

Leyda, M.

1369 - A Genomics Driven, Inducible Pluripotent Stem Cell Model of Infant Lymphoblastic Leukemia
2710 - Stem Cell Model of Novel RPL30 Variant in Diamond Blackfan Anemia with Downregulated GATA1-HSP70 in Early Erythroid Progenitors

Leypoldt, L.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Leypoldt, L.

3286 - Functional Genomics Studies Decipher the Genetic Perturbations and Unravel Mechanisms of Response/Resistance upon Mutant-Specific KRAS Inhibition in Multiple Myeloma

Leyronnas, C.

892 - Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Lheritier, V.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Lhermitte, L.

4218 - A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Lhomme, F.

4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Lhoumeau, A. C.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Li, A.

1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Li, A. L.

1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients

Li, A. H.

3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Li, A.

5089 - An Evaluation of Andexanet Alfa v. Standard of Care for Reversal of Doac-Induced Intracranial Hemorrhage – a Systematic Review and Meta-Analysis

Li, A. M.

1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Li, A.

13 - Association of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with Incidence of Venous Thromboembolism Varies By Age: The Atherosclerosis Risk in Communities Study
161 - Optimized Multi-Class VTE-BERT Large Language Model for Prediction of Cancer Associated Thrombosis Phenotype
688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study
812 - External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations
1247 - Anticoagulation and Major Bleeding or Recurrent Thrombosis in Patients with Isolated Cancer-Associated Splanchnic Vein Thrombosis: A Multi-Center Cohort Study
2604 - Tissue Kallikrein 1 and Alternative Complement Pathway Activation in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
3633 - Patient-Centered Management of Heavy Menstrual Bleeding on Anticoagulants: An International Survey
3641 - Implementation of Automated Thrombosis and Bleeding Risk Assessment in Cancer Patients Undergoing Systemic Therapy
3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
4013 - Circulating Tumor DNA Predicts Venous Thromboembolism in Minority Patients with Cancers
4017 - Validation of Dynamic Deep Learning for the Prediction of Cancer-Associated Thrombosis
- Transplant Associated TMA: The Conundrum of Diagnosis and Treatment
- Circulating Tumor DNA and Thrombosis in Cancer

Li, A.

1164 - Protein Arginine Methyltransferase 1 Expands and Mobilizes Immune Megakaryocytes and Generates Hyperactive Platelets in Stress Conditions

Li, B.

1415 - Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)

Li, B.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Li, B.

874 - CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis

Li, B.

2871 - Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1-Mutated Myeloid Neoplasms with Less Than 10% Blasts
3193 - Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1^S34F Mutant Myelodysplastic Syndromes
3195 - A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes
4135 - An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Li, B.

836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
958 - KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity
1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
1940 - Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy
1998 - Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Li, B.

503 - Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Li, B.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Li, B.

3467 - The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

Li, C.

1676 - Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era
3036 - Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Li, C.

2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Li, C.

3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Li, C. Y.

2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia

Li, C.

2052 - All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma

Li, C.

2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation

Li, C.

1510 - Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) As an Effective Treatment Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML

Li, C.

4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPA^bZIP-Inf Acute Myeloid Leukemia

Li, C. K.

1545 - Single-Cell Transcriptomic Analyses Reveal Distinctive Immune Features between Childhood and Adult Acute Myeloid Leukemia

Li, C.

594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide

Li, C.

2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)

Li, C.

4941 - Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR_αβ-Depleted Haplo-HSCT

Li, C.

2899 - A Multicenter Clinical Study of Cccg - APL-2017 in the Treatment of Children with Acute Promyelocytic Leukemia

Li, C.

1197 - IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway
2052 - All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma
2888 - A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
3614 - In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells
3993 - Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis
4540 - Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study
4816 - Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature
4847 - mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells
4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Li, C.

498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Li, C.

2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence

Li, C.

2996 - Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Li, D.

4818 - Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Li, D.

2727 - Modulating mRNA Translation Fidelity As a Novel Mechanism for AML Chemoresistance

Li, D.

923 - A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Li, D.

1538 - Optical Genome Mapping As Standard-of-Care in Acute Leukemia: Diagnostic and Clinical Impacts 10 Months Post-Implementation

Li, D.

125 - Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3407 - Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Li, D.

1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Li, D. M.

1968 - Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma

Li, D.

988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Li, E.

316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Li, E.

821 - Bone Marrow Microenvironment Dictates the Progression of Clonal Hematopoiesis through Stromal-Macrophage Cell-Cell Interactions
2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids

Li, F.

1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
1883 - Blockade of Gq Coupled P2Y6 Receptor Inhibited Myeloma Cells Proliferation and Survival Via Suppression of Camkiiγ-NF-Κb Pathway
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3015 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3057 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3465 - Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma
4554 - Revealing the Hidden Impact: Essential Thrombocythemia (ET) and Its Effects on Ocular Blood Vessels through Optical Coherence Tomography Angiography (OCTA) Imaging
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Li, F.

1338 - ENO1 Activity Inhibition Induce Ferroptosis Susceptibility in BCR-ABL TKIs Resistant CML Cells through GPX4 Autophagy Degradation
3244 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China
4624 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
1875.1 - Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Li, F.

1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Li, F.

4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Li, F.

3544 - Chimeric Antigen Receptor T Cell Therapy Bridged to the Second Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Toxicity Conditioning for B-Cell Acute Lymphoblastic Leukemia Relapsed after the First Transplant

Li, F.

3356 - MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Li, F.

3195 - A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Li, G.

3971 - The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients

Li, G.

2127 - Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia
2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Li, G.

1810 - Clonal Dissection of MDS and Secondary AML Resolves Shared Splicing Neoantigens and Mechanistic Underpinnings of Hypomethylating Agent Therapeutic Response

Li, G.

4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Li, G.

1187 - Sirolimus Combined Dexamethasone As the First-Line Therapy for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Open-Label, Prospective, Randomized Controlled Clinical Trial

Li, G.

4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Li, H.

177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2513 - Duffy Status and Hydroxyurea Dosing in Adult Patients with Sickle Cell Disease: A Potential for Iatrogenic Harm?

Li, H.

2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Li, H.

34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia

Li, H.

1579 - Single-Nucleus Transcriptomics of FFPE Specimens from Mucosa-Associated Lymphoid Tissue Lymphoma Patients Reveal Tumor Heterogeneity and Changes in the Tumor Microenvironment during Relapse
4488 - Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

Li, H.

3230 - Aberrant c-AMP Signalling in Richter Syndrome Revealed By Single-Cell Transcriptome and 3D Chromatin Analysis
3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Li, H.

1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)

Li, H.

2145 - Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Li, H.

30 - Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis

Li, H.

567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
3123.2 - S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Li, H.

3087 - A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Li, H.

1757 - A Novel in-Vivo Model of Human Myelofibrosis Based on Transplantation of Thrombopoietin Overexpressing CD34+ Cells into Humanized Bone Marrows in NSG Mice Recapitulates Key Disease Hallmarks
4227 - In Situ Spatial mRNA Analysis Implicates Increased TGFB1 and PDGFA1 Expression As Potential Drivers of Fibrosis in Pediatric Acute Lymphoblastic Leukemia

Li, H. J.

802 - Fertility Preservation Outcomes for People with Ovaries and Sickle Cell Anemia: A Multi-Center Study

Li, H.

559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

Li, H.

663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Li, H.

4145 - Synergistic Effect of EZH2 Inhibitor Dznep and Flavonoid GL-V9 in AML through Inhibition Hells and Induction of DNA Damage

Li, H.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
2660 - Gut Microbiota Promote Chronic Inflammation in Jak2^V617F Mice

Li, H.

3544 - Chimeric Antigen Receptor T Cell Therapy Bridged to the Second Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Toxicity Conditioning for B-Cell Acute Lymphoblastic Leukemia Relapsed after the First Transplant

Li, H.

2474 - TGF-β1 Reverses Hemoglobin Switching in Erythroid Progenitor Cells before Erythropoietin Induction
2553 - Multi-Omics Integration Analysis Identifies Lipoproteins As Biomarkers for Glucocorticoid Response in Immune Thrombocytopenia
3583 - Prophylactic Administration of Glucocorticoids and Tacrolimus in AAV8-F8 Gene Therapy of Severe Haemophilia-a Achieved a Significant Long-Term Efficacy

Li, J.

3271 - The Immune Inhibitory Hematopoietic Adaptor Protein Hacs1(Sly2) Suppresses the Proinflammatory Macrophage Function Contributing to Multiple Myeloma Progression

Li, J.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Li, J.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Li, J.

3230 - Aberrant c-AMP Signalling in Richter Syndrome Revealed By Single-Cell Transcriptome and 3D Chromatin Analysis

Li, J.

3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Li, J.

1723 - Exploration of Rituximab Plus Lenalidomide（R²）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy
4447 - The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma
4490 - Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Li, J.

839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Li, J.

4496 - Preliminary Efficacy of Orelabrutinib Targeted Therapy in Induction Therapy of Primary Central Nervous System Diffuse B-Cell Lymphoma

Li, J.

663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Li, J.

893 - Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study
923 - A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease
1656 - Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study
1728 - Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R²) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study
1978 - Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd
4988 - The De Novo Sequencing of Full-Length Amyloidogenic Light Chain By Peripheral Blood Mass Spectrometry

Li, J.

2705 - PLK1 Acts in Homologous Recombinatorial Repair and in Mitosis As Synthetically Lethal with the Fanconi Anemia/BRCA Pathway

Li, J. M.

4299 - VIP Expression Drives an Immunosuppressive Tumor Microenvironment in TP53-Mutated AML
4964 - Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity

Li, J.

1457 - Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1^plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia
4291 - Prognostic Implications of KMT2A Rearrangements and Partial Tandem Duplications in AML: Outcomes and the Role of Allogeneic Hematopoietic Cell Transplantation

Li, J. Y.

2051 - Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Li, J.

2898 - Venetoclax Plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for Elderly or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia: A Multicenter, Prospective Study

Li, J.

2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail

Li, J.

576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1501 - Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Unrelated Umbilical Cord Blood Stem Cell Microtransplantation and IL-2 Treatment in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
1549 - Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia
1610 - Rwtc-Mbta Vaccine Induces Potent Immune Responses Against Central Nervous System Lymphoma
1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
1793 - Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R^T618I: A Multi-Centre Retrospective Study
1902 - Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma
2033 - Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy
2702 - Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
3036 - Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies
3244 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
4378 - Role and Mechanisms Exploration of Histamine and Its Receptors in the Progression of Peripheral T-Cell Lymphoma
4612 - Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor
4627 - Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study
4822 - LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Li, J.

538 - Polycomb Repressive Complex 2 Regulates Differentiation-Stage-Specific Autophagy Gene Expression and Safeguards Normal Erythropoiesis

Li, J.

1732 - Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Li, J.

1188 - Efficacy of Combined Herombopag and Recombinant Human Thrombopoietin Therapy Compared to Monotherapy on Platelet Engraftment after Autologous Hematopoietic Stem Cell Transplantation in Patients
1192 - Efficacy and Safety of Mesenchymal Stem Cells in Improving Thrombocytopenia after Chemotherapy in Malignant Tumors
1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study

Li, J.

4700 - Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques
5159 - Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Li, J.

599 - Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
4922 - Influence of Somatic and Germline Gene Variants on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

Li, J.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Li, J. J.

426 - Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands

Li, J.

1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Li, J.

2075 - CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Li, J.

272 - Machine Learning-Based Predictive Modeling Maximizes the Efficacy of mTOR/TP53 Co-Targeting Therapy Against Acute Myeloid Leukemia

Li, J.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Li, J.

4203 - Influence of Methotrexate Concentration and MTHFR Gene Polymorphism on Drug Metabolism in Chinese Children with Acute Lymphoblastic Leukemia

Li, J.

4679 - Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China
4710 - Predictors and MRD-Driven Treatment Strategies of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
4727 - Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma

Li, J.

4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells

Li, J.

4551 - Comparison of the Clinicopathological Findings of Patients with SF3B1/JAK2, SF3B1/Calr, or SF3B1/MPL co-Mutations
4599 - Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations

Li, J.

1162 - Ras-Associated Autoimmune Lymphoproliferative Disorder: Retrospective Case Series
1322 - Distinguishing Childhood Non-Severe Aplastic Anemia from Dyskeratosis Congenita through Telomere Length Analysis
2561 - Protein and Gene Levels of DNAJC21 and RNF5 Proven to be Novel Drug Targets for Immune Thrombocytopenia: Insights from Mendelian Randomization-Based Post-GWAS Research
2833 - HSC/MPP-like Signature Predicts Inferior Outcome of Multiple Pediatric Leukemias

Li, J.

1528 - Identification of Novel Genes Underlying Human AML Expansion at Relapse from Chemotherapy
4151 - AML Blasts Intrinsic Interferon Production Causes Resistance to Venetoclax in Human Acute Myeloid Leukemia Via Upregulation of MCL1, BCL2A1 and BCL-XL

Li, J.

4970 - Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein Interaction Methodology

Li, J.

3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused

Li, J.

2206 - The Endocannabinoid N-Arachidonoyl Dopamine Induces Leukemia Cell Pyroptosis to Overcome the Venetoclax Resistance

Li, J.

2882 - High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Li, J.

2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Li, K.

4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Li, K. L.

4258 - Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Li, K.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Li, K. Y.

3303 - Clinical Characteristics and Therapeutic Response of Patients with Heavy Chain (AH) and Heavy and Light Chain (AHL) Amyloidosis

Li, K.

1549 - Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Li, K.

4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment

Li, L.

4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Li, L.

1635 - Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
3015 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3057 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3119 - Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma
3730 - Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Li, L.

4822 - LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Li, L.

123 - Loss of LDH-a Accelerated CD8⁺ T Memory Cell Differentiation but Impairs Anti-Tumor Responses

Li, L.

1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
3404 - HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells

Li, L.

61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Li, L.

3661 - Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma

Li, L.

3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia

Li, L.

773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Li, L.

3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Li, L.

4851 - Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Li, L.

2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Li, L.

54 - Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation
625 - Mitochondrial RNA Methylation By METTL17 Rewires Metabolism and Regulates Retrograde Mitochondrial-Nuclear Communication in AML
1398 - High HDAC8 Creates Targetable Vulnerabilities in Acute Myeloid Leukemia through Dysregulation of BRCA1-Related RNA Splicing Machinery and Defective DNA Damage Repair
3041 - Treatment Outcomes for Patients with TP53-Mutated Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis
3345 - Early Responders (Time to Best Response ≤3 months) Predicts Functional High-Risk Multiple Myeloma
3590 - Targeting Cytidine Triphosphate Synthase 1 Promotes Anti-AML Immunity
3792c - Real-World Data of Maintenance Therapy for Newly Diagnosed Multiple Myeloma: Ixazomib Versus Lenalidomide

Li, L.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Li, L.

1932 - Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Li, L.

829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Li, L.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Li, L.

559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1062 - Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

Li, L.

836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Li, L.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

Li, L.

1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging

Li, L.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Li, L.

4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Li, L.

1078 - Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

Li, L.

682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBB^T87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Li, L.

923 - A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Li, M.

4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Li, M.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Li, M. M.

316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance

Li, M.

3073 - ΔSUV_max between Baseline and Interim ¹⁸f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma

Li, M.

4065 - Immune Checkpoint Inhibitors Reverse the Mesenchymal Stromal Cell-Mediated Immunosuppression in Acute Myeloid Leukemia Microenvironment

Li, M.

2787 - Targeting Nucleotides Dependency Via SIRT3 Inhibition to Overcome Metabolic Plasticity and Flexibility of Dlbcls

Li, M.

2148 - Diagnosis and Prognosis of aGVHD By Metabolic Biomarkers after Allogeneic Hematopoietic Stem Cell Transplantation

Li, M. L.

300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
425 - β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Li, M.

1028 - A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease

Li, M.

2651 - DCAF13 Is Essential for Hematopoietic Stem Cell Function By Stabilization of Ribosome Biogenesis and P53 Pathway

Li, M.

1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Li, M.

5159 - Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Li, M.

270 - Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML

Li, M. Y.

855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma
2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Li, M.

3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Li, M.

1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Li, N.

2565 - Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index

Li, N.

4746 - SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Li, N.

1694 - Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring

Li, N.

948 - IL-11 Signaling Drives Clonal Hematopoiesis-Associated Cardiac Dysfunction

Li, N.

99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)
3533 - Regulatory Effects of IL-17A Monoclonal Antibody and Fibronectin on Chronic Graft-Versus-Host Disease

Li, N.

2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)

Li, N.

1098 - Estimated Prevalence of β-Thalassemia in the United States in 2023

Li, P.

4562 - Remarkable Molecular Response in Patients with Polycythemia Vera Treated with Ropeginterferon Alfa-2b

Li, P. P.

1908 - OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

Li, P.

2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Li, P.

2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia

Li, P.

786 - Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Li, P.

3475 - Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T—a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Li, P.

1742 - The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

Li, P.

5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Li Pira, G.

3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Li, Q.

958 - KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Li, Q.

2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence
4764 - Single Cell RNA-Seq Analysis Revealed MIF/CD74 Pathway Determinants of BCMA CART Resistance in Relapsed/Refractory Multiple Myeloma

Li, Q.

345 - Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes

Li, Q.

1728 - Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R²) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Li, Q.

4972 - Analytical Validation of a Next-Generation Sequencing Assay for Detecting Minimal Residual Disease in Lymphoid Malignancies

Li, Q.

4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies

Li, Q.

3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis

Li, Q.

437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells
2656 - PERK Maintains Hematopoietic Stem Cells Pool Integrity By Promoting Proliferation
3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Li, Q.

4763 - Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Li, Q.

1590 - Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Li, Q.

4776 - Donor T-Derived Memory Progenitors Differentiated into CD103^+/-CXCR6⁺CD4⁺ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease

Li, Q.

1736 - Zanubrutinib Combined with R-CHOP in Patients of Newly Diagnosed DLBCL with p53 Expression: A Single-Arm Prospective Study

Li, Q.

1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)

Li, Q.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Li, Q.

4659 - Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

Li, R.

621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease

Li, R.

421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Li, R.

4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Li, R. S.

2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML

Li, R.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Li, R.

682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBB^T87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Li, R.

726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Li, S.

2843 - Gestational Epigenetics and Risk of Childhood Leukemia

Li, S.

1546 - p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53

Li, S.

3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Li, S.

4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Li, S.

191 - Hematopoietic Stem Cell Aging Promotes Expansion of Tet2 Mutant Clones By Cell Intrinsic Mechanisms
2671 - Title: In Vivo Clonal Tracing of Hematopoietic Stem and Progenitor Cells Reveals Increased Clonal Heterogeneity during Aging, Alongside Critical Changes in Selection Patterns
- Altered Immune Environment in Clonal Hematopoiesis

Li, S.

1355 - TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Li, S.

360 - Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Li, S.

4650 - BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Li, S.

4987 - Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

Li, S.

2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Li, S.

2148 - Diagnosis and Prognosis of aGVHD By Metabolic Biomarkers after Allogeneic Hematopoietic Stem Cell Transplantation

Li, S.

1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Li, S.

3979 - Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Li, S.

4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

Li, S.

3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Li, S.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Li, S.

761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Li, S.

1345 - AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Li, S.

1656 - Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Idiopathic Multicentric Castleman Disease: A Single-Center, Retrospective Study

Li, S. S.

2268 - Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey

Li, S.

3085 - Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Li, T.

1414 - Exposure-Response Analyses Supporting Optimal Epcoritamab Full Dose and Dosing Schedule in Relapsed or Refractory Follicular Lymphoma
1701 - Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy

Li, T.

3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Li, V.

1796 - Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Li, W.

4482 - Mechanism and Updated Results of Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations

Li, W.

1300 - Mesenchymal Stromal Cell Expansion in FLT3-ITD+ Zebrafish Treated with Gilteritinib
4066 - Decoding Transcription Factor Dependent Enhancer-Gene Regulatory Networks That Define Hematopoietic Niche Function
4067 - Hepatocyte Growth Factor Is Overexpressed in AML and Remodels the Mesenchymal Stromal Cell Niche

Li, W.

539 - A Novel Role of LKB1 in Erythroblast Enucleation

Li, W.

3730 - Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Li, W.

2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease

Li, W.

3192 - TET1 Drives Myelodysplastic Syndromes and Represents a Promising Therapeutic Target

Li, W.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Li, W.

3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Li, W.

2888 - A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia
4540 - Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Li, W.

345 - Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes
682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBB^T87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Li, W.

4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Li, W.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Li, W.

1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones

Li, W.

4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes

Li, W.

1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Li, W.

260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Li, W.

1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)

Li, W.

4627 - Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Li, X.

3041 - Treatment Outcomes for Patients with TP53-Mutated Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Li, X.

420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPA^bZIP-Inf Acute Myeloid Leukemia

Li, X.

413 - Association of LRF with MBD3-NuRD Versus MBD2 NuRD Mediates Opposing Effects on Developmental Globin Gene Regulation

LI, X.

3120 - Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Li, X.

3539 - Protein Language Model-Based Intra-Gene Disparity of Donor HLA Alleles Informs Prognostic Risk in Hematologic Malignancy Patients Undergoing Haplo-Identical HSCT: A Combined Xinqiao-CIBMTR Analysis
3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Li, X.

3533 - Regulatory Effects of IL-17A Monoclonal Antibody and Fibronectin on Chronic Graft-Versus-Host Disease

Li, X.

839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Li, X.

1162 - Ras-Associated Autoimmune Lymphoproliferative Disorder: Retrospective Case Series
2120 - Development and Validation of a prediction model for severe PES during the treatment of unrelated UCBT in pediatric patients
4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia

Li, X.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Li, X.

2561 - Protein and Gene Levels of DNAJC21 and RNF5 Proven to be Novel Drug Targets for Immune Thrombocytopenia: Insights from Mendelian Randomization-Based Post-GWAS Research

Li, X.

711 - Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)

Li, X.

2701 - A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Li, X.

3924.1 - Trials in Progress: A Phase 3 Study to Investigate Efficacy, Safety, and Tolerability of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders

Li, X.

4260 - BL-M11D1, a Novel CD33 Antibody-Drug Conjugate (ADC), in Patients with Relapsed/ Refractory Acute Myeloid Leukemia: Initial Results from First-in-Human Phase 1 Study

Li, X.

5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Li, X.

4710 - Predictors and MRD-Driven Treatment Strategies of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Li, X.

2678 - Chemotherapy-Induced Bone Defects Stem from Skeletal Progenitor Dysfunction

Li, X.

2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Li, X.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
3291 - Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8⁺ T Cell-Mediated Immunity Against Multiple Myeloma

Li, X.

1625 - Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages
4763 - Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Li, X.

4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Li, X.

2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Li, X.

3260 - Comprehensive Translatomic Analysis of Multiple Myeloma Unveils Novel Insights into Disease Pathogenesis

Li, X.

4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Li, X.

643 - Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy

Li, X.

3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Li, X. P.

192 - Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology
3066 - Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission
3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Li, X.

270 - Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML

Li, X.

2971 - Decoding the Epigenetic and Transcriptional Signatures of Pathogenic B-Cells in Patients at High Risk of Transformation to Lymphoma

Li, Y.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Li, Y.

436 - The Role of Canonical Glycolytic Endpoints in the Development and Function of Hematopoietic Stem and Progenitor Cells
1280 - The Cell-Type-Specific Essentiality of the Tricarboxylic Acid (TCA) Cycle in the Hematopoietic System

Li, Y.

1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)

Li, Y.

1413 - Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing
1675 - The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study
4175 - BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Li, Y.

4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)

Li, Y.

2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Li, Y.

3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Li, Y.

539 - A Novel Role of LKB1 in Erythroblast Enucleation

Li, Y.

164 - Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells

Li, Y.

2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1^st Line Imatinib

Li, Y.

4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Li, Y.

4240 - Lower Dose of Arsenic Trioxide in Induction Therapy for Acute Promyelocytic Leukemia Achieves Same Long-Term Survival Outcome: A Real-World Retrospective Study

Li, Y.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Li, Y.

628 - EZH2-Mediated Methylation Regulates JARID2 Protein Stability in Normal and Neoplastic Hematopoiesis
630 - Fetal Differentiation Programs Afford a Protective Barrier to NUP98 Fusion-Driven AML That Dissipates Shortly after Birth
3398 - In Vivo and Ex Vivo Expansion of Functional Human Repopulating Cells through JARID2 Inhibition

Li, Y.

1333 - Recurrent Amplification of Chromosome 7 in Murine AML with Dnmt3a^R878H and Npm1^cA Mutations Identifies Gab2 As a Possible Therapeutic Target in AML

Li, Y.

4693 - Lactate Metabolism-Related Genes to Predict the Clinical Outcome and Molecular Characteristics of Multiple Myeloma

Li, Y.

2222 - Measuring the Mosaicism of Genome Integrity and Toxicity Events Associated with Gene and Cell Therapies at a Single-Cell Level

Li, Y.

54 - Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation
3590 - Targeting Cytidine Triphosphate Synthase 1 Promotes Anti-AML Immunity

Li, Y.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study

Li, Y.

1605 - Single-Cell Analysis Reveals an Exhaustion of TEM and CTL CD8⁺ T Cells in Hemophagocytic Lymphohistiocytosis with EBV Infection
2822 - Single-Cell RNA-Sequencing Identifies TCF1 and BCL11B Upregulation As Predictors of Blinatumomab Efficacy in B-Cell Acute Lymphoblastic Leukemia Patients

Li, Y.

2138 - Effective Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (iMSC) in a Clinical Setting

Li, Y. C.

3372 - Small Molecule Kinetic Stabilizers Reduce Amyloidogenicity of Free Light Chain Proteins of Diverse Sequences in λ Light Chain Amyloidosis

Li, Y.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Li, Y.

725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia

Li, Y.

3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Li, Y.

1902 - Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

LI, Y.

4842 - First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients

Li, Y.

2425 - Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Li, Y.

4081 - Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

Li, Y.

1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

LI, Y.

498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Li, Y. M.

1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Li, Y.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease
940 - An Essential Role for the N-Terminus of GATA1 in Metabolic Regulation during Erythropoiesis

Li, Y.

3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect

Li, Y.

3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Li, Y.

1356 - Super-Enhancer-Associated Long Noncoding RNA Lnc-SPI1U Participates in PU.1 Feedback Regulation By Interacting with HNRNPH1 and Hnrnpf

Li, Y.

116 - Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
3470 - Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Li, Y.

3473 - In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Li, Y.

2143 - Immune Reconstitution and Readiness for Vaccination after Pediatric Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
2504 - Hydroxyurea Initiation and Occurrence of Cerebrovascular Outcomes in Sickle Cell Disease

Li, Y.

4976 - Blood Preservation Workflows for Single Cell Technologies Using Off-the-Shelf Reagents

Li, Y.

3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Li, Y.

4843 - A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Li, Y.

383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Li, Y. D.

4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Li, Y.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

Li, Y.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Li, Y.

4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis

Li, Y.

1197 - IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
3614 - In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells
3993 - Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis
4847 - mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Li, Y.

1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Li, Y.

1050 - Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Li, Y.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Li, Y. H.

4914 - The Dominant Effect of the Gut Microbiome on GvHD in Mouse Models of Allo-BMT

Li, Y.

830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Li, Y.

4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Li, Y.

1273 - CD38 Inhibition Enhances Human Hematopoietic Stem Cell Maintenance in Ex Vivo Cultures

Li, Y.

92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Li, Y.

3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations

Li, Y.

1232 - Coagulation Abnormalities in Post-Acute COVID-19 Syndrome: A Cross-Sectional Study

Li, Y.

576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Li, Y.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Li, Y.

4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Li, Y.

2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease

Li, Y.

426 - Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands
3927 - Identification of Megakaryocytes As a Functional Component of Circulation Blood

Li, Y.

1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
3036 - Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Li, Y.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
1050 - Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3087 - A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma
4457 - Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Li, Y.

3940 - Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders

Li, Y.

1362 - Complementary Roles of DNMT3A and TET2 KO in Sculpting CD4-T Cells for Sustained Proliferation without Exhaustion to Promote Lymphomagenesis

Li, Y.

353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Li, Y.

4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li, Z.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Li, Z.

1732 - Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study
1742 - The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Li, Z.

977 - Faecalibacterium Prausnitzii Confers a Protective Effect Against the Development of NKTCL

Li, Z.

4490 - Chidamide: A New Exploration of Maintenance Therapy for DLBCL Patients with HBV Infection

Li, Z.

3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Li, Z.

270 - Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Li, Z.

3971 - The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients

Li, Z.

830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Li, Z.

4972 - Analytical Validation of a Next-Generation Sequencing Assay for Detecting Minimal Residual Disease in Lymphoid Malignancies

Li, Z.

1686 - Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma
1978 - Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study
3103 - EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Li, Z.

4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Li, Z.

2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Li, Z.

452 - Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome
1621 - CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression

Li, Z.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Li, Z.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
599 - Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
2164 - Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment
3544 - Chimeric Antigen Receptor T Cell Therapy Bridged to the Second Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Toxicity Conditioning for B-Cell Acute Lymphoblastic Leukemia Relapsed after the First Transplant
4922 - Influence of Somatic and Germline Gene Variants on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

Li, Z.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Li, Z.

1413 - Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing
1632 - Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
1674 - Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study
3087 - A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma
3120 - Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results
4457 - Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma
4987 - Early Assessment of Lymphoma Therapeutic Efficacy Via a Blood-Based Multi-Omics Test

Li, Z.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Li, Z.

1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Li, Z.

4785 - Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Li, Z.

507 - Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant
3418 - Chimeric Antigen Receptor T-Cell Therapy Associated Cerebral Glucose Hypometabolism (CART-CGHM): A Novel Cerebral Metabolic Complication
5129 - Impact of Extranodal Involvement on Outcomes with Chimeric Antigen Receptor T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Li, Z.

210 - Disrupting Mitochondrial Dynamics and Metabolism in Leukemic Stem Cells through Mitochondrial PCNA Inhibition: The Role of AOH1996

Li, Z.

950 - Systematic Evaluation of GAPs and Gefs Identifies ARHGAP45 As a Targetable Leukemia-Specific Dependency

Li, Z.

4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Li, Z.

4829 - CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies

Li, Z.

4396 - Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Li, Z.

3451 - GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
4843 - A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Li, Z.

1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World
2815 - Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
3141 - Immune-Related Signatures Predict Prognosis in Chronic Myeloid Leukemia (CML) Patients Receiving the 3^rd-Generation Tyrosine-Kinase Inhibitors (3G-TKIs)
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Li, Z.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Lia, S.

3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Liacos, C. I.

1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging

Liakopoulos, P.

3867 - Single-Cell Transcriptomic Analysis of Bone Marrow from Humanized Sickle Cell Mice Reveals a Subpopulation of Highly-Expressing S100A8/A9 Mesenchymal Stem Cells

Liam, C.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Lian, Q.

1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Liang, A.

4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Liang, A.

3377 - Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study
3475 - Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T—a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Liang, C.

97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
2127 - Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia

Liang, C.

2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Liang, F.

3405 - Changes in Glycosylation on the Cell Surface Result in Highly Potent and Long-Lasting Allogeneic CAR-T Therapy in Patients

Liang, H.

1002 - The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Liang, J.

3882 - Feasibility of Validating a Screening Tool for Neurocognitive Function in Adults with SCD

Liang, J.

1063 - Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2302 - Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2304 - Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease

Liang, J.

576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Liang, J. H.

576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Liang, J.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Liang, J. F.

4466 - The Population-Scale Analysis of DLBCL Patients Receiving Standard-Dose RCHOP Identified Impactful Prognosticators in the Real World

Liang, L.

4972 - Analytical Validation of a Next-Generation Sequencing Assay for Detecting Minimal Residual Disease in Lymphoid Malignancies

Liang, L.

1694 - Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring

Liang, L.

1775 - Tyrosine Kinase Inhibitors Short Exposure in Pregnant Female Patients with Chronic Myeloid Leukemia

Liang, L.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Liang, M.

2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia

Liang, M.

1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Liang, P.

99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Liang, P.

174 - Molecular Mechanism Underlying Excessive Phosphatidylserine Exposure in Sickle Red Blood Cells and Potential Therapeutics
2459 - Targeting Gardos Channel to Regulate Lipid Scrambling in Red Blood Cells

Liang, S.

203 - ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell MYB Enhancer in the T-Cell Leukemia Context

Liang, T.

2822 - Single-Cell RNA-Sequencing Identifies TCF1 and BCL11B Upregulation As Predictors of Blinatumomab Efficacy in B-Cell Acute Lymphoblastic Leukemia Patients

Liang, T.

2790 - EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases

Liang, X.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia

Liang, X.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Liang, X.

1345 - AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells

Liang, X.

1516 - Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Liang, X.

4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis

Liang, Y.

192 - Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4693 - Lactate Metabolism-Related Genes to Predict the Clinical Outcome and Molecular Characteristics of Multiple Myeloma

Liang, Y.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia

Liang, Y.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Liang, Z.

1415 - Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)
4150 - APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Antileukemic Activity and Enhances Lisaftoclax (APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia (AML)
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Liani, A.

758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Liao, A.

4736 - An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study

Liao, A.

2024 - Potent and Effective Targeting of AML with ‘Off-the-Shelf’ Engineered CD45-Targeting CAR T-Cells

Liao, C.

1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Liao, C.

4133 - Deciphering Drivers of Functional and Phenotypic Changes through Genome-Wide Screen (DRIVE-Genome) to Identify Genes Inducing Genomic Instability in Myeloma

Liao, C.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Liao, C. K.

5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Liao, D.

4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Liao, E.

2035 - CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Liao, J.

4157 - Targeting Chronic Myeloid Leukemia with Potent and Specific BCR::ABL1 Degraders

Liao, L. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Liao, M.

1386 - Magic-PDX Models Can be Easily Established for Fast Drug Screening and Mechanism Study of Primary Drug-Resistant Hematological Malignancies

Liao, R.

939 - Multiomic Analyses of Erythropoiesis and Anemia Mechanisms Reveal a Signaling Network with Converging Cytokine and Sphingolipid Inflammatory Pathways

Liao, S.

3029 - Comparative Efficacy of Zanubrutinib Plus Obinutuzumab Versus Last Prior Treatment in Relapsed/Refractory Follicular Lymphoma: Growth Modulation Index Analysis from ROSEWOOD Study

Liao, W.

4129 - Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching

Liao, X.

1701 - Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy

Liao, Y.

2898 - Venetoclax Plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for Elderly or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia: A Multicenter, Prospective Study

Liao, Y.

1187 - Sirolimus Combined Dexamethasone As the First-Line Therapy for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Open-Label, Prospective, Randomized Controlled Clinical Trial

Liao, Y. C.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Liao, Z.

4843 - A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Liapis, K.

3211 - Prevalence of Comorbidities at Diagnosis in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

Liapodimitri, A.

4127 - Mapping the Dynamic DNA Methylation Landscape in Pre-B ALL from Diagnosis to Relapse Reveals a Role for Aberrant PRC2 Regulation

Libbrecht, C.

90 - Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

Libby, E.

891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Libby, E.

4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials

Liberati, A. M.

674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study

Liberatore, C.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Liberzon, E.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Librale, F.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients
4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma

Libura, M.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results

Licht, J. D.

4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Lichter, T.

2790 - EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases

Lichtin, A. E.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria

Lichtman, E. I.

1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Lichtman, E. I.

1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1958 - Population-Level Outcomes in Solitary Plasmacytoma: A Surveillance, Epidemiology, and End Results (SEER) Study

Licitra, E.

3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Lico, A.

1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Liddell, S. S.

5204 - Call Me Maybe: An Analysis of Hematology Fellowship Home-Call Burden, Perceptions, and Attitudes

Lidonnici, M. R.

- Clonal Hematopoiesis in Hemoglobinopathies

Liebenberg, N.

1599 - CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma

Lieberman, M.

3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Lieberman-Cribbin, A.

897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Liebman, H. A.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Liebman, M.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study
4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Liede, A.

3723 - Patient Characteristics and Treatment Patterns for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) By CAR T Eligibility and Treatment Status in France, Germany, Italy, Spain, the UK, and Japan

Liedtke, M.

308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4677 - Evaluation of Functional Cardiac Measures and Response to Treatment Initiation in Patients with Systemic Light-Chain (AL) Amyloidosis: Results from a Single Site Retrospective Study
- MGUS Where Do We Stand Today?

Liefaard, M. C.

93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Liegel, J.

1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Liem, R. I.

512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Liersch, R.

4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Liesveld, J. L.

733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
1302 - Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment
3798 - Associations between Myeloid Malignancies and Osteoporosis Using Real-World Data from the Trinetx Database
4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial
5054 - An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study

Liévin, R.

1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

Liew-Littorin, M.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Lifermann, F.

3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Light, D. R.

173 - A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice
2482 - Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Light, J.

2239 - Reproductive Health Surveys Administered in Sickle Cell Clinics Can Inform Personalized Care and Multidisciplinary Collaboration
3897 - Heavy Menstrual Bleeding in Adult Women with Sickle Cell Disease

Lightbody, E. D.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Lightfuss, O. B.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function
4167 - Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

Ligon, J. A.

680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group

Ligtvoet, R.

4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Lihoradova, O.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Likhosherstov, V.

1544 - Karyotype AI for Precision Oncology

Lile, A.

2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting

Liles, D.

4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Lilja, M.

4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years

Liljeholm, M.

4543 - Myelofibrosis Therapies and Risk of Major Bleeding, Thrombotic Events and Mortality, a Matched Nationwide Population-Based Study

Lillestolen, D.

5016 - Revisiting the Use of Unfractionated Heparin As VTE Prophylaxis: A Single Institution, Retrospective Review

Lillicrap, D.

3959 - A Therapeutic siRNA Targeting Plasminogen Acts As a Long-Lasting Antifibrinolytic in Nonhuman Primates

Lilyquist, J.

4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Lim, B. Y.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lim, B. S.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Lim, C. C.

1950 - Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)

Lim, E. L.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Lim, E.

1214 - Bleed Patterns in Infants, from Birth to 12 Months of Age, with Hemophilia A Treated with Emicizumab: Exploratory Analysis of the HAVEN 7 Study
2589 - FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Lim, F. Q.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Lim, F.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Lim, H. I.

3961 - Proteolysis of Annexin A2 Leads to Inflammasome-Mediated Proinflammatory Response in Human Sepsis

Lim, H. J.

3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study

Lim, J. J.

1416 - A Combinatorial Functional Precision Medicine Platform to Evaluate Immunotherapy-Based Combinations in Non-Hodkin Lymphoma

Lim, J. E.

775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Lim, J. Y.

4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach

Lim, J. Q.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma
4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lim, K. S.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lim, K.

1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Lim, K. J.

1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
2385 - Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Lim, K. M. H.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma

Lim, L. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lim, L. S.

590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Lim, M. S.

1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes
1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Lim, M. S.

1581 - NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Lim, M. Y.

2617 - Can Machine Learning Supplant the Plasmic Score in Improving the Early Diagnosis of Thrombotic Thrombocytopenic Purpura?
3820 - Defining and Developing a Curriculum for Systems-Based Hematology: A Qualitative Thematic Analysis of Expert Interviews
5014 - Comparative Analysis of Perioperative Anticoagulation Management Guidelines across U.S. Institutions

Lim, N. A.

3660 - Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity

Lim, S. Y.

2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies

Lim, S. M.

4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Lim, S. T.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma
3660 - Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity
4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Lim, S.

3429 - The Role of Gut Microbiota in Modulating Efficacy and Adverse Effects of CAR T-Cell Therapy in the Pediatric Population
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Lim, S. L.

4755 - Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) – the FRAIL-M Study (AMaRC 19-01; ALLG MM22)
2000.2 - A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lim, S. N.

1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)
3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07
3120 - Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Lim, X. Y.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Lim, Y.

1758 - Iron Deficiency Correction in Myeloproliferative Neoplasms Reduces Thrombosis Risk Via Decreased P-Selectin

Lim, Z. Y.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Lima, J.

3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification

Lima, K.

2802 - Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings

Lima, L. G.

720 - Immune Mechanisms and Cytokine Profiles in Hemophilia a Patients Undergoing Low-Dose ITI and Emicizumab Prophylaxis: Implications for ITI Success and Failure

Limerick, E.

177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
802 - Fertility Preservation Outcomes for People with Ovaries and Sickle Cell Anemia: A Multi-Center Study
2167 - Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease
3888 - Race-Based Creatinine Egfr Equations Outperform Nonrace-Based and Cystatin C-Based Equations in a Population of Adults with Sickle Cell Disease

Lin, A. Y.

473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Lin, A.

2293 - Integrating the Sunnybrook Biobank into the Future of Healthcare – Exploring Patient and Healthworker Biobanking Perspectives

Lin, B. B.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Lin, B.

1803 - The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Lin, C. H.

2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
5098 - Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs

Lin, C. Y.

4970 - Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein Interaction Methodology

Lin, C.

447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Lin, C. H.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lin, C. W.

3795 - Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy

Lin, C. C.

1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions

Lin, C.

1628 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study

Lin, C. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lin, C.

2680 - C-Type Natriuretic Peptide Signaling Promotes Bone Marrow Hematopoietic Regeneration and Alleviates Systemic Lymphopenia

Lin, C.

4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Lin, C.

3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager

Lin, D.

2998 - Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Lin, D.

3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Lin, D. S.

1292 - Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A^R882- Mutant Hematopoietic Stem Cells

Lin, D.

933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Lin, D.

2696 - Single Cell Profiling of Hematopoietic Stem and Progenitor Cells in Pediatric Acquired Aplastic Anemia

Lin, D.

2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Lin, D. T.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

Lin, D.

1516 - Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Lin, D.

144 - Silent Cerebral Infarction Is Progressive during Clinical Remission and Associated with Stroke in Immune TTP Survivors

Lin, D.

4229 - Comprehensive Genomic Profiling (CGP) of Acute Lymphoblastic Leukemias with Foundation One Heme Identifies Actionable Genomic Alterations and Biomarkers

Lin, E.

758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy

Lin, F.

3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia

Lin, F.

3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
3761 - Understanding Frontline Therapy Pattern, Attrition Rates and Survival Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Underwent Transplant
5138 - Frontline Treatment Patterns and Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Did Not Undergo Transplant: A US Electronic Health Records Database Analysis

Lin, F.

1793 - Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R^T618I: A Multi-Centre Retrospective Study

Lin, F.

1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Lin, G.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Lin, G.

1886 - CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4^CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Lin, G.

1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Lin, G.

3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients

Lin, H.

1002 - The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Lin, H. P.

4192 - Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Lin, H.

420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE

Lin, H.

3166 - Long Term Follow-up of Methotrexate and Cytarabine in Adult Patients with Langerhans Cell Histiocytosis

Lin, H.

4807 - Obesity Attenuates CAR T-Cell Function in Pediatric B-Cell Acute Lymphoblastic Leukemia

Lin, H. Y.

198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder

Lin, H. Y.

1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Lin, H.

1166 - CircFUT8 Promotes Megakaryocyte Proplatelet Formation By Regulating Actin Cytoskeleton Reorganization

Lin, H. M.

3164 - Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Lin, J.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease

Lin, J.

839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Lin, J.

3265 - Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma
3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager

Lin, J. K.

786 - Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Lin, K. H.

203 - ETS1 Recruits the Canonical Baf Complex to Reactivate the Hematopoietic Stem Cell MYB Enhancer in the T-Cell Leukemia Context
4131 - Crispri Essentiality Screen Reveals the Essential Enhancers and Oncogenes Comprising the “Regulome” of the Notch-Collaborating Transcription Factor ETS1 in Human T-ALL

Lin, K. H.

1262 - Risk of Pregnancy-Associated Venous Thromboembolism in Sickle Cell Trait

Lin, L.

477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Lin, L. L.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Lin, L.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Lin, L.

513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
4957 - Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial Data from the BEACON Phase 1/2 Study of Autologous CD34⁺ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease

Lin, L.

4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Lin, M.

991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure

Lin, N.

3033 - Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
4175 - BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Lin, P.

3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Lin, P.

767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3327 - Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Lin, P. C.

4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Lin, Q.

4746 - SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Lin, R.

4897 - Signifcance of Intestinal CD8+CD69+CD103+ Tissue-Resident Memory T Cells in Human Intestinal Acute Graft-Versus-Host Disease
4910 - Donor Neutrophil Subsets in G-CSF Mobilized Peripheral Blood Stem Cell to Predict the Risk of Agvhd

Lin, R.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study
4923 - Increased EBV Infection and Relapse Rates Following Haploidentical Hematopoietic Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis: A Propensity Score Matching Analysis

Lin, R. J.

46 - SF3B1 Mutation Drives Loss of Y Chromosome in Chronic Lymphocytic Leukemia

Lin, R.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Lin, R. J.

267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies
686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Lin, R.

4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Lin, S.

626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia

Lin, S.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia

Lin, S. W.

3648 - Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States
5029 - Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Lin, S. W.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Lin, S.

5084 - Comparative Venous and Arterial Thromboembolism Profiles Associated with Different Cyclin-Dependent Kinase 4/6 Inhibitors: A Real-World Study

Lin, S.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1

Lin, T. L.

Lin, T. L.

151 - Novel Small Molecule Inhibitor Against IGF2BP3 with Potent Anti-Leukemic Activity
2743 - Regulation of Metabolism and Epitranscriptomic Modifications By RNA Binding Protein IGF2BP3

Lin, T. S.

675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
4753 - Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results

Lin, T.

2450 - A CRISPR Screen in Enucleated Red Blood Cells Identifies Critical Factors for Terminal Erythroid Differentiation

Lin, T. A.

1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Lin, T.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Lin, T.

1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Lin, T. Y.

1435 - T-Cell Receptor Signaling and Dysfunction during Blinatumomab Therapy in Pediatric Acute Lymphoblastic Leukemia

Lin, T.

1968 - Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma

Lin, V. S.

1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Lin, V. T. G.

1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Lin, W.

312 - Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia
4214 - Single-Cell Sequencing Analysis Reveals Cellular Dynamics Underlying Different Responses to Blinatumomab in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Lin, W.

959 - Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Lin, W. H.

1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Lin, X.

3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Lin, X.

2215 - Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients
4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPA^bZIP-Inf Acute Myeloid Leukemia

Lin, X. X.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
4305 - Integrating Genomics and Functional Phenotypes to Refine Risk Assessment in Acute Myeloid Leukemia across the Age Spectrum: Insights from Singapore

Lin, X.

4077 - Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Lin, X.

4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial

Lin, Y. H.

234 - A Single-Cell Atlas of Classical Mantle Cell Lymphoma Reveals Paired Tumor-Immune Malignant States Correlating with Prognosis

Lin, Y.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Lin, Y.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Lin, Y.

3120 - Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Lin, Y.

1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Lin, Y. C.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lin, Y.

4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Lin, Y.

1386 - Magic-PDX Models Can be Easily Established for Fast Drug Screening and Mechanism Study of Primary Drug-Resistant Hematological Malignancies

Lin, Y.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia

Lin, Y.

3467 - The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

Lin, Y.

793 - Ferric Derisomaltose Versus Iron Sucrose in Pregnancy (FLIP): A Retrospective Observational Study on Outpatient Intravenous Iron Infusion Capacity

Lin, Z.

938 - The LSD1 Inhibitor RN1 Rescues Congenital Dyserythropoietic Anemia Type II

Lin, Z.

3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL

Lin, Z.

452 - Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome
1621 - CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression
4379 - Suvmax Linked to Intrafollicular Macrophage Infiltration Is Associated with Poor Outcome of Follicular Lymphoma

Lin, Z.

951 - CRISPR/RfxCas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)

Linares, M.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Linari, S.

715 - Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Lincoln, R.

3469.1 - A Study of Kyv-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis

Lind, E. F.

4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Lind, K.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Lind, K.

3827 - Implementation of a Pediatric Subspecialty Boot Camp Is Feasible and Increases Resident Confidence in Managing Hematologic and Oncologic Emergencies

Lindahl, H.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Linde, N. S.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Lindemans, C.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
4876 - Standard Fludarabine Dosing Results in Overexposure in Young Children Undergoing Hematopoietic Cell Transplantation

Lindenberg, L.

2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Lindenfeld, L.

947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation

Linder, K.

4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Linder, K.

1448 - Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Linder, M. I.

2524 - Illuminating the Functional Architecture of iPSC-Derived Neutrophil Granulocytes with Split Fluorescent Proteins

Lindner, D.

Lindquist, J. N.

4965 - Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies

Lindquist, K.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Lindsay, J.

773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
3023 - Focal Symptomatic Bone Involvement with Waldenström’s Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma
3039 - Bing-Neel Syndrome – a Case Series of 46 Patients from the United Kingdom

Lindsay, K.

2816 - Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia

Lindsley, J.

2328 - Practice Patterns and Clinical Outcomes of Thromboprophylaxis during Pregnancy

Lindsley, R. C.

60 - AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
3220 - Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Lindström, V.

3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Lindvall, C.

792 - Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers

Linendoll, N.

785 - Churn, Churn Churn! a Mixed Methods Analysis of Young Adult Leukemia and Lymphoma Survivors’ Experience Navigating the Insurance Landscape in a Post Affordable Care Act Era

Linette, G.

4792 - EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Ling, D.

2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
2778 - The Mitochondrial Unfolded Protein Response (UPR^mt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPR^mt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML

Ling, G. S.

2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML

Ling, J.

2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Ling, K.

1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Ling, M.

184 - HDL and HDL-Mimetic Nanoparticles Prevent Induced TTP and Interrupt the Course of Ongoing Episodes of the Disease

Ling, Q.

4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPA^bZIP-Inf Acute Myeloid Leukemia

Ling, R. E.

199 - The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Ling, S.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Ling, T.

195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
818 - Targeting EBF1-ITGB8 Axis in MPN Bone Marrow Niche
940 - An Essential Role for the N-Terminus of GATA1 in Metabolic Regulation during Erythropoiesis
1082 - A Novel GATA1 (E200K) Germline Mutation Causing Hydrops Fetalis with Spontaneous Resolution of Erythropoiesis
1272 - Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Ling, V.

1347 - Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1^c-Flt3^ITD Acute Myeloid Leukemia

Ling, W.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Ling, Y.

3087 - A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Ling, Y.

345 - Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes

Ling, Z.

964 - CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study
3466 - Safety and Feasibility of Intrathecal Infusion of CD19 and/or CD22 CAR T Cells in r/r B-ALL Patients with CNSL or High-Risk CNS Relapse

Lingamaneni, P.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Linguet, S. L.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies

Linhares, Y.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
2104 - Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide

Linhares, Y. P.

1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

Link, A.

4775 - MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

Link, B. K.

567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
1744 - Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Link, D. C.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
- Are TP53 Mutations All Alike?

Linn, S.

3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Linn, S. M.

1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Linn, Y. C.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Linton, J.

344 - MDS-Associated SF3B1 Mutations Promote Aberrant Hematopoietic Cell Fate Choice By Disrupting Mediator Kinase Module Component CDK8

Linton, K.

342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
581 - Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial
1627 - Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3
1703 - Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Lion, T.

2829 - Differential in Vitro Sensitivity of BCR::ABL1 Kinase Domain Mutations to Tyrosine Kinase Inhibitors Depending on the p190 or p210 Background

Lionakis, M. S.

3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Lionel, A.

238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
1680 - Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Lionel, S. A.

3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Lionetti, M.

2928 - Intrinsic and Microenvironmental Determinants of AML Response to HMA-Venetoclax Therapy at the Single-Cell Transcriptomic Level
4550 - Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Lionnet, F.

3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Liot, C.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Lioure, B.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Lipe, B.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial
3381.3 - A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Lipka, D.

1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Lipke, J.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)

Lippert, E.

485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Lippert, E.

3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study

Lipsitt, A.

2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Lipsky, A. H.

1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
3077 - Diagnostic Utility of the ¹⁸f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Lipton, J. H.

2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Lipton, J. M.

195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
1076 - Dexamethasone Targets E2F4 to Induce Erythroid Progenitor Renewal

Liquori, A.

2111 - Current Challenges in the Assessment of Related Donors for Hematopoietic Stem Cell Transplantation

Lira, I.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS^® Antibody-TCR Platform in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Lischer, C.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Lischer, H.

1764 - Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Lisi, C.

5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Lisi, R.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Lisignoli, G.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Lisk, C.

1116 - Circulating Peripheral Blood Mononuclear Cells from Adults with Sickle Cell Disease (SCD)- Associated Pulmonary Hypertension (PH) Patients Have Increased Iron Content and a Unique Multi-Omic Signature
1143 - Peripheral Blood Macrophages (PBMCs) from Adults with Sickle Cell Disease Have a Unique Phenotype
3847 - Got Oxygen? the Impact of Band 3 on RBC Function during Exercise
3874 - Low Dose Clodronate Improves Exercise Tolerance, Right Ventricular Function, and Alters Resident Lung Macrophage Phenotypes

Lissat, A.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
2827 - Rescuing of the Chemotherapy Sensitivity in Relapsed/Refractory, Pediatric Acute Lymphoblastic Leukemia (r/r ALL) through the Combination of Navitoclax (NAV) and Venetoclax (VEN): Results of Compassionate Use across Four European Countries

Lissitchkov, T.

717 - Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

List, J.

881 - Ly6C⁺ Inflammatory Monocytes Create a Leukemia-Initiating Niche

Lister, J.

1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging

Lister, N.

2441 - Prospective, Multicenter Study to Assess the Effect of the Speaking Book on Patients’ Understanding of Clinical Research Knowledge: The SOUND Study

Litalien, V.

1419 - Co-Targeting BCL-2 and MCL1 (via CDK9) in Pre-Clinical Models of High-Risk Acute Lymphoblastic Leukemia
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Litichevskiy, L.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Little, D.

3632 - “I Didn’t Know I Had a Choice” – Patient Values and Preferences Regarding Resumption of Oral Anticoagulants after Gastrointestinal Bleeding

Little, J. A.

1101 - Voxelotor and Red Blood Cell Pyruvate Kinase Activator Enhance Sickle Erythrocyte Deformability By Calcium Efflux
3683 - Low Uptake of FDA-Approved Medications for Sickle Cell Disease Amongst the Adult Medicaid Population in North Carolina
5000 - Joint Sickle Cell-Gynecology Clinic Improves Access to Reproductive Health
5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Little, J. S.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Little, K.

2480 - Blockade of Angiotensin II Signaling Ameliorates Cardiac Fibrosis and Improves Diastolic Dysfunction in Mice with Sickle Cell Anemia

Little, L.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Little, L.

680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Little, M.

2271 - Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Little, R. F.

736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Little-Ihrig, L.

3861 - Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease

Littman, N.

1546 - p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53

Liturri, M.

3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms

Litvinov, R. I.

2462 - Red Blood Cell Aggregation within a Blood Clot Causes Clot Shrinkage

Litzow, M. R.

221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41^MT Germline Predisposition Syndrome
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Liu, A.

4185 - Clinical Characteristics and Prognostic Analysis of Testicular Relapse in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study from China

Liu, A. K.

876 - Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Liu, A.

2719 - Depletion of CD59 Inhibits the Proliferation and Survival of Acute Myeloid Leukemia Cells By Altering Lipid Raft Composition and Suppression of Raf/MEK/ERK Signaling
4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Liu, A. Z.

2767 - The Proteostasis Network Is a Therapeutic Target in Acute Myeloid Leukemia

Liu, A.

2514 - Buprenorphine Is Associated with Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease
3625 - Validation of a Low-Burden Quality Metric for the Care of Acute Sickle Cell Pain in the Emergency Department
3902 - Hemolysis Score Is Associated with Increased TNF Cytokines, Elevated BNP, and Hospitalizations in Individuals with Sickle Cell Disease (SCD)

Liu, A.

4225 - NOTCH1 gene Fusions Occur Frequently in Refractory or Relapsed (R/R) T-Cell Lymphomablastic Lymphoma

Liu, B.

2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Liu, B.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Liu, B.

438 - SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

Liu, B.

477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
480 - Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1^st Line Imatinib

Liu, B.

4496 - Preliminary Efficacy of Orelabrutinib Targeted Therapy in Induction Therapy of Primary Central Nervous System Diffuse B-Cell Lymphoma

Liu, B.

1590 - Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Liu, B.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Liu, B.

2784 - Sky-1214, a Small Molecule Splicing Modulator Targeting FANCL and Fanci, Provides a New Mechanism of Action Targeting Multiple Myeloma and Non-Hodgkin’s Lymphoma

Liu, C.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Liu, C.

2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Liu, C.

2045 - A Layered Cloaking Strategy to Generate Allogeneic iPSC-Derived CD8 T-Cells That Evade NK Clearance
4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Liu, C.

3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS^® Antibody-TCR Platform in Acute Myeloid Leukemia

Liu, C.

4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia
4569 - Genetic Characteristics and Clinical Prognosis of JMML with RAS Mutations

Liu, C. J.

4021 - Assessing Venous Thromboembolism Risk in Patients with Multiple Myeloma: A Nationwide Population-Based Study in Taiwan
5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Liu, C. J.

4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Liu, C. H.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Liu, C. L.

96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
2993 - Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Liu, C.

92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Liu, C.

2888 - A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia

Liu, C.

1653 - Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
4448 - Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch

Liu, C.

1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Liu, C.

1319 - Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia
4083 - Role of IRF-1 in Regulating the Proliferation and Function of Bone Marrow NK Cells in Patients with Severe Aplastic Anemia

Liu, C.

3608 - AI-Powered Evaluation of Bone Marrow Biopsies Can Distinguish Myeloid Neoplasms from Clinical Mimics

Liu, D.

1519 - A Phase I Study of Chidamide in Combination with Dcag and Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis
2135 - Lymphocyte Dynamics during the Treatment of SR-aGVHD with Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood - a Phase III, Multi-Center, Prospective, Single-Arm Pivotal Study
3462 - CMV-Specific TCR-T Cells for the Treatment of CMV Reactivation after Allogeneic Hematopoietic Stem-Cell Transplantation
3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Liu, D.

3467 - The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

Liu, D.

1742 - The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma

Liu, D.

3537 - Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation
3546 - Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Liu, D.

2477 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Hbb^d3th β-Thalassemia Mouse Model
2488 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model
4140 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in

Liu, D.

4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Liu, E.

768 - Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences

Liu, E.

1882 - Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts
4644 - Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma
4657 - Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment
4667 - Non-Hotspot DIS3 Mutations in Multiple Myeloma Result in Loss of Function Accompanied By Transcriptional and Proteomic Dysregulation

Liu, E.

1591 - North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist
1720 - Safety and Efficacy of AZT-Interferon-α with Belinostat (AI-BEL) for HTLV-1 Related Adult T-Cell Leukemia-Lymphoma
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Liu, E.

4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Liu, F.

1443 - Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (R/R Ph⁺ ALL): First Report from a Phase 1 Study
2120 - Development and Validation of a prediction model for severe PES during the treatment of unrelated UCBT in pediatric patients
2174 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 86 Pediatric Patients with Aplastic Anemia: A Single-Center Experience
4185 - Clinical Characteristics and Prognostic Analysis of Testicular Relapse in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study from China
4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia

Liu, F.

4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Liu, F.

4842 - First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients

Liu, F. T.

1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Liu, F.

1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Liu, F. F.

470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Liu, F.

915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Liu, G.

360 - Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Liu, G.

1092 - Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6

Liu, H.

1902 - Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Liu, H.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics
2593.1 - Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Liu, H.

437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

Liu, H.

1735 - Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Liu, H.

896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Liu, H.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Liu, H.

1449 - Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Liu, H.

4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Liu, H.

1451 - Comprehensive Fusion Gene Landscape in B-Cell Lymphoblastic Leukemia: Insights from Transcriptome Sequencing of 1015 Cases
1467 - Recurrent Focal Mkks-SLX4IP Deletion in ETV6::RUNX1 and Ph/Ph-like B-ALL
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype
2148 - Diagnosis and Prognosis of aGVHD By Metabolic Biomarkers after Allogeneic Hematopoietic Stem Cell Transplantation
3325 - NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations
4212 - Advances in B-ALL Diagnosis and Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5 and International Consensus Classification
4323 - Investigation of Viral Gene Transcripts and Viral-Human Gene Fusions in Acute Leukemia Poly(A) RNA-Seq Data
4326 - Extensive Fusion Gene Profiling in Acute Myeloid Leukemia Revealed By Whole Transcriptome Sequencing of 1614 Cases

Liu, H.

3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Liu, H. C.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Liu, H.

2159 - Clinical Study on the Treatment of Poor Erythroid Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation with Luspatercept

Liu, H.

4941 - Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR_αβ-Depleted Haplo-HSCT

Liu, H.

2736 - Ketogenic Regulation of Histone Modification By CDK4 Promotes Leukemogenesis

Liu, H.

2087 - Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Liu, H.

1078 - Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

Liu, H.

712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
1691 - Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Liu, H.

4319 - Overexpression of GAD1 in Pediatric Acute Myeloid Leukemia Cells Impairs Cytotoxic T Lymphocyte Response to Tumor Cells

Liu, H.

972 - High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial
4923 - Increased EBV Infection and Relapse Rates Following Haploidentical Hematopoietic Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis: A Propensity Score Matching Analysis

Liu, H.

3512 - Lower Respiratory Tract Pathogen Colonization Detected By Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage Fluid before Allogeneic Hematopoietic Stem Cell Transplantation and Its Predicting Value for Post-Transplant Infection

Liu, H.

1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
4481 - Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Liu, H. L.

5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Liu, J. J.

1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Liu, J. M.

4965 - Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies

Liu, J.

2072 - Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients

Liu, J.

2099 - Safety and Efficacy of Etoposide Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma
2380 - Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
3759 - A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
5025 - The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies

Liu, J.

2159 - Clinical Study on the Treatment of Poor Erythroid Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation with Luspatercept

Liu, J.

1187 - Sirolimus Combined Dexamethasone As the First-Line Therapy for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Open-Label, Prospective, Randomized Controlled Clinical Trial

Liu, J.

1197 - IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway

Liu, J.

1605 - Single-Cell Analysis Reveals an Exhaustion of TEM and CTL CD8⁺ T Cells in Hemophagocytic Lymphohistiocytosis with EBV Infection

Liu, J.

2474 - TGF-β1 Reverses Hemoglobin Switching in Erythroid Progenitor Cells before Erythropoietin Induction

Liu, J.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Liu, J.

1285 - Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts

Liu, J.

4810 - Oncolytic Herpes Simplex Virus-Loaded CD19 CAR-T Cells Improves the Therapeutic Effect of Diffuse Large B-Cell Lymphoma

Liu, J.

2072 - Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients
3451 - GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma

Liu, J.

1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Liu, J.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Liu, J.

455 - An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL

Liu, J.

426 - Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands

Liu, J.

874 - CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis
3193 - Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1^S34F Mutant Myelodysplastic Syndromes
3195 - A Correlation of Ineffective Erythropoiesis and Dysregulated Pathways in Myelodysplastic Syndromes

Liu, J.

3278 - Lipid Nanoparticle-Mediated Combinational mRNA Vaccine for Multiple Myeloma: The Next Stage of Cancer Immunotherapy

Liu, J. M.

1220 - An Equation to Distinguish Acute Blood Loss from Dilutional Changes in Serum Hemoglobin Concentration in Patients Who Receive Intravenous Fluids

Liu, J.

3325 - NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma

Liu, J.

172 - A Novel Small Molecule Drug-Based Approach for Treating Beta-Globinopathies

Liu, J.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Liu, J.

1166 - CircFUT8 Promotes Megakaryocyte Proplatelet Formation By Regulating Actin Cytoskeleton Reorganization

Liu, J.

4679 - Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Liu, K.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1^st Line Imatinib

Liu, K.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Liu, K.

300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia

Liu, K.

811 - The AI-Mayo PE (AIM PE) Study: Validation of an Artificial Intelligence Algorithm Using Electrocardiograms to Predict Pulmonary Emboli

Liu, K.

12 - Rbm38 Regulates Heme Biosynthesis Via Fine-Tuning the RNA Alternative Splicing, Stability and Translation of Porphyrin Metabolic Enzyme Gene Ferrochelatase (Fech)

Liu, K.

1674 - Safety and Preliminary Efficacy of F0002, an Anti-CD30 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-1 or PD-L1 Therapy: Results from F0002-101 Phase 1 Study

Liu, L.

3262 - Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma
4668 - TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

Liu, L.

2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Liu, L.

2058 - Development of a Novel Allogeneic Super-Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
4785 - Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Liu, L.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Liu, L.

848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
4278 - Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Liu, L.

2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Liu, L.

2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia

Liu, L.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Liu, L.

2701 - A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Liu, L.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Liu, L.

3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Liu, L.

2882 - High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Liu, L.

1686 - Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma
3132 - Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial
4746 - SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Liu, L.

3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Liu, L.

682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia

Liu, L.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Liu, L.

3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Liu, L.

4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Liu, L.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Liu, L.

1653 - Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Liu, L.

2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence

Liu, L.

2120 - Development and Validation of a prediction model for severe PES during the treatment of unrelated UCBT in pediatric patients
2174 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 86 Pediatric Patients with Aplastic Anemia: A Single-Center Experience
4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia

Liu, L.

3260 - Comprehensive Translatomic Analysis of Multiple Myeloma Unveils Novel Insights into Disease Pathogenesis

Liu, L.

948 - IL-11 Signaling Drives Clonal Hematopoiesis-Associated Cardiac Dysfunction

Liu, L.

993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Liu, L.

4455 - Molecular Biology Study of Primary Immuno-Privileged Lymphomas

Liu, L.

97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Liu, L.

843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Liu, L.

452 - Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome
1621 - CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression
4379 - Suvmax Linked to Intrafollicular Macrophage Infiltration Is Associated with Poor Outcome of Follicular Lymphoma

Liu, L.

12 - Rbm38 Regulates Heme Biosynthesis Via Fine-Tuning the RNA Alternative Splicing, Stability and Translation of Porphyrin Metabolic Enzyme Gene Ferrochelatase (Fech)
437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells
2656 - PERK Maintains Hematopoietic Stem Cells Pool Integrity By Promoting Proliferation

Liu, M. J.

1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Liu, M.

4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Liu, M.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation

Liu, M.

54 - Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation
3590 - Targeting Cytidine Triphosphate Synthase 1 Promotes Anti-AML Immunity

Liu, M.

2748 - Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Liu, M.

3004 - Spatial-Resolved Transcriptomics Reveals Immune Landscape Variations in Primary Central Nervous System Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Liu, M.

1467 - Recurrent Focal Mkks-SLX4IP Deletion in ETV6::RUNX1 and Ph/Ph-like B-ALL
3325 - NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
4323 - Investigation of Viral Gene Transcripts and Viral-Human Gene Fusions in Acute Leukemia Poly(A) RNA-Seq Data

Liu, M.

3244 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Liu, M.

3271 - The Immune Inhibitory Hematopoietic Adaptor Protein Hacs1(Sly2) Suppresses the Proinflammatory Macrophage Function Contributing to Multiple Myeloma Progression

Liu, M.

5011 - Contemporary Screening and Treatment Practices for Iron Deficiency in Pregnancy

Liu, M.

3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations
4323 - Investigation of Viral Gene Transcripts and Viral-Human Gene Fusions in Acute Leukemia Poly(A) RNA-Seq Data

Liu, N.

3268 - A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

Liu, N.

4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells

Liu, N.

1635 - Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
3119 - Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Liu, N.

449 - FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
4432 - Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors
5093 - Timing of End-of-Treatment PET Scans and Impact on Subsequent Testing in Diffuse Large B-Cell Lymphoma
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Liu, P. P.

198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder
798 - Minority Patients in the NIH RUNX1-FPDMM Natural History Study Present Mostly with Large Deletions Affecting RUNX1
1324 - Single Cell Transcriptome Analysis of CD34+ Cells from Patients with RUNX1-Fpdmm at Different Stages of Disease Progression

Liu, P.

1998 - Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple
4700 - Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study
5159 - Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Liu, P.

1325 - Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics
2657 - YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate
4091 - GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Liu, P.

2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Liu, P.

1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
2206 - The Endocannabinoid N-Arachidonoyl Dopamine Induces Leukemia Cell Pyroptosis to Overcome the Venetoclax Resistance

Liu, P.

3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients

Liu, P.

1273 - CD38 Inhibition Enhances Human Hematopoietic Stem Cell Maintenance in Ex Vivo Cultures

Liu, Q.

3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial
4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Liu, Q.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Liu, Q.

1355 - TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Liu, Q.

4910 - Donor Neutrophil Subsets in G-CSF Mobilized Peripheral Blood Stem Cell to Predict the Risk of Agvhd

Liu, Q.

696 - Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial
839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial
972 - High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial
1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
1386 - Magic-PDX Models Can be Easily Established for Fast Drug Screening and Mechanism Study of Primary Drug-Resistant Hematological Malignancies
1516 - Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
1773 - Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML
1803 - The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study
2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study
2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
2915 - FLT3-ITD Mutation Expands HSPC Compartment to Initiate AML Development
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
3412 - IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention
3979 - Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study
4138 - Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp
4191 - Evaluating the Effectiveness and Security of Antifungal Prophylaxis in Acute Lymphoblastic Leukemia Induction Chemotherapy
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4283 - The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study
4372 - EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3
4897 - Signifcance of Intestinal CD8+CD69+CD103+ Tissue-Resident Memory T Cells in Human Intestinal Acute Graft-Versus-Host Disease
4910 - Donor Neutrophil Subsets in G-CSF Mobilized Peripheral Blood Stem Cell to Predict the Risk of Agvhd
4923 - Increased EBV Infection and Relapse Rates Following Haploidentical Hematopoietic Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis: A Propensity Score Matching Analysis

Liu, Q.

2888 - A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia

Liu, Q.

2899 - A Multicenter Clinical Study of Cccg - APL-2017 in the Treatment of Children with Acute Promyelocytic Leukemia

Liu, Q.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Liu, Q.

1808 - A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
3180 - First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Liu, Q.

4153 - Pharmacological Inhibition of METTL3 Enhances the Acute Myeloid Leukemia Cell Death Induced By Venetoclax Via the METTL3-YTHDF2-FBXW7-MCL1 Axis

Liu, Q.

1519 - A Phase I Study of Chidamide in Combination with Dcag and Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis

Liu, Q.

266 - Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlled Clinical Study

Liu, Q.

4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Liu, Q.

2231 - Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders

Liu, Q.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Liu, R.

2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)

Liu, R.

1670 - SUVR (SUVmax Lymphoma/SUVmax Liver) Vs Deauville Score for Predicting Relapse in Hodgkin Lymphoma

Liu, R.

4225 - NOTCH1 gene Fusions Occur Frequently in Refractory or Relapsed (R/R) T-Cell Lymphomablastic Lymphoma

Liu, R. X.

4065 - Immune Checkpoint Inhibitors Reverse the Mesenchymal Stromal Cell-Mediated Immunosuppression in Acute Myeloid Leukemia Microenvironment

Liu, R.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Liu, R.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)

Liu, R.

1745 - The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma
3079 - Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3387 - Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy
4856 - Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Liu, R.

2411a - Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2

Liu, R.

3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Liu, S.

857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
4122 - Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies

Liu, S.

4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Liu, S.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Liu, S.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Liu, S. (.

4838 - BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells

Liu, S.

3711 - Patient Reported Outcomes in Vexas Syndrome

Liu, S.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Liu, S.

743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors

Liu, S. A.

5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Liu, S.

164 - Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells

Liu, S.

4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Liu, S.

2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Liu, S.

1200 - The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir

Liu, S.

1172 - Molecular Delineation and Targeting of a Megakaryocyte Ontogenic Switch for Therapeutic Applications

Liu, S.

4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Liu, S.

3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Liu, S.

3586 - Discovery of BTC-86, a Novel Second-Generation Menin-MLL Inhibitor to Overcome the Acquired Resistance in MEN1 for R/R Acute Leukemia

Liu, S.

437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells
2656 - PERK Maintains Hematopoietic Stem Cells Pool Integrity By Promoting Proliferation

Liu, T.

317 - Genome-Wide Association Study of Acute Lymphoblastic Leukemia in Hispanic/Latino Children Identifies a Putatively Novel Risk Locus at Chromosome 5q31.1

Liu, T.

3143 - SETBP1 Regulates Myst Acetyltransferase Complexes to Drive a Leukemogenic Gene Expression Program

Liu, T.

1736 - Zanubrutinib Combined with R-CHOP in Patients of Newly Diagnosed DLBCL with p53 Expression: A Single-Arm Prospective Study

Liu, T. H.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Liu, T.

1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia
4129 - Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching

Liu, T.

1162 - Ras-Associated Autoimmune Lymphoproliferative Disorder: Retrospective Case Series
1443 - Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (R/R Ph⁺ ALL): First Report from a Phase 1 Study

Liu, T.

3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Liu, T.

4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Liu, T.

1049 - Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia
1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)
2840 - Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia
3512 - Lower Respiratory Tract Pathogen Colonization Detected By Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage Fluid before Allogeneic Hematopoietic Stem Cell Transplantation and Its Predicting Value for Post-Transplant Infection

Liu, T.

2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Liu, T.

1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Liu, T.

1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study

Liu, T.

2430 - Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting
3187 - Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Liu, T.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Liu, V. M.

4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Liu, W.

4061 - Single-Cell Transcriptomic and Spatial Characterization of Multipotent Stromal Cells in Homeostatic,Remodeled, and In Vitro Expanded Human Bone Marrow

Liu, W.

1447 - Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Liu, W.

1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
4347 - Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study
4481 - Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Liu, W.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Liu, W.

1213 - A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors
1815 - MISTRG6kit^W41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model
3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
3583 - Prophylactic Administration of Glucocorticoids and Tacrolimus in AAV8-F8 Gene Therapy of Severe Haemophilia-a Achieved a Significant Long-Term Efficacy

LIU, W.

1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Liu, W.

2899 - A Multicenter Clinical Study of Cccg - APL-2017 in the Treatment of Children with Acute Promyelocytic Leukemia

Liu, W. H.

3401 - Overcoming NK Cell-Mediated Allograft Rejection By Anti-3^rd Party Central Memory Veto CD8 T Cells through Down-Regulation of the Activating Receptor DNAM-1 on Alloreactive NK Cells

Liu, W.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Liu, W.

960 - CD93⁺ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Liu, W.

1686 - Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma

Liu, W.

1457 - Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1^plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia
4210 - Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

Liu, W.

1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration

Liu, W.

3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Liu, W.

328 - Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2734 - CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4289 - ADGRG1/GPR56 As a Marker of CD8⁺ Tumor-Reactive T Cells in Acute Myeloid Leukemia

Liu, W.

1501 - Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Unrelated Umbilical Cord Blood Stem Cell Microtransplantation and IL-2 Treatment in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
1549 - Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Liu, W.

2612 - Dilute Russel Viper Venom Time (DRVVT) Ratio Predicts the Identification of Triple Positive Antiphospholipid Antibody Profile

Liu, X.

743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors

Liu, X.

3539 - Protein Language Model-Based Intra-Gene Disparity of Donor HLA Alleles Informs Prognostic Risk in Hematologic Malignancy Patients Undergoing Haplo-Identical HSCT: A Combined Xinqiao-CIBMTR Analysis
3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Liu, X.

3730 - Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Liu, X.

4347 - Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study

Liu, X.

2553 - Multi-Omics Integration Analysis Identifies Lipoproteins As Biomarkers for Glucocorticoid Response in Immune Thrombocytopenia
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3583 - Prophylactic Administration of Glucocorticoids and Tacrolimus in AAV8-F8 Gene Therapy of Severe Haemophilia-a Achieved a Significant Long-Term Efficacy

Liu, X.

938 - The LSD1 Inhibitor RN1 Rescues Congenital Dyserythropoietic Anemia Type II

Liu, X.

3251 - Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Liu, X.

1653 - Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Liu, X.

1773 - Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML
1793 - Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R^T618I: A Multi-Centre Retrospective Study
1803 - The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Liu, X.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Liu, X.

1443 - Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (R/R Ph⁺ ALL): First Report from a Phase 1 Study

Liu, X.

4265.4 - PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML

Liu, X.

4171 - Revealing the Synergistic Potential of Mosunetuzumab Plus Polatuzumab Vedotin through CD20 Upregulation

Liu, X.

1977 - Shengxuening Tablets for the Treatment of Cancer Related Anemia in Hematologic Malignancies: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Liu, X.

3271 - The Immune Inhibitory Hematopoietic Adaptor Protein Hacs1(Sly2) Suppresses the Proinflammatory Macrophage Function Contributing to Multiple Myeloma Progression

Liu, X.

2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Liu, X.

2140 - Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease

Liu, X.

2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML

Liu, X.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Liu, X.

1736 - Zanubrutinib Combined with R-CHOP in Patients of Newly Diagnosed DLBCL with p53 Expression: A Single-Arm Prospective Study

Liu, X.

4910 - Donor Neutrophil Subsets in G-CSF Mobilized Peripheral Blood Stem Cell to Predict the Risk of Agvhd

Liu, X.

1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study

Liu, X.

2655 - Tcf15 Negatively Regulates T and B Lymphopoiesis

Liu, X.

1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells
1358 - Generating a Model of Human CD8⁺ T-Cell Lymphoma from Genetically Modified Normal T-Cells
1360 - RHOA^G17V Mutation Exhibits Markedly Different Functions in the Presence of TET2 Loss in T-Cells
1362 - Complementary Roles of DNMT3A and TET2 KO in Sculpting CD4-T Cells for Sustained Proliferation without Exhaustion to Promote Lymphomagenesis

Liu, Y. L.

194 - Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation

Liu, Y.

4033 - Characterization of a Colony Stimulating Factor Receptor (CSF1R) Upstream Regulatory Element in Haematopoiesis

Liu, Y.

2097 - RNA-Lnp-Mediated CAR-T Cell Manufacturing: A Paradigm Shift in Precision Immunotherapy
2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4109 - Protein Tyrosine Phosphatase PRL2 Promotes MLL-Rearranged Acute Myeloid Leukemia Development through Inhibiting the p53 Pathway
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML

Liu, Y.

1732 - Time-Limited of Zanubrutinib, Rituximab and Lenalidomide (ZR2) Regimen for the Treatment of Super-Elderly Diffuse Large B-Cell Lymphoma (DLBCL): A Prospective, Exploratory Clinical Study

Liu, Y.

2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Liu, Y.

3405 - Changes in Glycosylation on the Cell Surface Result in Highly Potent and Long-Lasting Allogeneic CAR-T Therapy in Patients

Liu, Y.

4679 - Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China

Liu, Y.

1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
2994 - Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Liu, Y.

1243 - Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination
2565 - Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index

Liu, Y.

50 - A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4⁺ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Liu, Y.

2307 - Delayed Physical Growth and Related Factors in Pediatric Patients with Transfusion-Dependent Thalassemia
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBB^T87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Liu, Y.

539 - A Novel Role of LKB1 in Erythroblast Enucleation
1164 - Protein Arginine Methyltransferase 1 Expands and Mobilizes Immune Megakaryocytes and Generates Hyperactive Platelets in Stress Conditions
3033 - Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Liu, Y.

2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Liu, Y.

4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Liu, Y.

1028 - A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
1188 - Efficacy of Combined Herombopag and Recombinant Human Thrombopoietin Therapy Compared to Monotherapy on Platelet Engraftment after Autologous Hematopoietic Stem Cell Transplantation in Patients
1192 - Efficacy and Safety of Mesenchymal Stem Cells in Improving Thrombocytopenia after Chemotherapy in Malignant Tumors
1193 - Herombopag for Preventing Chemotherapy-Induced Thrombocytopenia in Lymphoma: A Single Center, Randomized Controlled, Phase II Study
1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study
2099 - Safety and Efficacy of Etoposide Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma
2380 - Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
3759 - A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
4488 - Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study
4867 - The Role of Total Body Irradiation in Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma: A Multicenter Retrospective Study in China
5025 - The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies

Liu, Y. C.

1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement

Liu, Y. L.

3966 - Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Liu, Y. L.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

Liu, Y.

4685 - Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd

Liu, Y.

712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial

Liu, Y.

2068 - NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Liu, Y.

3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Liu, Y. H.

2392 - Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
5170b - Real-World Step-up Dosing Practice for Patients Who Initiated Talquetamab in US Hospitals: An Analysis of the All-Payer US Hospital Administrative Premier Healthcare Database

Liu, Y.

1320 - The Therapeutic Effect of Myeloid-Suppressor Cells Induced By Umbilical Cord Blood CD34⁺cells in Mice with Aplastic Anemia
4073 - Antithymocyte Globulin Enhances Myeloid-Derived Suppressor Cell Expansion and Function in Severe Aplastic Anemia

Liu, Y.

3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Liu, Y.

4225 - NOTCH1 gene Fusions Occur Frequently in Refractory or Relapsed (R/R) T-Cell Lymphomablastic Lymphoma

Liu, Y.

1694 - Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring

Liu, Y.

2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Liu, Y.

1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
5175 - Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Liu, Y.

4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Liu, Y.

1653 - Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Liu, Y.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

Liu, Y.

4319 - Overexpression of GAD1 in Pediatric Acute Myeloid Leukemia Cells Impairs Cytotoxic T Lymphocyte Response to Tumor Cells

Liu, Y.

328 - Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4289 - ADGRG1/GPR56 As a Marker of CD8⁺ Tumor-Reactive T Cells in Acute Myeloid Leukemia

Liu, Y.

3927 - Identification of Megakaryocytes As a Functional Component of Circulation Blood

Liu, Y. L.

3719 - A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)

Liu, Y. Q.

1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Liu, Y.

498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma
1457 - Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1^plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Liu, Y.

3433 - Engineering a Controllable and Reversible Switch for CAR-T Cell Immunotherapy Via a Genetic Code Expansion System

Liu, Y.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Liu, Y.

3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL

Liu, Y.

1586 - Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Liu, Y.

3927 - Identification of Megakaryocytes As a Functional Component of Circulation Blood

Liu, Y.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies
4176 - Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models

Liu, Y.

619 - IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD
1108 - Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease
3834 - Effect of Obexelimab Surrogate Monoclonal Antibody on Inhibition of Autoimmune Hemolytic Anemia (AIHA) Induction in Mice

Liu, Y.

1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo

Liu, Y.

1961 - Genetic Insusceptibility Mediated Inflammation Contributes to Bortezomib-Induced Peripheral Neuropathy

Liu, Y.

2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1^st Line Imatinib

Liu, Y.

3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
3389 - A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia
4709 - T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

Liu, Y.

950 - Systematic Evaluation of GAPs and Gefs Identifies ARHGAP45 As a Targetable Leukemia-Specific Dependency

Liu, Y.

331 - Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma

Liu, Y.

4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Liu, Y.

488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Liu, Y.

1590 - Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Liu, Y.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Liu, Y.

1990 - First-in-Human, Phase Ia_, Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Liu, Z.

3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Liu, Z.

3931 - Post-Injury Treatment with Rapid Intraosseous Injection of Lyophilized Synthetic Platelets Enhances Survival, Hemostasis, and Hemodynamics in a Rat Model of Liver Laceration

Liu, Z.

1187 - Sirolimus Combined Dexamethasone As the First-Line Therapy for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Open-Label, Prospective, Randomized Controlled Clinical Trial

Liu, Z.

2164 - Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment

Liu, Z.

4856 - Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Liu, Z.

627 - Rbmx Regulates YTHDC1 Nuclear Condensates to Promote Nascent Transcription in Acute Myeloid Leukemia

Liu, Z.

1078 - Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH
1897 - T-Lymphocyte Suppression By ULK2 High Expression of CD14⁺ Monocytes in Patients with Multiple Myeloma

Liu, Z.

4540 - Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Liu, Z.

477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Liu, Z. Z.

3166 - Long Term Follow-up of Methotrexate and Cytarabine in Adult Patients with Langerhans Cell Histiocytosis

Liu, Z.

1146 - A Novel Engineering Platelet Platform Target the Macrophages to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis

Liu, Z.

1049 - Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia
3512 - Lower Respiratory Tract Pathogen Colonization Detected By Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage Fluid before Allogeneic Hematopoietic Stem Cell Transplantation and Its Predicting Value for Post-Transplant Infection

Liu, Z.

1702 - Promising Outcomes with Pola-R-CHP in Newly Diagnosed Diffuse Large B Cell Lymphoma with Aberrant p53 Expression

Liu, Z.

4291 - Prognostic Implications of KMT2A Rearrangements and Partial Tandem Duplications in AML: Outcomes and the Role of Allogeneic Hematopoietic Cell Transplantation

Liu, Z.

477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3251 - Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Liu, Z.

690 - Parvovirus B19 Originates from Infected Hematopoietic Stem Cells Following Hematopoietic Stem Cell Transplantation

Liu, Z.

4077 - Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Liu, Z.

4083 - Role of IRF-1 in Regulating the Proliferation and Function of Bone Marrow NK Cells in Patients with Severe Aplastic Anemia

Liu, Z.

3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Liu-Michael, Q.

3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Livak, K. J.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
928 - Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling

Livak, K. J.

758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Livingston, J.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Livnat, T.

430 - A Novel Murine Model Rebalancing Coagulation Enables Gene Therapy Studies for Severe Protein C Deficiency, a Lethal Pro-Thrombotic Disorder

Liyasova, M.

1921 - Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Lizee, G.

4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Lizotte, K.

1107 - Dual Activation of PKR and PKM2 Reduced the Development of Fibrosis and Iron Deposition in a Sickle Cell Disease Nephropathy Mouse Model

Ljevar, S.

3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Ljungman, P. T.

3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Llácer Ferrandis, M. J.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Llamas Gutierrez, F.

1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Llanos, L.

3583.1 - RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

Lloid, M.

4862 - Baseline Salivary Microbiota Predicts Severe Oral Mucositis after Allogeneic Hematopoietic Cell Transplantation
4880 - Differential Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Supragingival Plaque Microbiota and Oral Mucositis after Allogeneic Transplantation

Llopiz, D.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Llorca-Cardenosa, M.

2772 - First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

Lloret Madrid, P.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Lloret, P.

2111 - Current Challenges in the Assessment of Related Donors for Hematopoietic Stem Cell Transplantation

Lloyd, E.

4757 - In-class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Lo, A. C.

461 - Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Lo Celso, C.

4152 - Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Lo, C.

550 - T Cell Clonality in Paediatric Immune Thrombocytopenia
3943 - Clinical Study to Determine the Pathogenesis of Autoimmune Thrombocytopenia in Pediatric Patients

Lo Nigro, L.

3086 - CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review
4217 - Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study

Lo Presti, V.

168 - TNFα Plays Essential Role in Resolution of Anemia of Inflammation in Tnfαko Mice Treated with Heat-Killed Brucella Abortus

Lo Riso, L.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain

Lo, S.

1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Lo-Rossi, A.

3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Lob, H. E.

2473 - TMPRSS6 Inhibition Rapidly Reverses Liver Iron Overload and Prevents an Increase of Splenic Pro-Inflammatory Macrophages in a Mouse Model of Beta-Thalassemia

Lobbardi, R.

467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, in Patients with Non-Hodgkin’s Lymphoma
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Lobbes, H.

2674 - Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group

Lobello, C.

1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications

Löber, J.

230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Lobet, S.

1205 - Impact of Emicizumab on Mental Liberation in Adult Patients with Severe and Moderate Factor VIII Deficiency

Lobitz, S.

4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Lobo, C.

619 - IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD
1108 - Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease
- Impact of RBC Metabolism on the Disease Outcomes of Transfusion Dependent Patients

Lobry, C.

4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Locantore-Ford, P. A.

1184 - Platelet Transfusion-Sparing Regimens for Severe Thrombocytopenia in Patients Undergoing Autologous Stem Cell Transplantation - a Comparative Retrospective Analysis
1270 - Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds

Locastro, M.

5054 - An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study

Locatelli, F.

309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
640 - Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
1388 - Role of the Interferon Alpha Inducible Protein 6 (IFI6) in Establishing Chemoresistance in Acute Myeloid Leukemia
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2827 - Rescuing of the Chemotherapy Sensitivity in Relapsed/Refractory, Pediatric Acute Lymphoblastic Leukemia (r/r ALL) through the Combination of Navitoclax (NAV) and Venetoclax (VEN): Results of Compassionate Use across Four European Countries
2910 - Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML
3086 - CD20-Negative Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphomas and Mature B-Cell Leukemia in Children, Adolescent and Young Adults: A Retrospective Review
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS^® Antibody-TCR Platform in Acute Myeloid Leukemia
3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4217 - Frequency and Early Prognostic Significance of Gene-Class Fusions Identified By RNA-Seq in Children and Adolescent with T-Cell Acute Lymphoblastic Leukemia Enrolled on AIEOP-BFM ALL 2017 Study
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia
4830 - CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
4864 - Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Locher, B. N.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Lochner, J.

2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Lock, D.

485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Lock, M.

41 - The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome

Locke, F. L.

232 - Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large B Cell Lymphoma
247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies
- Response and Resistance: A Tale of Tumor and T Cells
- Moderator Introduction

Locke, M.

1492 - Influence of COVID-19 on Acute Myeloid Leukemia Treatment Efficacy: Insights from a Propensity Score-Matched Cohort Study

Locke, M.

1199 - Preclinical Evaluation of NXT007 Using in Vitro and In Vivo Models of Hemostasis and Thrombosis

Lockey, T.

146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Lodaya, A.

511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials

Lodaya, K.

3722 - Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
3738 - Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events

Lodi, A.

1400 - Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

Lodish, H. F.

164 - Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells

Loeffen, J. L.

2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups

Loeffler, B.

5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Loeffler, D.

1272 - Hematopoietic Stem Cell Function and Differentiation Is Regulated By DCAF7 through Polycomb Repressive Complex 1 (PRC1) Modulation

Loeffler, M.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Loefgren, C.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Loera, B.

2758 - Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

Loftus, J.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Loftus, J. P.

3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL

Logan, A. C.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
2037 - Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial
4854 - Multiplexed Cytokine Assessment of T- and NK-Cell Responses to Tumor Cells: Parallel Assessment of Biomarkers Associated with Efficacy, Safety, and Persistence

Logan, B. R.

685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
3514.1 - OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Logan, E. K.

4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Logan, N.

784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Loggers, E. T.

2297 - Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT)

Loggetto, S.

2310 - Thalassemia Scenario in Brazil: A Descriptive Study

Loghavi, S.

Loglisci, G.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Logothetis, C.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Loh, C. K.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Loh, J. W.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Loh, K. P.

3652 - Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
3676 - Hematologists' Approach to Discussing Older Patients' Values in the Context of Allogeneic Hematopoietic Cell Transplantation
5054 - An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study
- Closing Remarks

Loh, K. P. (.

- Challenges in Hospice and End-of-Life Care in the Transfusion-Dependent Patient

Loh, M. L.

1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
90 - Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Loh, Y.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Lohman, C.

2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Lohmann, T.

2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Lohoff, C.

276 - Unraveling Molecular Subgroup-Specific Pathway Dependencies in Chronic Lymphocytic Leukemia through Drug-Perturbed Transcriptomic Profiling and Statistical Modeling
3584 - Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing

Lohr, J. G.

1898 - Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies
4223 - Genome-Wide CRISPR Screen Reveals IRF1 and TFAP4 As Transcriptional Regulators of Galectin-9 in T-Cell Acute Lymphoblastic Leukemia

Lohray, R.

1679 - Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

Loi, E.

3326 - Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Loi, K.

1245 - Risk Determination in Pediatric Patients for Venous Thromboembolism

Loigom, D.

1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Loinaz, X.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Lok, V.

2904 - Extended Vs Standard Hypomethylating Agent Dosing in Combination with Venetoclax in Newly Diagnosed Acute Myeloid Leukemia

Lokare, A.

3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Loke, J. C.

120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
188 - In Vivo barcoded CRISPR-Cas9 Screen Identifies Ncoa4-mediated Ferritinophagy As a Dependence in Tet2-Deficient Haemopoiesis
1291 - The Effect of TET2 Loss on Macrophage Phagocytosis
4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation

Loken, M. R.

967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
1543 - Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Lokko, L.

3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies

Loko, G.

3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Loksa, V.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Lollar, P.

428 - Cryoem Structures and Conformational Landscapes of Activated Blood Coagulation Factor VIII and the Intrinsic Tenase Complex
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

Lomaia, E.

3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Lomas, O.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Lombardi, C.

4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Lombardi, G.

301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial

Lombardo, A.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Lomeli, D.

2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates

Lomeli, R. A.

3871 - Mechanism-Based Treatable Targets for Organ Damage and Pain in Sickle Cell Disease

Lomonosova, Y.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Lonardi, C.

1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Lonardi, S.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Lonchamp, C.

4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

Loncharich, A.

1921 - Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

London, E.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

London, W. B.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate

Londono, D.

1556 - Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS, DNMT3A and WT1 and Poor Outcome

Lone, W. G.

456 - An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities
1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells
1362 - Complementary Roles of DNMT3A and TET2 KO in Sculpting CD4-T Cells for Sustained Proliferation without Exhaustion to Promote Lymphomagenesis

Lonergan, S.

494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Long, E.

3168 - Treatment of Myeloproliferative Neoplasms with Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety

Long, G. D.

2001 - Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Long, J.

5127 - Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center

Long, J.

3492 - Improved Outcomes with Bu/Cy+Melphalan and Bu/Cy+Thiotepa Regimens in Haploidentical Hematopoietic Stem Cell Transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Long, L.

825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Long, M.

2783 - Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

Long, M.

2233 - Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Long, M.

2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Long, N.

1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
4815 - Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Long, S.

2922 - A Rapid Diagnostic Assay to Detect a DNA Methylation Signature of Menin Inhibitor Response in Acute Myeloid Leukemia

Long, T.

3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance

Long, W.

2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates

Long, Z.

4138 - Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp

Longarón, R.

4351 - Genetic Characterization of Marginal Zone Lymphomas in Tissue and cfDNA
4566 - Diagnostic Challenges in Patients with Clinical Suspicion of Myeloproliferative Neoplasms and JAK2V617F≤1%

Longcor, J.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)

Longhini, A. F.

637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment

Longley, D.

3144 - Interferon Alpha Activates the Unfolded Protein Response Resulting in Synergy with Bortezomib in JAK2 V617F Myeloproliferative Neoplasms

Longo, F.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Longo, G.

640 - Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia
2910 - Novel Promising Therapeutic Strategies for Advancing the Treatment of KMT2A-Rearranged AML

Longo, W.

1039 - Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
2374 - Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL
3448 - Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies
3459 - Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Longu, F.

2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Lonial, S.

251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
255 - A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
1973 - Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial
1983 - Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3311 - Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
3780 - Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4672 - A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
5142 - Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
5152 - Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Loo, S.

223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Loo, T. Y.

3709 - Inhibitors Significantly Impair Quality of Life for Hemophilia a Patients

Looi, W. S.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Loosveld, M.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Lopedote, P.

1633 - Acalabrutinib, Umbralisib and Ublituximab Regimen (AU2) Demonstrates High Response Rate and Undetectable Molecular Minimal Residual Disease (MRD) in Patients (pts) with De Novo Mantle Cell Lymphoma (MCL)
- Reduced Blood Transfusions in Patients with Chronic Liver Disease Undergoing Paracentesis

Lopes De Menezes, D.

4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Lopes, M.

41 - The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome

Lopes, O.

1295 - Associations of Lineage-Specific Clonal Hematopoiesis with COVID-19 Hospitalization and Mortality

Lopes, R.

4664 - Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

Lopez, A.

4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

López, A.

1658 - Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients
1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4471 - Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Lopez, A. F.

3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Lopez Ansoar, E.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Lopez, B.

3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Lopez, C. A.

3748 - Treatment-Related Neuropathy Following Brentuximab-Vedotin in African Americans Treated for Lymphoma: A Retrospective Chart Review

Lopez Corral, L.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

López, C.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

López de la Guía, A.

3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

López del Amo, R.

4000 - External Validation of the French Score in Thrombotic Microangiopathies: Real-World Experience in a Large Retrospective Cohort of 1483 Patients

López del Amo, R.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain
2618 - ADAMTS13 Activity Measurement Using a Chemiluminescence-Based Technique. Prospective Multicenter Comparative Study of the Spanish Apheresis Group (GEA)- Spanish Society of Hematology and Hemotherapy (SEHH)

Lopez, E.

3439 - Improved Expansion of Peripheral Blood and iPSC-Derived Natural Killer Cells for Clinical Applications

Lopez, E.

2239 - Reproductive Health Surveys Administered in Sickle Cell Clinics Can Inform Personalized Care and Multidisciplinary Collaboration

López, E.

2093 - Comparison of Cryopreserved Versus Non-Cryopreserved Strategies for Autologous Stemcell Transplantation in Multiple Myeloma in Two Centers in Uruguay

Lopez, F.

666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3545 - Long-Term Outcomes and Late Complications of Allogeneic Stem Cell Transplant with CD34+ Positive Selection in Adults with Acute Leukaemia and Myelodysplastic Syndrome: A Single-Centre Study

López Fresneña, C.

4872 - At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience

Lopez Garcia, A.

598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

López Godino, O.

4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Lopez Gomez, L. A.

1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo

López Gómez, L. A.

1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

López Gómez, L. A.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lopez, G.

2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

López Granados, E.

2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing

Lopez Hernandez, G.

4868 - Different Donors and Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Inherited Bone Marrow Failure Syndromes: A Tale of Custom-Made Suits

López Jaime, F. J.

2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

López, J.

3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
3349 - Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation
4471 - Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Lopez, J.

1824 - Single-Tube Flow Cytometry 12-Color Combination for the Screening, Classification, and Staging of Chronic Myelomonocytic Leukemia. Correlation with NGS Molecular Data

Lopez Jimenez, J.

805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Lopez, J. M.

677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

López, J. A.

2547 - Declining Autophagic Flux Underlies Mitochondrial and Platelet Defects in Aging

Lopez, J. A.

3998 - Streptococcus Gordonii Binds VWF Via Its Sialoglycan-Binding Adhesins Under Shear to Initiate Infective Endocarditis

López, J. A.

182 - An Important Role for P-Selectin in Thrombotic Microangiopathy
184 - HDL and HDL-Mimetic Nanoparticles Prevent Induced TTP and Interrupt the Course of Ongoing Episodes of the Disease
3864 - Erythrocytes from Sickle Cell Mice Activate the Endothelium and Blood Cells and Induce Vaso-Occlusion When Transfused into ADAMTS13-Deficient Mice: Role of Lipid Degradation

Lopez, J. F.

1395 - Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Lopez, K.

463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas
3097 - Radiation Therapy for Burkitt Lymphoma: Multi-Decade Insights from a Single Center

Lopez Lopez, J. A.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Lopez Lorenzo, J. L.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

López Lorenzo, J. L.

2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
3583.1 - RP-L301, a Lentiviral-Mediated Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase 2 Clinical Trial Design

López Marin, J.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Lopez Pereira, P.

1658 - Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Lopez Picado, A.

2618 - ADAMTS13 Activity Measurement Using a Chemiluminescence-Based Technique. Prospective Multicenter Comparative Study of the Spanish Apheresis Group (GEA)- Spanish Society of Hematology and Hemotherapy (SEHH)
3999 - Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)

Lopez Quiñones Pimentel, A. R.

2270 - Home Care in Oncohematological Patients Not Candidates for Intensive Chemotherapy: From Active Treatment to the End of Life. Ambispective Multicentric Study on Dual and Early Assessment of Palliative Care and Hematology in a Rural Environment

Lopez, R.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

López Rubio, M.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain

Lopez, S.

2297 - Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT)

Lopez, W.

1868 - A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

López-Cadenas, F.

2129 - Donor Chimerism Monitorization for Relapse Prediction in Ex-Vivo CD34-Selected Allogenic Hematopoietic Stem Cell Transplant

Lopez-Cayuqueo, K.

3147 - Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis

Lopez-Cobo, S.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

López-Corral, L.

508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

López-Díaz De Cerio, A.

4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Lopez-Esteban, M.

5050 - Integration of Geriatric Assessment and Genetic Profile Facilitates Personalized Treatment Selection and Follow-up in Old Patients with Newly Diagnosed Acute Myeloid Leukemia

López-Fernández, E.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Lopez-Garcia, Y. K.

1665 - Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial
2364 - Identifying Barriers to Sexual Health in Patients with Hematological Malignancies and Underprivileged Circumstances
4898 - Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Lopez-Girona, A.

169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease
957 - BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin’s Lymphoma
1881 - Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma

López-Guerra, M.

225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Lopez-Guillermo, A.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy
1613 - Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma

Lopez-Jimenez, F.

811 - The AI-Mayo PE (AIM PE) Study: Validation of an Artificial Intelligence Algorithm Using Electrocardiograms to Predict Pulmonary Emboli

Lopez-Masi, L.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

López-Mora, Y. A.

4030 - Reassessing Blood Product Irradiation in Haploidentical Transplantation: A Single-Center Perspective

Lopez-Muñoz, N.

3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Lopez-Ocasio, M.

2167 - Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

López-Pardo, J.

3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Lopez-Pentecost, M.

4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD

Lopez-Plaza, I.

1244 - Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression

López-Santamaría Castro, C.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Lopresti, S.

3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification

Lorch, U.

3953.1 - A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Lorcy, F.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Lord-Bessen, J.

118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Loren, A. W.

588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
- General Session 1: Paving a Career in Medical Education & Scholarship
- Plenary Introducer

Loren, A.

316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance

Lorenc, R.

2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia

Lorente Alegre, P.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lorenz, I.

3406 - Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia

Lorenz, N.

2425 - Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Lorenzi, A.

2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Lorenzi, L.

3928 - Chromatin Remodeling By GATA1s Alters Megakaryocytic Gene Expression

Lorenzi, L.

453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements

Lorenzi, P. L.

2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Lorenzini, T.

4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Lorenzo, A.

3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion

Lorenzo Algarra, J.

1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Lorenzo Vizcaya, A.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

LoRusso, P.

3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Loscertales, J.

4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Loschi, M.

596 - Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1314 - Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Loscocco, F.

1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Loscocco, G. G.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

Loseto, G.

3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Losi, G.

2168 - HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Lossos, C.

828 - CCRL2 As a Novel Target in Acute Erythroid Leukemia

Lossos, I. S.

337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Lotesoriere, I.

2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Lotfi, K.

3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Lotfollahzadeh, S.

3962 - Dietary Tryptophan Contributes to Indoleamine 2,3-Dioxygenase 1(IDO-1)-Mediated Cancer-Associated Venous Thrombogenicity in Mice

Lotia, D.

4931 - Impact of Cannabis Use on Clinical Outcomes in Bone Marrow Transplant Patients: A Nationwide Analysis
4951 - Ulcerative Colitis and Adverse Outcomes in Hematopoietic Stem Cell Transplantation: A Nationwide Analysis

Lotter, J.

32 - Longitudinal Contribution of Distinct Hematopoietic Clones during Marrow Recovery in Immune Aplastic Anemia
439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
1323.1 - Trial in Progress: A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Lotterman, C.

531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Lotti, F.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Lotze, M.

4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Lou, C.

1024 - Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Lou, J.

1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype

Lou, J.

793 - Ferric Derisomaltose Versus Iron Sucrose in Pregnancy (FLIP): A Retrospective Observational Study on Outpatient Intravenous Iron Infusion Capacity

Lou, S.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Lou, S.

1213 - A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

Lou, S.

98 - Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study

Lou, X.

3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Lou, Y.

1635 - Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
3119 - Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Lou, Y.

836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPA^bZIP-Inf Acute Myeloid Leukemia

Loubert, A.

3358 - The Impact of Patient-Reported Adverse Events on Quality of Life: An Analysis of the Dreamm-7 and Dreamm-8 Randomized Controlled Trials

Loughran, C.

4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms

Loughran, Jr., T. P.

4363 - Characterization of Cellular Heterogeneity in NK Large Granular Lymphocyte Leukemia Using Cite-Seq

Louie, S.

4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Louis, C.

924 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Louissaint, A.

335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion
4973 - Hi-C Allows Genome-Wide Characterization of Enhancer-Driven Oncogene Rearrangements in Formalin-Fixed Lymphoid Cancer Biopsies

Louissaint, Jr., A.

3610 - Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Louizos, E.

2584 - Characterizing an Underdiagnosed Condition: Hemophilia in Females

Louka, E.

2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Louka, E.

822 - Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia

Louloudis, I. E.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Lourenço, D.

4664 - Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

Louzada, M. L.

703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Love, C. L.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Love, T. J.

1015 - Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Loveless, S.

441 - Outcomes of Hematopoietic Stem Cell Transplantation for High-Risk Marrow Features without Malignancy in Shwachman-Diamond Syndrome
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study

Lovette, Q.

481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Lovins, D.

1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Low, J. S.

1950 - Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)

Low, M. S.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Low, P. S.

1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress

Low, R.

1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Lowden, M.

4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Lowe, D. M.

120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Lowe, E. J.

1581 - NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Lowe, G.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant
3953.1 - A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Lowe, M.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Lowe, N.

3862 - Transcriptional Control of Gene Expression By O-Glcnacylation during Erythropoiesis

Löwe, P. F.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients

Lowenberg, B.

2718 - DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia
4329 - Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Lowenstein, C.

189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis

Lowenton-Spier, N.

1582 - Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test

Lowery, A.

1114 - The Impact of Chronic Hemolysis on Placental Angiogenesis in a Mouse Model of Sickle Cell Disease

Lownik, J.

3922 - Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines
4202 - Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study

Lowrey, C. H.

3830 - The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune-Antibody-Mediated Hemolytic Anemia

Lowry, L.

3731 - Patient Experience with Venetoclax+Rituximab and BTK Inhibitors in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL): A Qualitative Interview Study in the UK (ELECTRIC)

Lowsky, R.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
382 - Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Loyaux, R.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Loyd, M.

4031 - Identification of Breakpoints of RHD Hybrid Alleles By Long-Read Sequencing

Loza, L.

1850 - Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers

Lozada, C.

1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Lozada, J. R. R.

- An Integrated Systems Biology Approach to Understanding the Phenotypic and Functional Diversity of Natural Killer Cells in Cancer

Lozano, C.

429 - F5-Atlanta induced Exitron Splicing

Lozano, J.

4070 - Dissecting the Interactions between Leukemic Cells and the Aging Bone Marrow Niche

Lozano, M. L.

714 - Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study
2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Lozano, M.

787 - Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project
3510 - Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Lozanski, G.

4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Lu, B.

3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Lu, B.

5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

Lu, C.

3897 - Heavy Menstrual Bleeding in Adult Women with Sickle Cell Disease

Lu, C.

1735 - Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lu, C.

823 - Crebbp Inhibition Potentiates JAK2 Inhibition in Post-MPN Acute Myeloid Leukemia

Lu, C.

3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lu, D.

4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Lu, F.

1521 - Venetoclax Plus Idarubicin and Cytarabine Chemotherapy As First-Line Treatment for Adults with Acute Myeloid Leukaemia

Lu, G.

4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Lu, G.

3964 - A Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Improves Hemostatic Outcomes in Severe Swine and Rat Injury Models

Lu, G.

2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Lu, H.

353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Lu, H.

1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Lu, H. J.

5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Lu, H.

2591 - Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment

Lu, H.

3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Lu, J.

3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System

Lu, J.

4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Lu, J.

30 - Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis

Lu, J.

3103 - EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Lu, J.

2996 - Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lu, J.

1808 - A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
3180 - First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Lu, J.

4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Lu, J.

891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
4679 - Clinical Characteristics and Prognostic Analysis of Non-Amyloid Monoclonal Gammopathy of Renal Significance (MGRS) in China
4736 - An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Lu, J. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Lu, J.

1940 - Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy

Lu, J.

971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Lu, J.

2072 - Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients
3451 - GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma

Lu, J.

4175 - BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Lu, J.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Lu, J.

2882 - High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Lu, J.

276 - Unraveling Molecular Subgroup-Specific Pathway Dependencies in Chronic Lymphocytic Leukemia through Drug-Perturbed Transcriptomic Profiling and Statistical Modeling
3584 - Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing

Lu, K.

2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation

Lu, M.

150 - Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery System

Lu, M. Y.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
2839 - Validating Low Flow Cytometry Events with Next-Generation Sequencing for Precise Detection of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia

Lu, M.

2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Lu, M.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
1377 - Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu
3588 - KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells

Lu, M.

978 - Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma
2988 - BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Lu, N.

4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Lu, P.

2075 - CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial
3492 - Improved Outcomes with Bu/Cy+Melphalan and Bu/Cy+Thiotepa Regimens in Haploidentical Hematopoietic Stem Cell Transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia
3537 - Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation
3546 - Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia
4874 - Clinical and Immunological Characteristics of Patients with CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Lu, P.

1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
2214 - Clinical Validation of a Personalized NHL-TME Model System: One-on-One Comparison between Modeled Drug Responses and Patients’ Clinical Responses
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications

Lu, Q.

498 - A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Lu, Q.

4442 - Study of Autologous Versus Allogeneic Stem Cell Transplantation in 56 Patients with Advanced High-Risk Extranodal NK/T-Cell Lymphoma

Lu, Q.

1632 - Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
3033 - Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Lu, R.

4588 - Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes

Lu, R.

3669 - Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule

Lu, R.

1391 - The Arginine Methyltransferase PRMT5 Regulates Maintenance and TKI Resistance of Self-Renewing FLT3-ITD AML LSC
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction

Lu, S.

4820 - Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy

Lu, S.

3072 - Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

Lu, S. X.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms

Lu, T.

833 - ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation

Lu, W.

1775 - Tyrosine Kinase Inhibitors Short Exposure in Pregnant Female Patients with Chronic Myeloid Leukemia
2651 - DCAF13 Is Essential for Hematopoietic Stem Cell Function By Stabilization of Ribosome Biogenesis and P53 Pathway
3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis

Lu, W. S.

645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Lu, X.

3244 - Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)
4612 - Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Lu, X.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Lu, X.

2362 - Real-World Treatment Patterns and Clinical Outcomes Among Patients with Diffuse Large B-Cell Lymphoma in a US Healthcare Claims Database

Lu, X.

421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Lu, X.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Lu, X.

1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients

Lu, Y.

1166 - CircFUT8 Promotes Megakaryocyte Proplatelet Formation By Regulating Actin Cytoskeleton Reorganization

Lu, Y.

2355 - Analysis of the Nervous System Adverse Events Associated with Blinatumomab: A Real-World Study Using the FDA Adverse Event Reporting System Database
2962 - Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma

Lu, Y.

836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients
1786 - Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China
4399 - Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Lu, Y.

1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Lu, Y.

3537 - Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation
3546 - Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Lu, Z.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Lu, Z.

4985 - Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization

Lu, Z.

2586 - Assessment of Bleeding Severity and Prevalence of Iron Deficiency Among Hemophilia B Carriers By Factor IX Activity Levels

Lu-Emerson, C.

4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Luan, D.

2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Luan, J.

3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Luan, R.

4856 - Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Lub-de Hooge, M. N.

1037 - Whole Body CD8⁺ T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy

Lübbert, M.

1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML
2864 - A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Luberto, C.

939 - Multiomic Analyses of Erythropoiesis and Anemia Mechanisms Reveal a Signaling Network with Converging Cytokine and Sphingolipid Inflammatory Pathways

Lubetsky, A.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Lubin, A.

1283 - Statin Therapy Is Associated with Reduced Clonal Expansion in TET2 Mutated Clonal Haematopoiesis of Indeterminate Potential

Lubnau, M.

528 - Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Luc, J.

2762 - Inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) Selectively Kills Acute Myeloid Leukemia Cells

Luc, N. F.

3931 - Post-Injury Treatment with Rapid Intraosseous Injection of Lyophilized Synthetic Platelets Enhances Survival, Hemostasis, and Hemodynamics in a Rat Model of Liver Laceration

Lucarelli, B.

3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation

Lucas, M. S.

4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Lucca, U.

4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study

Lucchesi, A.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Lucchini, E.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Lucchini, G.

4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Lucchini, G.

4849 - Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies

Lucena-Araujo, A. R.

4321 - The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b

Luchtman-Jones, L.

5018 - Bivalirudin Monitoring By Dilute Thrombin Time Is Cost-Efficient in Pediatric ECMO Patients

Luciani, F.

1253 - Rivaroxaban in Paediatric Venous Malformations: Preliminary Data from a Retrospective Single-Center Study

Luciani, M.

1253 - Rivaroxaban in Paediatric Venous Malformations: Preliminary Data from a Retrospective Single-Center Study

Luciano, L.

995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
4535 - Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Lucini, C.

2829 - Differential in Vitro Sensitivity of BCR::ABL1 Kinase Domain Mutations to Tyrosine Kinase Inhibitors Depending on the p190 or p210 Background

Lucioni, M.

4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Lück, C.

2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Luckie, T. M.

2567 - Predictors of Response to Emergent Therapies in Pediatric Immune Thrombocytopenia

Ludewig, B.

1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

Ludford-Menting, M.

4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Ludlage, H.

495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Ludlow, L.

1419 - Co-Targeting BCL-2 and MCL1 (via CDK9) in Pre-Clinical Models of High-Risk Acute Lymphoblastic Leukemia

Ludvigsen Al-Mashhadi, A.

3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Ludvigsen, M.

2997 - Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era

Ludwig, H.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Ludwig, H.

674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Ludwig, I.

1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
4739 - Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma – Long-Term Follow-up of the HOVON 143 Trial

Ludwig, K.

4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia

Ludwig, L. S.

926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Ludwig-Kraus, B.

4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Lue, J.

1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Lue, J. K.

340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Lue, M. J.

1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Luebke, J.

660 - Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors
1801 - Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting
4544 - Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density

Luelf, S.

2646 - UV-C Irradiation: Virus Inactivation in Fibrinogen Concentrate Manufacturing Process

Luengo-Oroz, M.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Luger, S.

6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Lugli, E.

1754 - Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

Lugli, E.

665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Lugo, D.

722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Lugovykh, N.

3610 - Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Lugtenburg, P.

342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Lugthart, S.

522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring
1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring

Lui, G. Y.

169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Luikart, H.

648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Luis, E.

796 - Post-Partum Hemorrhage in Sub-Saharan Africa: A Prospective, Multi-Faceted Intervention Study in Metropolitan Mozambique

Luis-Navarro, J.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Luisi, F.

462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Luistro, L.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models
2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Lukacs, J. L.

4726 - Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Lukanen, E.

2245 - Understanding the Experiences of Caregivers for Children Five Years and Above Living with Sickle Cell Diseases in Kaduna, Nigeria

Lukangu, A.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Lukas, J.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Lukavetsky, L.

4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Luke, C.

4041 - Loss of Microtubule Protein Stathmin-1 Impairs Autophagy in Hematopoietic Stem Cells

Lukic, I.

3615 - Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms - All Clones Are Not Equal
4337 - Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission

Lukowski, J. D.

4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Lulla, P. D.

5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Lumia, E.

2690 - Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Luminari, S.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
1628 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
2269 - A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Lummertz Da Rocha, E.

415 - Path of Differentiation Distinctly Influences Macrophage Identity
2043 - Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Luna, A.

912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Luna De Abia, A.

3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Luna De Abia, A.

4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Luna, L.

910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy

Luna, S. E.

- Engineering Hematopoietic Stem Cells to Generate Therapeutic Antibody Secreting B Cells

Lund, I.

5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Lund, J. L.

3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Lund, J.

3318 - A Lightweight Risk Scoring System for Stratification of Newly Diagnosed Multiple Myeloma Patients
4686 - Predictive Biosignature and Risk Scoring for Bone Disease in Multiple Myeloma

Lund, J.

3320 - Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care

Lund, K.

1097 - Donor Trait Status Determines Haematological Outcomes Post-Haemopoietic Stem Cell Transplantation in Transfusion Dependent Thalassaemia Independent of HLA Matching and Chimerism Status
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure

Lund, T.

1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Lund, T.

2677 - Mesenchymal Stem Cells Regulate Oxidative Stress-Induced Hematopoiesis Via Peroxisomal Metabolism

Lundberg, A.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Lundberg, L.

865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
987 - Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Lundberg Willians, T.

1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Lundin, J.

4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Lundmark, A.

1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Lundqvist, A.

2999 - NPM-ALK Oncoprotein Suppresses Anti-Tumor Immune Responses Partially through Cgas-Sting Pathway in ALK+ Anaplastic Large Cell Lymphoma

Lundt, M.

2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy

Lunghi, F.

1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Lunghi, F.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study

Lunghi, M.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
5188 - Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Lungu, O.

4660 - Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma

Lungu, O.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Lunn, B. W.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Lunn, M. P.

3039 - Bing-Neel Syndrome – a Case Series of 46 Patients from the United Kingdom

Lunn-Halbert, M. C.

2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Lunney, N.

610 - Temporal Association and Risk Window for Secondary Malignancies Post CAR-T
2361 - Venous Thromboembolism Following CAR-T Therapy in Lymphoma Patients - Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS) Database
5102 - Comparative Analysis of Mortality from Serious Adverse Events Associated with CAR-T Therapies

Lunning, M.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
2351 - Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma
2368 - Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3126 - A Prospective Clinical Trial of Boom-Boom Radiation As Bridging Therapy for Patients with Large B-Cell Lymphoma Undergoing Treatment with Lisocabtagene Maraleucel (Liso-cel) Therapy
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Lunsford, K.

4127 - Mapping the Dynamic DNA Methylation Landscape in Pre-B ALL from Diagnosis to Relapse Reveals a Role for Aberrant PRC2 Regulation

Luntz, S.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Luo, B.

3412 - IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Luo, C.

4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

Luo, C.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Luo, C. L.

99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Luo, C.

3041 - Treatment Outcomes for Patients with TP53-Mutated Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis

Luo, H.

959 - Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Luo, H.

627 - Rbmx Regulates YTHDC1 Nuclear Condensates to Promote Nascent Transcription in Acute Myeloid Leukemia
4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells

Luo, H.

4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Luo, H.

3132 - Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Luo, J.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Luo, J.

893 - Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study
1735 - Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma
1978 - Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Luo, L. Z.

189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL

Luo, L.

1197 - IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway
3993 - Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis

Luo, M.

564 - Leptin Receptor+ Stromal Cells Create a Perisinusoidal Niche for Thrombopoiesis in the Bone Marrow By Synthesizing Cxcl14

Luo, M.

3230 - Aberrant c-AMP Signalling in Richter Syndrome Revealed By Single-Cell Transcriptome and 3D Chromatin Analysis

Luo, M.

2989 - Lymph Node Stromal Cells Underlie the Clinicopathologic Features of Castleman Disease

Luo, O.

4019 - The Incidence and Risk of Venous Thromboembolism in Patients with Active Malignancy and Isolated Superficial Venous Thrombosis: A Systematic Review and Meta-Analysis. (The IROVAM-iSVT review)

Luo, Q.

30 - Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis
3843 - ULK1 Regulates the Proliferation and Differentiation of Erythroid Progenitors

Luo, R.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation

Luo, S.

814 - Elimination of Modifiable Risk Factors for Anticoagulant-Related Bleeding in Patients with Cancer Reduces the Probability of Bleeding

Luo, W.

2052 - All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
4816 - Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Luo, X.

2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Luo, X.

1605 - Single-Cell Analysis Reveals an Exhaustion of TEM and CTL CD8⁺ T Cells in Hemophagocytic Lymphohistiocytosis with EBV Infection

Luo, X.

2148 - Diagnosis and Prognosis of aGVHD By Metabolic Biomarkers after Allogeneic Hematopoietic Stem Cell Transplantation

Luo, X.

2038 - Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 Eradicate Antigen-Heterogeneous Multiple Myeloma, Address Antigen Escape and Enhance Expansion

Luo, X.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Luo, X.

2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation

Luo, Y. W.

1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Luo, Y.

91 - Rituximab, Lenalidomide, and Zanubrutinib (ZR²) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3400 - Combined Single-Cell and Spatial Transcriptomics Reveals the Cellular Landscape of Bronchiolitis Obliterans Syndrome in Chronic Graft-Versus-Host Disease Mouse Model
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3599 - Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study

Luo, Y.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation

Luo, Y.

4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes

Luo, Y.

2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Luo, Y.

1485 - Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML
1505 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
2885 - 7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia
4279 - Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Luo, Z. C.

5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Luoma, S.

4648 - Deciphering Variability in Light Chain Amyloidosis and Amyloidosis with Co-Occurring Multiple Myeloma By Single-Cell RNA Sequencing

Luong, A.

1435 - T-Cell Receptor Signaling and Dysfunction during Blinatumomab Therapy in Pediatric Acute Lymphoblastic Leukemia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Luong, V.

3318 - A Lightweight Risk Scoring System for Stratification of Newly Diagnosed Multiple Myeloma Patients
3320 - Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care

Lupas, A.

4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Lupia, M.

1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders

Lupo, P. J.

317 - Genome-Wide Association Study of Acute Lymphoblastic Leukemia in Hispanic/Latino Children Identifies a Putatively Novel Risk Locus at Chromosome 5q31.1
4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Lupova, D.

3610 - Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Luppi, M.

835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Luppi, M.

404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema

Lupu, C.

3988 - Treatment with a Novel Small Molecule Dual Factor IIa/Xa Inhibitor Protects Against Coagulopathy and Organ Dysfunction in a Baboon Model of Staphylococcus Aureus Sepsis

Lupu, F.

3988 - Treatment with a Novel Small Molecule Dual Factor IIa/Xa Inhibitor Protects Against Coagulopathy and Organ Dysfunction in a Baboon Model of Staphylococcus Aureus Sepsis

Luqmani, A.

2497 - Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease

Luque, M.

2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Luque Paz, D.

485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Luque Paz, D.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Luque-Paz, D.

1755 - SH2B3 Loss of Function Variants Are Potential Drivers of Severe Thrombocytosis
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Luquet, I.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Lurain, K.

1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease

Luskin, M. R.

219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
321 - Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN
479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
- Ph+ ALL: New Approaches for Upfront Therapy

Lussana, F.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
838 - Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph⁺ Acute Lymphoblastic Leukemia Patients
2106 - Early Mixed Lymphoid Chimerism in Acute Myeloid Leukemia Patients Undergoing Allogeneic Transplantation after a Myeloablative Busulfan-Based Conditioning Regimen
2192 - Effective Cytoreductive Treatment before Allogeneic Hematopoietic Stem Cell Transplantation May Improve the Outcome of Patients with Blast Phase Myelofibrosis
2834 - CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2849 - CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Lussier, A.

1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Luszczewska, G.

1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea

Lutchman, D.

4527 - ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs

Lutfi, F.

389 - Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Lutge, M.

1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

Luther, S.

1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Luthra, R.

455 - An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory

Luts Khoroz, I.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lutsey, P.

13 - Association of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with Incidence of Venous Thromboembolism Varies By Age: The Atherosclerosis Risk in Communities Study

Lutska, Y.

55 - A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Luttwak, E.

569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
4509 - CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Lutz, C.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Lutzko, C.

1084 - Loss of ATG5 in Humans Causes Syndromic Congenital Dyserythropoietic Anemia with Impaired Mitophagy in Late Stages of Terminal Erythropoiesis
2458 - The Dominant Negative Acting VPS4A^E228Q Mutation Causes Dyserythropoiesis in Human iPSC-Derived Erythroblast Cultures That Phenocopies Cimdag Syndrome-Associated Anemia

Luu, B.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Luukkonen, L.

916 - W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response

Lux, D.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Luxembourg, B.

2543 - Low Thrombopoietin and Elevated Fas-L Are Independent Predictors of Immune Thrombocytopenia

Luxenhofer, R.

3287 - Novel NOTCH1 Effector NFIL3 Is a Therapeutic Target to Combat Drug Resistance and Improve Patient Outcomes in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

Luyten, S.

2340 - Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Luzardo Henríquez, H. D.

1708 - Primary Mediastinal B Cell Lymphoma (PMBCL): A Multicentric Observational Study of Spanish Lymphoma Group Geltamo
1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?

Luzi, D.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Luznik, L.

3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Lv, F.

1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
1738 - Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lv, J.

330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Lv, K.

437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

Lv, K.

1200 - The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir

Lv, L.

833 - ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation

Lv, L.

682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
2058 - Development of a Novel Allogeneic Super-Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4785 - Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Lv, M.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial

Lv, M.

1422 - Safety and Efficacy Results of Dose-Adjusted Inotuzumab Ozogamicin in Adults with B Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Experience

Lv, R.

1932 - Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma
3385 - BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Lv, S.

4941 - Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR_αβ-Depleted Haplo-HSCT

Lv, X.

1961 - Genetic Insusceptibility Mediated Inflammation Contributes to Bortezomib-Induced Peripheral Neuropathy

Lv, X.

536 - HEXIM1 Regulates Early Erythropoiesis and Participates in Multiple Complexes in Erythroid Cells
540 - STAT5 Facilitates Terminal Erythroid Maturation in Concert with the Integrator Complex

Lv, X.

562 - Procr⁺ Endothelial Progenitor Cells Modulate Adult Hematopoiesis and Microenvironment Homeostasis Via Notch Signaling

Lv, Y.

562 - Procr⁺ Endothelial Progenitor Cells Modulate Adult Hematopoiesis and Microenvironment Homeostasis Via Notch Signaling

Lv, Y.

1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Lv, Z.

2940 - Ribosome Profiling Sequencing Reveals LPIN1 As a Potential Therapeutic Target for Acute Myeloid Leukemia with FLT3 -ITD Mutation

Lv, Z.

164 - Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells

Ly, A. M.

1623 - Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
2995 - Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression
4370 - Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Ly, C. P.

1059 - Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
2681 - Multimodal Spatial Profiling in Acute Myeloid Leukemia

Ly, T.

2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Lydeard, J. R.

1558 - Multimodal Atlas of Paired Diagnosis and Relapse AML Reveals Surface Antigens for Multi-Specific Immunotherapy

Lyden, E. R.

3550 - Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT

Lykins, J.

819 - Cytokine Secretion from Megakaryocytes Is Governed By Small GTPASES through Autophagy

Lykkesfeldt, J.

3201 - Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Lykon, J.

932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Lykon, J. L.

4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD

Lyman, G. H.

4025 - Systematic Review, Meta-Analysis, and Quality Appraisal of Advanced Machine Learning Risk Models for Cancer-Associated Thrombosis: The Emergence of Artificial Intelligence in Thrombosis Research

Lymberi, P.

975 - Structural and Functional Analysis of the Clonotypic B Cell Receptor Immunoglobulin in Splenic Marginal Zone Lymphoma: Ontogenetic and Therapeutic Implications

Lynch, K. L.

502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates

Lynch, R. C.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
783 - Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
- Has PD1 Blockade Changed the Standard of Care for cHL?

Lynch, S.

5117 - Sex, Race and Geographic Disparities in Early Age at Onset Hematologic Malignancies

Lynen, L.

3664 - Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Lynn, R.

4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Lynton-Pons, E.

3232 - Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Lyon, E. J.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Lyon, P. D.

4051 - Vitamin A Directly Enhances TET2 Activity and Suppresses Clonal Hematopoiesis

Lyons, K.

1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia

Lyons, N. C.

3302 - Minimal Residual Disease Testing in Relapsed Systemic AL Amyloidosis

Lysa, T.

4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Lysak, D.

1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Lysén, A.

4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
4745 - Krd Consolidation Abrogates Poor Prognosis of FDG PET/CT Positivity after ASCT: Results from a Phase II Study (CONPET)

Lysenkova-Wiklander, M.

2212 - Mapping the Spatial Proteome of Individual Leukemia Cells Undergoing Fludarabine Treatment

Lytle, A.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
742 - A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy
855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma
2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Lytton, W. W.

2616 - Leveraging Generative Artificial Intelligence in Diagnosis of Thrombotic Microangiopathies: Focus on Thrombotic Thrombocytopenic Purpura

Lytvynova, O.

4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics

Lyu, F.

1653 - Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Lyu, H.

926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations

Lyu, J.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Lyu, J.

986 - Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Lyu, M. A.

999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lyu, R.

1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
3389 - A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Lyu, Z. S.

2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia

Author Index: L